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Abstract 
A novel model system for the study of anti-tumour T-eell memory 
Y. Mahnke, Dept. of Cellular Immunology, DKFZ, Heidelberg, Germany. 
An adoptive immunotherapy (ADI) protocol was developed where the fate and requirements of long-
term persisting memory T-cells can be monitored. Anti-tumour immune peritoneal exudate cells 
(iPEC) were produced by injecting a subtumorigenic dose of the highly metastatic, l3-gal+ 
T-Iymphoma into the ear pinna of syngeneic DBN2 mice, followed by an intraperitoneal challenge 
with irradiation-inactivated tumour cells. 33.9 % of CD8+ iPEC were shown to be recognising the 
immunodominant peptide of l3-gal (aa 876-884), and, consistently, the iPEC exerted specific lysis of 
l3-gal+ cells. Upon adoptive transfer into sublethally irradiated, ESbL-Gal tumour-bearing, athymic 
Balb/c nu/nu mice, they conferred protective and long-lasting anti-tumour immunity. ADI-treated 
animals were able to reject subsequent high dose tumour challenges, and memory T -cells 
appeared to be only partially affected by y-irradiation. l3_gaI876-884 peptide/MHC class I tetra mer 
stainings identified the bone marrow as the major compartment for the long-term perSistence of 
memory T -cells, as l3_gaI876-884 specific T -cells occurred at elevated frequencies in this 
microenvironment as compared to the spleen and lymph nodes. In a "parking experiment", Ag-
removal led to a decrease of tetramer-binding cells below background levels. Tumour-reactive 
memory T-cells could be reisolated from AD I-treated animals by recruitment to the peritoneal cavity 
via Ag-specific challenge at this anatomical site. Reisolated memory PEC (mPEC) retained their 
reactivity and conferred tumour protection even after multiple transfers to subsequent tumour-
bearing nude mice. 
The present model proved to be a valuable tool for the evaluation of the factors and mechanisms 
involved in the long-term maintenance of T-cell memory, and promises to yield further invaluable 
data in this field of research. 
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Introduction 
Introduction 
1.1 General introduction on host responses to infectious agents 
(Janeway and Travers 1996, Male 1994) 
The function of the immune system is to protect the body from invading organisms, such as 
bacteria, viruses, fungi and parasites. Leukocytes, together with a number of accessory cells, are 
responsible for this defensive function. They are distributed throughout the body and large 
accumulations are found at sites where infectious agents have the potential to invade (e.g. skin and 
mucosal surfaces of the lung and gastrointestinal tract). Immune cells are also localised in lymphoid 
organs including the bone marrow, thymus, spleen and lymph nodes. They use both the blood 
stream and the lymphatic system to migrate between tissues. A co-ordinated response aiming at 
the elimination of pathogens with minimal damage to host tissues is achieved by interaction of the 
different cellular and soluble components of the immune system. 
Immune responses can broadly be classified as belonging to either innate or adaptive immunity, 
although most immune responses involve elements from both systems. Innate or natural immune 
responses are not improved by repeated infection, and were classically not considered to be 
specific for particular pathogens. Such responses are dominated by phagocytes and natural killer 
cells (NK-cells), and by soluble factors including those of the complement system and acute phase 
proteins. In contrast to innate immunity, the key features of adaptive immune responses are 
specificity and memory, which is marked by enhanced responses upon repeated encounters with 
the same infectious agent. Such antigen (Ag)-specific immune responses are also referred to as 
acquired immune responses, with T-cells and antibodies constituting the main effector 
mechanisms. 
Recently, a family of Toll-like receptors (TLRs) have been identified which confer some degree of 
specificity to innate immune responses and represent a critical link between innate and adaptive 
immunity. TLRs are pattern-recognition receptors which are differentially expressed on APCs and 
the ten members identified to date have a broad specificity for conserved molecular patterns shared 
by large groups of pathogens. For example, TLR4 recognises lipopolysaccharides, whereas TLR2 
is specific for lipoproteins and glycolipids, and TLR9 binds bacterial DNA via unmethylated CpG 
motifs. The different TLRs activate similar but distinct signalling pathways, thus offering APCs a 
means of discriminating between different stimuli. How TLRs recognise their targets is still 
unknown, but binding of microbes or their products results in the activation of APCs, up-regulating 
the expression of co-stimulatory molecules and inducing the production of conditional cytokines 
(Akira et al. 2001). 
In the following sections I will concentrate on the nature of T-cell immunology. 
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1.2 T-eell immunology 
T-cells are lymphocytes which mature in the thymus. They can be subdivided into different 
populations based upon markers expressed on their cell surface, namely into CD4+ and CDS+ 
T -cells. Functionally, they can be classified according to their cytokine response profiles as being 
either TH1 or TH2 type cells, the former comprising inflammatory CD4+ T-cells and COS+ cytotoxic 
T-Iymphocytes (CTL), and the latter involving CD4+ helper T-cells and CDS+ suppressor T-cells. 
The multiple functions of T-cells include (i) recognition and destruction of infected cells, 
(ii) activation of phagocytes to destroy pathogens they have taken up, (iii) provision of 8-cell help, 
and (iv) control of immune responses, mainly by production of soluble mediators (cytokines). 
1.2.1 The T-cell receptor 
T-cell progenitors originate from the bone marrow and mature in the micro-environment of the 
thymus to express a functional T-cell antigen receptor (TCR), with which they recognise antigenic 
peptide presented on proteins encoded by genes of the major histocompatibility complex (MHC) 
expressed on the surface of Ag presenting cells (APC). 
In order to be able to recognise the enormous variety of possible infectious agents encountered in a 
lifetime, the TCR genes have evolved to provide a comparable diversity of Ag receptors for T -cells. 
Each T-Iymphocyte expresses only one type of TCR and can therefore recognise only a limited 
number of antigens. Every T-cell clone differs from the next in respect to its TCR. As a 
consequence, T-cells can, on a population level, recognise virtually every antigenic peptide 
presented in conjunction with a self MHC molecule. 
On most T-cells (> 90 %), the TCR heterodimer is composed of an 0.- and a ~-chain, while a small 
sub-population of T-cells express a yoTCR. In the following paragraph, the structure of the ~-chain 
will be discussed in more detail. 
The TCR ~-chain consists of a constant (C~), a joining (J~), a diversity (D~), and a variable (V~) 
segment (Fig. 1.1), each being encoded by more than one gene. The TCR genes are subject to 
allelic exclusion so that a unique receptor is expressed at the surface of a given T-cell clone. It is 
the V~ together with the Vo. region that constitute the peptide/MHC recognition site of the TCR. 
There are 24 murine V~ region genes, but some of these do not encode a functional V~-chain while 
others are clonally eliminated in some mouse strains due to superantigen mediated deletion during 
thymic selection of T -cells (Table 1.1). 
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Ca 
V/3 
MHC class II 
Fig. 1.1 Ribbon diagram of an a~TCR I peptide I MHC class II complex. 
During interaction of an APC with a T-cell , the TCR (a-chain : yellow, ~-chain : blue) 
recognises antigenic peptide (Pep) in combination with an MHC complex , here a class 
II complex (a-chain : red , ~-chain : green). TCR-segments are indicated as follows: 
V: variable region ; C: constant region ; J: joining segment; D: diversity segment. 
Adapted from Hennecke et al. 2000. 
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The total number of different Ag-specificities present in the mature T-Iymphocyte population is 
referred to as the T-cell repertoire. During an immune response, interaction between a 
peptide/MHC complex and the variable part of the TCR may lead to clonal expansion of T-cells 
carrying the appropriate TCR. Thus, immunodominant epitopes may lead to the activation of T -cells 
expressing certain TCR a- or p-chains, resulting in the skewing of the TCR-Va or -VP repertoire. 
T-cell responses to defined Ags or epitopes can range from a highly diverse TCR-repertoire to the 
dominance of a particular TCR-VP family or even a single TCR (D6ffinger et al. 1997). Likewise, a 
study on the TCR-VP repertoire in shigellosis patients revealed a temporary skewing in both the 
CD4+ and CDS+ T-cell compartments (Islam et al. 1996). 
TCR-VP reason for 
chain comment elimination reference 
VP1 expressed 
V~2 expressed 
Vp3 cion ally eliminated Mtv-1, -3, -6, -13 Hodes et al. 1996 
VP4 expressed 
Vp5.1 clonallyeliminated Mtv-S * McMahan et al. 2000 
Vp5.2 clonally eliminated Mtv-S * McMahan et al. 2000 
Vp5.3 pseudogene Abu-Hadid et al. 1996 
V~6 clonally eliminated Mtv-7, -43 Hodes et al. 1996 
Vp7 clonally eliminated Mtv-7, -43 Hodes et al. 1996 
V~S.1 clonally eliminated Mtv-7, -43 Hodes et al. 1996 
VpS.2 expressed 
V~S.3 expressed 
Vp9 clonallyeliminated Mtv-7, -43 Hodes et al. 1996 
VP10 expressed 
VP11 clonallyeliminated Mtv-S, -11 Hodes et al. 1996 
VP12 clonallyeliminated Mtv-S, -11 Hodes et al. 1996 
V~13 expressed 
VP14 expressed 
V~15 expressed 
VP16 expressed 
Vp17 pseudogene Abu-Hadid et al. 1996 
VP1S expressed 
VP19 pseudogene Abu-Hadid et al. 1996 
VP20 clonallyeliminated I-E Six et al. 1991 
Table 1.1 TCR-V~ chain expression in DBAl2 mice. Endogenous proviruses 
are encoded in Mtv-Ioci of mouse mammary tumour viruses (MMTV). * affects only 
CD4+ T-cells. VP5 chains are reportedly deleted in response to Mtv-9, but this is not 
expressed in DBN2 (Hodes et al. 1996). 
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1.2.2 T-cell activation 
T-cell responses are initiated in secondary lymphoid organs such as lymph nodes and spleen, 
where naTve T-cells encounter Ag-Ioaded professional APCs. Macrophages, 8-cells, and dendritic 
cells (DCs) represent the professional APCs of the immune system, but DCs are the only ones 
capable of activating naTve T -cells. They are activated by endogenous or exogenous danger signals 
to capture, process, and present Ag along with co-stimulatory signals. In order to generate a 
productive immune response, conditioned DCs can be a temporal bridge between Ag-specific CD4+ 
helper and CD8+ cytotoxic T-cells. In a dynamic system, the DC initially stimulates the CD4+ T-cell, 
which, in turn, stimulates and "conditions" it to differentiate into a state where it can then provide 
direct co-stimulation to the CTL (Ridge et al. 1998). 
Exogenous (foreign) and endogenous proteins from the cell itself, which are localised in the 
cytoplasm are processed into peptides and transported into the endoplasmatic reticulum (ER), 
where they are loaded onto MHC class I molecules. The peptide/MHC molecular complexes are 
transported to the cell surface for Ag-presentation to CD8+ T-cells, which are then activated and 
elicit their effector functions. In contrast to MHC class I, MHC class II molecules classically present 
peptides from exogenous proteins. Such Ags are taken up by phagocytosis, macropinocytosis, or 
receptor-mediated internalisation and are processed by proteases in intracellular vesicles, called 
Iysosomes. The MHC class II complexes, either newly synthesised or recycled from the cell 
surface, are loaded in specialised compartments of the endosomal pathway termed MIICs (MHC 
class II compartments), from where they are transported to the cell surface for Ag-presentation to 
CD4+ T-cells. This classical link of protein-origin and type of MHC involved in presentation is not 
strictly true, and it has been shown that MHC class I molecules can indeed present peptides from 
exogenous sources in a process termed cross-priming (Lanzavecchia et al. 1996). Likewise, MHC 
class II molecules can also present peptides derived from endogenous proteins (Pieters et al. 
1997). 
Ag-recognition of peptide/MHC complexes via the TCRlCD3 complex is the first step in T-cell 
activation. This interaction results in the up-regulation of CD40L on the T-cells, which in turn causes 
an up-regulation of the co-stimulatory molecules CD80, CD86, and ICAM-1 (intracellular adhesion 
molecule-1) on the APC via interaction with CD40. These interact with their ligands expressed on 
the T-cell's surface (CD28 for CD80 and CD86; LFA-1 (lymphocyte function-associated Ag-1) for 
ICAM-1), thus providing the second signal required for full T-cell activation, induction of proliferation 
and effector functions, and prevention of anergy or tolerance induction. The recently discovered 
CD28-related inducible co-stimulatory molecule (ICOS) that is expressed on activated T -cells, and 
which interacts with the CD80/CD86-related 87h on APCs, has been shown to be essential for 
T-cell activation and function, ICOS·I. T-cells exhibiting reduced proliferation and defective cytokine 
production upon activation (Dong et al. 2001). 
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1.2.3 Termination of an immune response: return to homeostasis and rescue of T-cells 
from apoptosis 
Following activation, rare Ag-specific T-cells undergo an enormous and rapid expansion. At the 
resolution of the immune response when the Ag has been cleared, most of the T-cells involved in 
the response will be eliminated by apoptosis. This is a physiologic effect necessary in the return to 
cellular homeostasis. During this process, the rescue of some activated T -cells from apoptosis is 
essential for the establishment of long-term Ag-specific T-cell memory. 
Two hypotheses have been proposed for the origin of memory T-cells (Fig. 1.2). One, referred to as 
the linear differentiation model, predicts that memory T-cells are the progeny of CTLs that escape 
activation-induced cell death (AICD), while the second, known as the decreasing potential model, 
proposes that weak antigenic stimulation could result in the development of memory T-cells which 
differentiate through a lineage parallel to effectors (Ahmed et al. 1996). Substantial evidence has 
recently been provided to support the linear differentiation model. Purified H-Y specific pre-CTLs 
adoptively transferred to H-Y negative hosts after having undergone 0 to 1 cell divisions did not 
produce any H-Y specific memory T-cells, while cells transferred after 9 divisions developed into 
long-term (3 weeks) surviving memory T-cells. Na'lve CDS+ T-cells thus have to undergo a 
certain number of cell divisions in the presence of the stimulating Ag in order to mature into CTLs 
which can further differentiate into long-term surviving memory T-cells (Opferman et al. 1999). 
Recently, a new aspect has been added to the linear differentiation model in that not all CTLs 
appear to be equally predisposed for further maturation into memory T -cells. In fact, CTL which 
exert high cytolytic activity during an immune response were found to succumb to suicide by 
degranulation of their perforin/granzyme granules, while those cells that exert low cytolytic activity 
could later form part of the memory compartment. It has, therefore, been proposed that CTL which 
arrive early at the site of infection and are thus confronted with high Ag-Ievels would perform 
cytolysis, killing infected or abnormal cells, as well as themselves. In contrast, those cells that arrive 
later when Ag-Ievels have waned would not perform cytolysis and, instead, differentiate into 
memory cells (Opferman et al. 2001). Consequently, subjecting all responding T-cells to prolonged 
antigeniC stimulation would result in full differentiation and a subsequent total elimination of the 
responding T-cell pool. No memory T -cells would develop under such conditions (Sprent et al. 
2001), which would actually argue in favour of the decreasing potential model. 
In addition to the death by suicide, Ag-stimulated T -cells can be killed by either AICD or cytokine 
deprivation. TCR-ligation on cells that are already in cycle results in AICD, involving a secondary 
interaction between CD95 (Fas/Apo-1) on the APC and CD95 ligand (CD95L) which is up-regulated 
on T -cells following activation. T -cells can thus be killed by over-stimulation. The second 
mechanism, cytokine deprivation, usually occurs during the resolution phase of an immune 
response when cytokines that signal through the interleukin-2 (IL-2) receptor (IL-2R) y-chain 
(y-chain cytokines: IL-2, IL-4, IL-7, IL-15) disappear from the site of inflammation. Such apoptotic 
clearance involves the down-regulation of intracellular apoptosis-inhibitory proteins (AlP), such as 
BcI-2 and BcI-xL' Although the continuous presence of y-chain cytokines can prevent apoptosis of 
Introduction 7 
activated T-cells by inducing a high expression of Bcl-2 and BcI-xL' they simultaneously induce 
clonal expansion (Akbar et al. 1997). 
Linear differentiation model 
Ag + costimulation Ag 
CD) ~ ~ @ ~~~ CO) ~ apoptosis 
efiecto' T.ce"~ CD) na'lve T-cell activated T-cell 
memory T-cell 
Decreasing potential model 
Ag + costimulation Ag Ag 
CD)~ ~ @~ • CQ)~ • CO) 
naNe T-cell\ activated T-ce~ activated I \ effector T-cell 
... \ effector T-cell \ 
CD) © ??? 
100 % 
.. apoptosis 
memory T-cell memory T-eell 
Fig. 1.2 Proposed pathways for the origin of memory T -cells. The top panel 
shows the linear differentiation pathway, while the lower panel illustrates the alternative 
decreasing potential hypothesis. 
Adapted from Ahmed et al. 1996. 
As early as 1990, Scott and colleagues proposed a fibroblast derived factor to be implicated in the 
retention of primed T-cells . They observed that IL-2 dependent T-cell lines that die upon IL-2 
deprivation could be rescued by co-culture with fibroblasts of inflamed synovia or even by culture in 
fibroblast-cond itioned medium (FCM = fibroblast culture supernatant) (Scott et al. 1990). 
Meanwhile, this stromal cell derived survival factor has been identified as being interferon-~ (IFN-~) , 
which does not cause cellular proliferation, and enhances the survival of primed T-cells by up-
regulating the expression of BcI-XL but not Bcl-2. As a result , activated T-cell blasts are converted to 
a resting memory state by IFN-~ (Pilling et al. 1999). Additionally, IFN -~ prevents the translocation 
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of protein kinase C-S (PKC-S) from the cytoplasm to the nucleus, where it would be cleaved by 
caspase-3 to produce the apoptosis-inducing active PKC-S enzyme. IFN-~ also induces up-
regulation of the intracellular antioxidant molecule glutathione, which further contributes to 
increased cell survival (Akbar et al. 2000). Although the anti-apoptotic effect of IFN-~ could be 
mediated indirectly by IL-15 induction, this is not the case, as IL-15 (a y-chain cytokine) would cause 
the T-cells to proliferate. It thus induces survival without inducing secondary cytokine release (Akbar 
et al. 2000). Survival and quiescence are induced only in a fraction of all activated T-cells due to the 
limited availability of the rescue factor IFN-~. 
A recently cloned member of the AlP family, survivin, has been shown to prevent AICD by inhibiting 
the terminal effector caspases-3 and -7. While it could be demonstrated that survivin does not play 
a role in the maintenance of memory T-cells per se (Kornacker et al. 2001), it remains to be 
investigated whether this molecule might be involved in rescuing activated T -cells during the return 
to cellular homeostasis following an immune response. 
1.2.4 T-cell memory 
Immunological T-cell memory is characterised by the persistence of Ag-primed T-cells over 
extended periods of time. At a time pOint when the effector phase against an infection is over and 
the immune system has returned to a state of homeostasis, the surviving Ag-specific T-cells are 
termed memory T-cells and are present in elevated precursor numbers (Hou et al. 1994). They 
differ from naIve cells, having less stringent requirements for activation as they are less dependent 
on co-stimulation and require lower Ag-concentrations for activation (Feuerer et al. 2001). As a 
consequence, memory T -cells exhibit a more rapid and vigorous response to Ag-stimulation than 
do their na"ive counterparts. Nevertheless, memory T -cells have been demonstrated to have a 
unique phenotype, in that they produce cytokines and commit to proliferation as rapidly as effector 
cells, while resembling na"ive T-cells in their slower development of cytolytic function (Bachmann et 
al. 1999). 
Whether Ag-persistence is required for the maintenance of memory T-cells has long been debated. 
In the early 1990s, the opinion was that this pool requires continuous restimulation provided by the 
persistence of Ag from the inoculum, cross-reactive Ag, non-specific prO-inflammatory stimuli or 
idiotype networks (Beverley et al. 1990). Several publications indicated that the presence of Ag is 
necessary in order to preserve the memory T-cell pool specific for that given Ag. As an example, 
Gray and Matzinger argued that the maintenance of T-cell memory for the minor histocompatibility 
Ag H-Y is only short-lived in the absence of Ag (Gray et al. 1991). 
More recently, data have accumulated indicating that long-term survival of memory T -cells is indeed 
possible without the continuous presence of Ag, and it has been postulated that CDS+ T-cell 
memory can survive in the absence not only of Ag (MOllbacher et al. 1994), but also of syngeneic 
MHC molecules (Tanchot et al. 1997), and that survival signals are provided by Ag non-specific 
stimuli (Sprent et al. 1997, Tanchot et al. 1998). Additionally, CD4+ and CD8+ memory T-cell pools 
have been demonstrated to be regulated independently (Varga et al. 2001). 
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Most of the work has been done on viral systems where low-level Ag may persist in specialised 
depots, such as follicular dendritic cells (FOC), or other as yet unidentified places. FOC have been 
shown to express non-phagocytic Fc-receptors (Fc-R) that allow them to hold unprocessed Ag : Ab 
immune complexes (ICs) on their surface for prolonged periods of time (Kelsoe 2000). Some of the 
retained ICs are converted into IC-coated bodies, called iccosomes, which can be endocytosed by 
germinal centre B-cells (Qin et al. 2000). These then process the iccosomal Ag and present it to 
T-cells, which in turn provide the help necessary for growth and differentiation of B-cells. 
Such depots of Ag may playa role in the maintenance of B-cell memory and CD4+ memory T-cells, 
but not for COS+ memory T-cells. Furthermore, as the continuous processing for MHC-presentation 
of a non-replicating Ag places a time limit on its availability for sustaining T-cell memory (Mullbacher 
et al. 1994), such specialised depots will be exhausted at some point in time. 
In order to exclude the possibility of Ag-persistence on FOC to influence the results, many 
researchers have taken to using adoptive transfer systems, where purified virus-specific T-cells 
generated either in vitro or in vivo are transferred to animals negative for the Ag of choice (Bruno et 
al. 1995, Veiga-Fernandes et al. 2000). 
Many model systems applied for T-cell memory research make use of transgenic T-cells. Such 
systems do not, however, reflect physiologic conditions, as transgenic T -cells will not undergo the 
same selective pressures as do T -cells under normal conditions, where T-cell clones compete with 
each other for survival factors and space. 
1.2.5 Tools for the detection and isolation of Ag-specific T-cells 
Identification of memory T -cells according to the differential expression of cell surface molecules 
has often proved to be rather inconclusive. In the murine system, there is no clear phenotypical 
distinction between effector and memory T -cells, although CD44 and CD62L expression are 
classically used to differentiate na'lve from effector/memory T-cells, where CD44hi CD62L'o would 
mark the effector/memory phenotype. 
Differential expression of the various isoforms of the lymphocyte marker CD45 has also been 
exploited. In the human system, this is quite reliable with the high molecular weight isoform 
CD45RA being expressed on na"lve T-cells and the low molecular isoform CD45RO on 
effector/memory T-cells. Analysis of the chemokine receptor-7 (CCR7) expression on CD45RO+ 
cells further allows to differentiate between central memory (CCR7+, resting) and effector memory 
(CCDT, cycling) cells (Sallusto et al. 1999). In mice, the high molecular weight isoform CD45RB is 
commonly expressed on all lymphocytes, with very high expression levels on na"lve T -cells. 
Following T-cell activation, CD45RB expression is down-regulated, and most memory T-cells are 
negative for this molecule. Nevertheless, there exist a sub-population of memory T -cells with a 
"revertant" C045RBhi phenotype (Table 1.2). Furthermore, this differential expression of CD45RB 
on na"lve vs. memory T-cells appears to apply only to the CD4+ compartment. 
Introduction 
memory primed 
low mol. wt. isoforms of CD45R 
Ag-dependent 
cycling 
rapid responder (20 kinetics) 
short lived 
effector-like 
memory revertant 
high mol. wt. isoforms of CD45R 
Ag-independent 
quiescent 
slow responder (1 0 kinetics) 
long lived 
naiVe-like 
Table 1.2 Characteristics of the two proposed CD4+ memory T-cell types. 
Effector-like CD4+ memory T-cells can revert to a naIve-like phenotype and vice versa. 
Adapted from Bell et al. 1998. 
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The cell surface markers could be used to differentiate between effector and memory T -cells when 
taking the time factor into consideration, defining all effector-phenotype T -cells present over one 
month after Ag-priming as memory T-cells. Nevertheless, this does not allow the identification of 
Ag-specific memory T-cells, as immune responses to environmental Ags, both in experimental and 
untreated control animals, will result in an increased frequency of memory phenotype T -cells with 
age. This will also occur under specific pathogen free (SPF) animal holding conditions, where 
responses can be elicited against food Ags. 
Different approaches have been tested to circumvent this problem. As mentioned in 1.2.4, 
transgenic models have been widely used for T-cell memory research (Zimmermann et al. 1996, 
Bachmann et al. 1999, Opferman et al. 1999, Veiga-Fernandes et al. 2000, Kaech et al. 2001) as 
they reduce the problem of how to identify memory T -cells in vivo and how to purify them for ex vivo 
analysis. However, the major drawback of such model systems is that they do not reflect 
physiological conditions. 
Another approach has been the quantification of Ag-specific memory cells by functional analysis. To 
this end, laborious limiting dilution assays have been set up where decreasing amounts of T -cells 
were cultured in the presence of Ag before evaluating Ag-reactivity in a 51Cr-release assay (Lau et 
al. 1994), while Brosterhus and colleagues detected Ag-specific T-cells based on cytokine secretion 
after in vitro stimulation (Brosterhus et al. 1999). 
More recently a novel technology for the detection of Ag-specific T -cells has emerged, namely the 
use of peptide/MHC tetrameric complexes. With the application of tetramers it was demonstrated 
that a significant fraction of herpes virus specific human CD8+ T-cells revert from a CD45RO+ to a 
CD45RA+ state after priming. Such memory revertants resembled naIve T-cells in respect to their 
cell surface phenotype and recirculation pattern. However, unlike naIve T-cells they had very short 
telomeres and exhibited high expression levels of CD11a, indicating a history of activation and high 
cell turnover as well as a high level of differentiation (Faint et al. 2001). 
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Fig. 1.3 Schematic representation of a peptide/MHC class I tetrameric 
complex. The MHC complexes are loaded with specific peptide sequences ( • ) and 
linked to streptavid in via linker peptides (bold lines) and biotin ( • ). <X1-<X3: domains of 
MHC class I a-cha in; ~2m : ~rmicroglobulin ; Lys: biotinylated lysine residue of the 
linker peptide. 
Adapted from Altman and Safrit, HIV Molecular Immunology Database. 
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In combination with FACS analysis , peptide/MHC tetramers have thus proved to be valuable tools in 
the identification and characterisation of Ag-specific T-cells directly ex vivo , as well as in the 
purification of such cells for subsequent in vitro analyses. 
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1.3 Tumour-host interactions 
1.3.1 Tumour immunology 
At the basis of all anti-cancer immunotherapeutic strategies lies the assumption that malignant cells 
differ from their healthy precursors in the expression of so called tumour-associated Ags (TAA). 
The emergence of tumours and tumour metastases are, therefore, sometimes viewed as a failure 
of the immune system to mount a productive response for the elimination of abnormal cells. 
CD4+ helper T-cells as well as CD8+ CTL are involved in cell-mediated tumour rejection. Many 
antigenic tumours develop immune escape mechanisms by somatic mutations. The selection of Ag 
loss variants (Bosslet et al. 1982), abnormalities in the expression and/or function of components of 
the Ag-processing and -presenting machinery (Alimonti et al. 2000, Seliger et al. 2000), expression 
of inhibitory molecules such as the non-classical Ags HLA-G and HLA-E (Carosella et al. 1999), 
and production of inhibitory cytokines such as IL-10 and TGF-~ (tumour growth factor-~) (Finke et 
al. 1999) represent only some of the strategies for immunosurveillance escape used by tumour 
cells. In cases where Ag-presentation via MHC molecules is functional, deficiencies in the 
expression of co-stimulatory molecules can result in the induction of T-cell anergy and tolerance of 
the tumour, as TCR recognition of the tumour cells occurs, but the secondary signal required for 
T-cell activation is missing (Zheng et al. 1999). The expression of Fas ligand (FasL) on many types 
of tumour cells together with increased resistance to Fas-mediated apoptosis results in the 
induction of apoptosis in tumour infiltrating lymphocytes (Fas counterattack) as well as in the 
induction of tumour tolerance. This has lead to the assumption that cancers might represent sites of 
immune privilege (O'Connell et al. 1999). 
1.3.2 Tumour immunotherapy 
Most solid primary tumours can be removed surgically, but if malignant cells have already 
metastasised, patients often suffer a relapse. Early diagnosis is, therefore, essential to prevent 
dissemination of tumour cells from the primary source, which can result in the formation of 
metastases in vital organs, eventually causing a loss of function of the affected organ and death of 
the patient. 
The most widely used non-surgical cancer treatments include radiotherapy, and chemotherapy, 
both acting non-specifically on proliferating tissues. They cause dramatic side effects, as they also 
affect healthy proliferating tissues, such as the bone marrow, intestinal epithelia, skin, and hair 
follicles. Additionally, the immune system is impaired or partly depleted. As a consequence, 
biological therapies, such as gene therapy or immunotherapy, are taking on an increasingly 
important role in the treatment of cancer, in that they are potentially more specific and reduce the 
likelihood of unwanted side effects. 
The goal of anti-cancer immunotherapies is to break tumour resistance to immune attack (see 
1.3.1), and to induce productive cell-mediated immune responses against abnormal cells. Cancer 
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patients have T-cells that are specific for TAA of the autologous tumour (Feuerer et al. 2001), but 
such cells are often anergised and non-reactive, and one immunotherapeutic goal is to provide the 
correct activation signals for these cells. Different approaches of immunotherapy include unspecific 
(application of cytokines or bacterial products), passive (Ab-therapy), adoptive (use of tumour-
reactive immune cells), and active (e.g. modulation of autologous tumour cells to attain increased 
immunogenicity) immunotherapies. Examples for the latter two are given in the following chapters. 
1.3.2.1 Adoptive immunotherapy (ADI) and introduction to ADI systems in the ESb 
T-Iymphoma model 
For cancer therapy, a broad spectrum of cell-based adoptive immunotherapies (ADI) using various 
types of anti-tumour effector cells are being evaluated, including Iymphokine activated killer cells, 
large granular lymphocytes, or tumour infiltrating lymphocytes. One problem has been the poor 
efficiency of tumour targeting by effector cells cultured in vitro (Schirrmacher 1995a). In vivo models 
have been set up to study the factors involved in the efficient priming and tumour targeting of 
tumour reactive CTL. 
Recently, a syngeneic murine model system of ADI against the highly metastatic DBN2-derived 
T-Iymphoma ESb has been developed, where whole-body irradiated, tumour-bearing DBN2 mice 
were treated by transfer of in situ activated peritoneal exudate cells (PEG) from ESb-immunised 
DBN2 mice (Schirrmacher et al. 1991, Schirrmacher et al. 1994b, Schirrmacher 1995b). It was 
demonstrated that the site of tumour inoculation is of critical importance in determining the type of 
systemic immune response generated and the clinical outcome, namely whether tumour growth or 
tumour resistance is obtained. Tumour growth was observed after injection of ESb cells at any 
anatomical site tested, except when tumour inoculation was carried out in the ear pinna. Here, the 
otherwise highly aggressive cells proved non-metastatic and non-tumourigenic. In comparison to a 
subcutaneous site, the ear pinna was shown to be superior in inducing a type 1 cytokine response 
after tumour injection, which could explain the difference in clinical outcome (Jurianz et al. 1998). 
Tumour cell integrity and viability were essential for the generation of tumour-reactive CD8+ CTL 
both in vitro and in vivo (Schirrmacher et al. 1993). 
A main metastatic target of the ESb T-Iymphoma is the liver, and it could be shown that syngeneic 
ADI resulted in the clustering of CD4+ and CD8+ T -cells with a subset of host macrophages 
expressing the lymphocyte adhesion molecule sialoadhesin (Sn). These Sn+ macrophages proved 
essential to the therapeutic success (MOerkoster et al. 1999). 
1.3.2.2 Active specific immunisation (ASI) 
DNA-vaccination and somatic gene therapy are gaining increasing importance, as they promise to 
be a relatively simple and economic procedure for the induction of Ag-specific immune responses in 
vivo. They can be applied to achieve gene transfer, gene repair, or gene deletion. Different ways of 
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gene transfer include the injection of naked DNA, protein vectors, viral vectors, or DNA-liposome 
complexes (Iipofection). 
In experimental animals, the superiority of the ear pinna over muscle tissue as a site for DNA 
vaccination has been demonstrated (Fbrg et al. 1998). Transfection of the skin proved to be an 
efficient route of immunisation, possibly because this, alongside mucosal surfaces, is the 
physiologic site where most exogenous antigens are normally encountered. It has been reported 
that many cell types within the dermis and epidermis, including keratinocytes, macrophages and 
Langerhans' cells, take up and express the injected DNA (pCMV~, coding for ~-gal) without any 
preference (Fbrg et al. 1998). Although only a small proportion of DCs are transfected after ear 
pinna immunisation with naked DNA, a general activation of all DCs in the draining lymph node is 
observed, providing optimal conditions for effective T-cell activation (Akbari et al. 1999). 
As for cellular injections in the ear pinna, the reasons for this as a privileged site for immunisation 
with plasmid DNA might be twofold. Local concentration of antigen in a restricted area connected 
with one major lymph node (superfiscia cervicalis) may result in fast stimulation of na'lve T-cells by 
antigen-loaded DCs. Secondly, mechanical irritation by needle injection may induce local cytokine 
secretion and activate and recruit additional antigen-presenting cells. Additionally, the unmethylated 
CpG motifs present in bacterial plasmid DNA are known to exert potent immunostimulatory activity 
by inducing macrophages to produce IL-12, which in turn activates T- and NK-cells (Pisetsky 1996). 
They are, therefore, referred to as immunostimulatory DNA sequences (ISS). Such ISS could be 
shown to circumvent the need of CD4+ helper T-cells in the induction of CTL activity by "licensing" 
the APC (see 1.2.2) for CTL-activation (Cho et al. 2000) via binding to TLR9 (see 1.1, Akira et al. 
2001). 
1.3.3 Tumour dormancy 
Micrometastases are microscopic « 2 mm) deposits of malignant cells that are segregated spatially 
from the primary tumour and have no specific blood supply. This might limit their growth as they 
depend on the passive diffusion for oxygen and nutrient supply (Kell et al. 2000). In patients with 
epithelial malignancies, such as breast, gastriC and colorectal carcinoma, as well as squamous cell 
carcinomas of the head and neck, bone marrow micrometastases have been found to be a 
predictor of poor prognosis. 
If proliferation and death rates are matched and angiogenesis is not induced, tumour cells can 
remain in a dormant state for long periods of time. By definition, tumour dormancy is a state in 
which potentially lethal tumour cells persist for a prolonged period of time in a clinically normal host 
with little or no increase in the tumour cell population. The microenvironment where they are located 
may affect the behaviour of tumour cells, and it has been shown that the persistence of tumour cells 
in a dormant state is closely associated with host immune responses (Matsuzawa et al. 1996). 
Lymph nodes and bone marrow appear to be privileged sites where tumour cells are proliferating, 
evidenced by expression of the S-phase specific proliferation marker Ki67, but prevented from 
expanding on a population level by an active host immune response involving CD8+ T -cells (Muller 
et al. 1998). Immunologically controlled tumour dormancy thus represents a delicate balance 
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between the immunological properties of tumour cells and the status of the host immune system, 
tumour cell immunogenicity and cell-mediated immunity playing significant roles in its establishment 
and maintenance. Dormant tumour cells thus resemble clinical situations such as minimal residual 
disease or stable disease, where tumour foci may exist for prolonged periods of time under host 
control without enlargement. 
Extracellular matrix (ECM) components such as the basement membrane play an important role in 
tumour dormancy (Pogany et al. 2001). They provide differentiation and survival signals (e.g. 
growth factors), as well as death neutralising Signals to cells (e.g. increasing repair of DNA-damage 
following UV-radiation), and reduce the proliferative capacity of tumour cells. Taken together, the 
overall effect is a balance between tumour cell proliferation and apoptosis, the hallmark of tumour 
dormancy. 
Tumour dormancy is a key limiting event in the treatment of malignant diseases, as the persistence 
of neoplastic cells represents a constant source for tumour recurrence and clinical relapse. The 
tumour dormancy state is, therefore, also included in the term minimal residual disease. Alterations 
in the host immune status, as well as tumour cell changes leading to increased malignancy or 
therapy resistance can both be involved in breaking the tumour dormant state. Nevertheless, the 
induction of long-lasting tumour dormancy might be a useful approach for the treatment of cancer 
patients, since it circumvents highly aggressive treatment strategies applied to eliminate even the 
last tumour cell (Morecki et al. 1996). 
Dormant tumour cells provide persistent Ag-stimulation, potentially playing an important role in the 
long-term maintenance of anti-tumour immunity. It was shown that long-term protection was not 
achieved by vaccination with irradiated tumour cells, which persist for only a few weeks « 3 weeks) 
in host bone marrow as compared to several months in the case of non-irradiated cells (Khazaie et 
al. 1994). 
1.4 Structural and functional characterisation of the bone marrow 
(Krstic 1994) 
The bone marrow consists of two components. One is the bone marrow stroma, which is composed 
of arterioles, blood sinuses, adipose cells, and macrophages, and provides the blood supply, as 
well as growth factors to the bone marrow parenchyma. The parenchyma is the second component, 
and consists exclusively of haematopoietic cells at various stages of development, differentiation 
and maturation. These fill up the spaces within the meshwork of the vascular stroma. 
The bone marrow is a primary lymphoid organ where haematopoiesis takes place. All blood cells 
are derived from the bone marrow, and B-cell, granulocyte, platelet, monocyte, thrombocyte, and 
erythrocyte maturation occurs in this special microenvironment. The bone marrow sinuses are lined 
by flattened endothelial cells which can produce openings to facilitate the release of mature blood 
elements into the circulation. Incorrectly developed blood elements are phagocytosed and 
destroyed by the numerous macrophages. 
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While the central role of the bone marrow in the successful development of the various immune 
system components is unquestioned, its potential of exerting secondary immune functions has 
hardly been addressed. Mature lymphocytes found in the bone marrow are mainly B-Iymphocytes, 
but low numbers of T-cells are also found (1-2 % in mice; 30-50 % of mononuclear cells in 
humans). Early investigations have shown that the majority of all Ig-secreting cells are actually 
localised in the bone marrow. In this microenvironment, induction of Ig-production is slower initially, 
but overall longer lasting than that observed in other lymphoid compartments (Benner et al. 1981). It 
has been proposed that the bone marrow microenvironment can also support primary T-cell 
immune responses in a situation of disrupted lymphocyte trafficking in splenectomised animals, 
where the bone marrow assumed the functions usually attributed to the spleen (Tripp et al. 1997). 
Whether or not such primary T-cell responses also occur under physiologic conditions has not been 
investigated to date. 
1.5 Athymic nude mice 
Nude mice have a congenital aplasia of the thymus resulting in a quantitative and functional T-cell 
deficiency. This makes them a useful research tool for immunological and oncological studies. 
Athymic mice exhibit numerous immune system defects, including a reduced lymphocyte population 
which is almost entirely composed of B-cells. As a result, their susceptibility to infections is 
elevated. 
As mice age, there is a gradual and partial development of limited T-cell function due to extrathymic 
maturation of bone marrow cells. Such extra thymic T-cells are also present in normal, euthymic 
animals, where reciprocal regulation between these T-cells and thymus-derived T-cells might occur. 
Extrathymic T-cells, also referred to as TCRint T-cells due to their intermediate expression levels of 
the TCRlCD3 complex, are few in number and comprise both a~ (CD4+, CD8+ or CD4-CD8-) and 
roT-celis. Like NKT-cells, they respond quickly to corresponding Ags, and are primitive T-cells 
which do not undergo selection. As a consequence, they harbour autoreactive "forbidden" clones, 
which can mediate autoreactive cytotoxicity to rapidly dividing self-cells. An increase in the number 
of extrathymic T-cells with age might, therefore, be important for the elimination of abnormal self-
cells, such as virally infected cells and malignant tumour cells, which appear in the body with ageing 
(Abo 2001). 
Although T-cells in nu/nu mice may arise from thymic rudiments, extrathymic differentiation is 
considered the major pathway of T-cell development in these animals. Extrathymic T-cell 
maturation can occur in several microenvironments, the most important being the intestinal 
epithelium (Emoto et al. 1996) and liver (Emoto et al. 1997). It is known that, during the foetal stage, 
the liver is a haematopoietic organ. In the adult liver, pluripotent stem cells still remain, which, by 
hepatocyte-derived IL-7, are induced to differentiate into TCRint T -cells. After migration to the 
sinusoidal lumen, these undergo functional maturation stimulated by Kupffer cell-derived IL-12, 
IL-15, and IL-18 (Abo 2001). 
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Though T-cells can develop in nude mice along extrathymic pathways, T-cell numbers and function 
never reach levels comparable to those in normal mice. 
1.6 Aims of this thesis 
The mechanisms underlying long-term maintenance of T-cell memory are still poorly understood. In 
the centre of debate lies the question whether or not Ag-persistence is required (1.2.3). Most work 
on T-cell memory has been dealing with responses to soluble or viral Ag. While it is not clear 
whether T-cells specific for either soluble, viral, or cell-bound Ag have different requirements for 
survival, this needs to be analysed. 
In the present work I set out to develop a novel model system to study anti-tumour T-cell memory. 
To this end, a graft-versus-Ieukaemia ADI system was established, comprising athymic nu/nu mice 
as therapy recipients where the fate of Ag-specific memory T -cells can be followed in vivo and ex 
vivo. The different components of this system were analysed, namely: 
• T -lymphoma lines which were used as a source of tumour cells for the ADI were characterised 
concerning the expression of cell surface markers. Their migration kinetics after ear pinna 
injection in the primary syngeneic host were analysed. 
• primary kinetics of CD8+ T-cells specific for the H-2Ld-restricted immunodominant peptide of 
~-galactosidase (~-gal) were followed using peptide/MHC tetrameric complexes. 
• immune peritoneal exudate cells used in the transfer were analysed for content of various 
immune cell populations, as well as for tumour specific cytotoxic activity. 
• AD I-recipient mice were monitored for long-term survival. 
• memory T-cells were tested for long-term survival, in vivo localisation, and requirement for Ag-
persistence. 
The final chapter of my work focuses on DNA-vaccination, which has emerged to be a promising 
tool in the design of new therapeutic strategies against a wide spectrum of diseases. As a hallmark 
of a good vaccine is not only its ability to prime a productive immune response, but also to induce 
long-term survival of T-cell memory, I addressed the question as to whether or not this is provided 
by DNA-vaccination. 
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1.7 Rationale for choice of model system 
ADI with immune T-cells (e.g. effector CTL, central memory or effector memory T-cells) requires 
MHC-compatibility between donor and host. If this is not the case, the therapy may not be effective, 
and there is the risk of GvH-development. In response to host alloantigens, in particular allo-MHC, 
sensitised donor CD4+ and CDS+ T-cells can recruit macrophages to cause a severe hypoplasia of 
host lymphocytes (Kataoka et al. 2001) as well as pathological damage, especially in the skin, gut 
epithelium and liver. This is referred to as acute GvH disease (GvHD). In the chronic form of GvHD, 
alloreactive CD4+ donor T-cells act as helpers of host B-cells, leading to B-cell activation and 
autoantibody production. Such complications are overcome by using ADI recipients which are either 
completely syngeneic or, if allogeneic, do not differ in the MHC gene complex. 
In addition, athymic nude mice provide an optimal environment for the study of the fate of adoptively 
transferred Ag-specific T-cells, as, by nature, they are T-cell deficient. Adoptively transferred T-cells 
will thus occur at higher frequencies than in normal mice. 
The present system is superior to the multiple transgenic T-cell models used for T-cell memory 
research, as it mimics physiological conditions where memory T-cell clones have to compete for 
survival factors and space. In this situation, the presence or absence of Ag might, therefore, be 
more critical to the maintenance of Ag-specific T -cells than it is in transgenic systems. 
Materials 
Materials 
2,1 Apparatus 
Automatic Gamma Counter 
commercial name, 
formula or clone 
AxioCam, camera for microscopy with Axioplan 2 
Axioplan 2 imaging microscope 
Centrifuge, Minifuge T 
Cytospin centrifuge 
Electrophoresis system, Easy-Cast 
ELISA reader 
FACScan 
FACSvantage 
Gammacell 1000, Caesium 137 
Gammatron F80S, Cobalt60 
Heating block, Grant QBT2 
Hybridisation oven 
Laminar flow, SterilGARO Hood 
(for cells) 
(for animals) 
Liquid Scintillation Analyser, Tri-Carb 2100 TR 
Magnet stands, MPC-E-1 and MPC-L 
Midi MACS Separation Unit 
Minigel migration trough, Mupid-21 
Nuaire US Autoflow Incubator 
OctoMACS Separation Unit 
Phase contrast microscope 
Roentgen film developing machine, Cuvix 160 
Rotation device 
Spectrophotometer, GeneQuant pro 
Ultracentrifuge L8-M 
UV-Iamp 
UV Stratalinker™ 2400 
Vertical shaker, HS 501 digital 
3 CCO video camera for ELiSPOT with Axioplan 2 
company or reference 
Wallac, Turcu (FI) 
Carl Zeiss, Gottingen (0) 
Carl Zeiss, Gottingen (0) 
Heraeus, Hanau (0) 
Shandon, Pittsburgh (USA) 
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Owl Separation Systems, Portsmouth 
(USA) 
Labsystems, Helsinki (FI) 
BO Biosciences, Heidelberg (0) 
BO Biosciences, Heidelberg (0) 
Gammaster, Ede (NL) 
Siemens, Braunschweig (0) 
Neolab, Heidelberg (O) 
Bachofer, Reutlingen (O) 
The Baker Company Inc., Sanford 
(USA) 
Packard, Groningen (NL) 
Dynal, Hamburg (0) 
Miltenyi Biotec, Bergisch Gladbach (0) 
Eurogentec, Seraing (B) 
Nuaire, Plymouth (USA) 
Miltenyi Biotec, Bergisch Gladbach (0) 
Carl Zeiss, Gottingen (0) 
Agfa, Koln (D) 
Heidolph, Schwa bach (D) 
Amersham Pharmacia Biotec, 
Freiburg (0) 
Beckman, Krefeld (O) 
Konrad Benda, Wiesloch (O) 
Stratgene, Heidelberg (D) 
IKA Labortechnik, Staufen (D) 
Sony Deutschland GmbH, Koln-
Ossendorf (D) 
Materials 
2.2 Single-use items 
BioMax MS-1 roentgen film 
cell scraper 
commercial name, 
formula or clone 
cover glasses for microscope slides, various sizes 
cryogenic vials, 2.0 ml 
cytospin filter mats 
ELISA plates, flexible, 96-well 
Eppendorf tubes 0.5/1.0/ 2.0 ml 
FACS-tubes 
gauze, 60 J.lm 
gel-blotting paper, 3 MM Whatman paper 
Hybond ™ -N+ hybridisation transfer membrane 
low-binding protein filter, 0.22 J.lm 
microscope slides 
MultiScreen plates, 0.45 J.lm cellulose ester membranes 
needles, sterile; 20 G, 25 G, 27 G 
NucTrap® probe purification columns 
Petri dishes, bacteriological quality 
Petri dishes, tissue-culture quality 
polystyrene tubes, 6.5 x 38 mm 
pony vials 
QIAshredder 
round-bottomed tubes, 5.0 ml 
scalpel 
separation columns; MS+, LS+ 
sterile filters, 0.45 Jlm 
syringe, sterile 
tissue culture flask; 25 cm3, 75 cm3, 150 cm3 
tissue culture plates, round- & flat-bottomed; several sizes 
company or reference 
Kodak, Stuttgart (D) 
TPP, Trasadingen (CH) 
R. Langenbrinck, Emmendingen (0) 
Corning BV., Schiphol-Rijk (NL) 
Shandon, Pittsburgh (USA) 
BO Biosciences, Heidelberg (0) 
Eppendorf, Koln (0) 
Greiner, Frickenhausen (0) 
Fritz Eckert GmbH, Waldkirchen (D) 
Schleicher & Schnell, Dassel (D) 
Amersham Pharmacia Biotec, 
Freiburg (0) 
Millipore, Eschborn (0) 
R. Langenbrinck, Emmendingen (D) 
Millipore, Eschborn (D) 
BD Biosciences, Heidelberg (0) 
Stratagene, Heidelberg (0) 
Greiner, Frickenhausen (0) 
TPP, Trasadingen (CH) 
BO Biosciences, Heidelberg (0) 
Packard, Groningen (NL) 
Qiagen GmBH, Hilden (D) 
Greiner, Frickenhausen (0) 
PfM Ag, Koln (0) 
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Miltenyi Biotec, Bergisch Gladbach (0) 
Millipore, Eschborn (0) 
Terumo, Louvain (B) 
TPP, Trasadingen (CH) 
TPP, Trasadingen (CH) 
Materials 
2.3 Reusable items 
BioMax MS intensifying screen 
centrifugal tubes, 500 ml 
Erlenmeyer flasks, 500 ml 
film exposure cassette 
glass tubes, 10 x 50 mm 
hybridisation bottles 
Neubauer chamber 
2.4 Chemicals 
agarose, electrophoresis grade 
commercial name, 
formula or clone 
alkaline phosphatase conjugate substrate kit 
ammonium acetate 
ammonium chloride 
assay diluent for OptEIA™ Sets 
bovine serum albumin 
5-bromo-6-chloro-3-indolyl-~-
D-galactopyranoside 
chloroform 
diethyl pyrocarbonate 
N ,N-dimethylformamide 
dimethyl sulfoxide 
BSA 
X-gal, C14H15BrCIN06 
CHCl3 
DEPC, C6H100S 
DMF, C3H7NO 
DMSO, C2H60S 
1,4-dithiothreitol OTT, C4HlO0 2S2 
Dynabeads® mRNA DIRECT™ buffer set 
ethanol p.a. 
ethidium bromide, 10 mg/ml 
ethylene diaminotetraacetate 
Ficoll, density: 1.077 
fluorescein di-~-D-
galactopyranoside 
formaldehyde, 37% 
glacial acetic acid 
glutaraldehyde, 25% 
glycerol 
glycogen 
C2H60 
C21 H20N3Br 
EDTA, ClOH16N20a 
Biocoll 
FOG, C32H3201S 
CH20 
C2H402 
CsHa0 2 
C3Hs03 
company or reference 
Kodak, Stuttgart (D) 
Nalgene, Rochester, NY (USA) 
Fisher Scientific, Nidderau (D) 
Appligene, Heidelberg (D) 
neolab, Heidelberg (D) 
Hybaid, Teddington, Middlesex (UK) 
Fisher Scientific, Nidderau (D) 
Life Technologies, Karlsruhe (D) 
BioRad, Hercules (USA) 
Merck, Darmstadt (D) 
Merck, Darmstadt (D) 
PharMingen, Hamburg (D) 
Sigma, Deisenhofen (D) 
Roche Molecular Biochemicals, 
Mannheim (D) 
Merck, Darmstadt (D) 
Sigma, Deisenhofen (D) 
Merck, Darmstadt (0) 
Merck, Darmstadt (D) 
Life Technologies, Karlsruhe (D) 
Dynal, Hamburg (D) 
Sigma, Deisenhofen (D) 
Sigma, Deisenhofen (D) 
Life Technologies, Karlsruhe (0) 
Biochrom KG, Berlin (D) 
Molecular Probes, leiden (Nl) 
Merck, Darmstadt (0) 
Merck, Darmstadt (0) 
Merck, Darmstadt (D) 
Merck, Darmstadt (D) 
Merck, Darmstadt (D) 
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commercial name, 
formula or clone company or reference 
heparin-sodium, 5.000 I.U.lml B. Braun Melsungen AG, Melsungen 
(D) 
hydrochloric acid HCI J. T. Baker B.V., Deventer (NL) 
isoamyl alcohol C5H12O Merck, Darmstadt (D) 
isopropanol p.a. C3HsO Sigma, Deisenhofen (D) 
Kaiser's glycerol gelatine Merck, Darmstadt (D) 
ketamine hydrochloride, ketanest, Parke-Davis GmbH, Berlin (D) 
50 mg/ml C13H16CINO 
lithium chloride LiCI Merck, Darmstadt (D) 
loading buffer, 6x MBI Fermentas, St. Leon-Rot (D) 
magnesium chloride MgCI2 Sigma, Deisenhofen (D) 
magnesium sulfate MgS04 Merck, Darmstadt (D) 
~-mercaptoethanol C2H6OS Merck, Darmstadt (D) 
Nonidet P-40 NP-40 Sigma, Deisenhofen (D) 
paraffin wax Vogel, Medizinische Technik & 
Elektronik, Giessen (D) 
phenol C6H60 Merck, Darmstadt (D) 
phosphate buffered saline PBS Biochrom KG, Berlin (D) 
polyoxyethylene sorbitan Tween 20 Gerbu, Gaiberg (D) 
monolaurate 
potassium chloride KCI Merck, Darmstadt (D) 
potassium ferricyanide K3Fe(CN)6 Sigma, Deisenhofen (D) 
potassium ferrocyanide ~Fe(CN)6 x 3 H2O Sigma, Deisenhofen (D) 
potassium hydrogen carbonate KHC03 Merck, Darmstadt (D) 
propidium iodide PI, C27H34N412 Sigma, Deisenhofen (D) 
sodium acetate NaC2H30 2 Merck, Darmstadt (D) 
sodium azide NaN3 Merck, Darmstadt (D) 
sodium bicarbonate NaHC03 Merck, Darmstadt (D) 
sodium carbonate Na2C03 Merck, Darmstadt (D) 
sodium chloride NaCI Merck, Darmstadt (D) 
sodium chromate Na251Cr04 NEN, Bad Homburg (D) 
sodium deoxycholate Sigma, Deisenhofen (D) 
sodium dodecyl sulfate SDS, NaC12H2504S Merck, Darmstadt (D) 
sodium hydrogen phosphate NaHP04 Merck, Darmstadt (D) 
sodium hydroxide NaOH J. T. Baker B.v., Deventer (NL) 
spermidine Sigma, Deisenhofen (0) 
sulphuric acid H2SO4 Merck, Darmstadt (D) 
tetramethylbenzidine (TMB) microwell KPL, Gaithersburg (USA) 
peroxidase substrate system 
Materials 
commercial name, 
formula or clone 
trihydroxymethyl Tris, C4H11N03 
aminomethane 
Tris-HCI, 1 M, DNA/RNA-free C4H11 N03 
trypan blue C34H24N6014S4Na4 
xylazine hydrochloride, 2% rompun, C12H16N2S 
2.5 Media and media supplements 
ampicillin 
foetal calf serum 
geneticin® 
gentamicin 
L-glutamin, 200 mM 
granulocyte/macrophage 
colony-stimulating factor 
N-2-hydroxyethylpiperazine-
C16H19N304S 
FCS 
G418 sulphate, 
C2oH40N4010 x H2S04 
-N'-2-ethanesulfonic acid 
~-mercaptoethanol C2H60S 
penicillin/streptomycin, 10,000 lU/ml/1 0,000 Ilg/ml 
phytohemagglutinin PHA-P 
RPMI1640 
tryptone peptone 
X-vivo 20. serum-free medium 
yeast extract 
bacto-tryptone 
bacto-yeast extract 
company or reference 
Sigma, Deisenhofen (D) 
Sigma, Deisenhofen (D) 
Merck, Darmstadt (D) 
Bayer AG, Leverkusen (D) 
Sigma, Deisenhofen (D) 
Biochrom KG, Berlin (D) 
Life Technologies, Karlsruhe (D) 
Life Technologies, Karlsruhe (D) 
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Life Technologies, Karlsruhe (D) 
own production; see cell line Ag8653 
Life Technologies, Karlsruhe (D) 
Life Technologies, Karlsruhe (D) 
Life Technologies, Karlsruhe (D) 
Sigma, Deisenhofen (D) 
Life Technologies, Karlsruhe (D) 
Difco, Heidelberg (D) 
BioWhittaker, Verviers (B) 
Difco, Heidelberg (D) 
2.6 Cells 
Materials 
commercial name, 
formula or clone 
Established murine cell lines 
Eb 288 Heidelberg subline of the methyl-
cholanthrene induced T -lymphoma 
L5178Y/E of the OBAl2 mouse; 
low metastatic variant 
ESb 289 spontaneous, high metastatic variant of 
Eb 288 
ESb-L more aggressive form of ESb 289, 
isolated from a liver metastasis 
ESbL-Gal bacterial/aeZ gene transduced ESb-L 
subline (clone: L-CI.5s); highly metastatic 
P815 methyl-cholanthrene induced mastocytoma 
of the OBAl2 mouse; non-metastasising 
P815-Gal bacterial/aeZ gene transduced subline of 
P815, commonly known as P13.1 
Ag8653 murine GM-CSF produCing cell line 
Primary murine tumour cell lines 
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company or reference 
Schirrmacher et al. 1979 
Schirrmacher et al. 1979 
KrOger et al. 1994a 
KrOger et al. 1994a 
Matter et al. 1976 
Carbone et al. 1990 
Zal et al. 1994 
ESbL-Gal-BM ESbL-Gal variant isolated from the bone marrow of ESbL-Gal-immunised OBAl2 
ESbL-Gal-ET 
ESbL-Gal-ST 
ESbL-Gal-TI 
ESbL-Gal variant isolated from an ear tumour 
ESbL-Gal variant isolated from a spleen tumour 
ESbL-Gal variant isolated from a throat tumour 
Bacteria 
OHSa competent cells 
2.7 Experimental animals 
OBAl2 mice, female 
Balb/c nu/nu mice, female 
C01 Swiss nu/nu mice, female 
E.eoli 
H-2Ld 
H-2Ld 
outbred 
Clontech, Heidelberg (0) 
Charles River, Sulzfeld (0) 
Iffa Credo, l'Arbresle (FR) 
Charles River, Sulzfeld (0) 
Materials 
commercial name, 
formula or clone 
2.8 Antibodies and ELISA-Sets 
anti-~7 integrin chain, purified 
anti-C02 (LFA-2), purified 
anti-C03£, FITC-conjugated 
anti-C04, CyChrome-conjugated 
anti-CD8a, CyChrome-conjugated 
anti-CD8a, FITC-conjugated 
anti-CD11a (LFA-1), purified 
anti-CD11c (integrin <Xx), FITC-conjugated 
anti-C019, FITC-conjugated 
anti-CD45R1B220, R-PE-conjugated 
anti-CDS2L (L-selectin), FITC-conjugated 
anti-CD80 (B7.1), R-PE-conjugated 
anti-C08S (B7.2), R-PE-conjugated 
anti-C090.2 (Thy1.2), FITC-conjugated 
anti-F4/80, FITC-conjugated 
anti-H-2Dd (MHC class I), R-PE-conjugated 
anti-H-2Ld (MHC class I), culture supernatant 
anti-I-Ad (MHC class II), R-PE-conjugated 
anti-ICAM-1, purified 
anti-PSGL-1, culture supernatant 
PanNK mAb, FITC-conjugated 
donkey anti-rat IgG (H+L), R-PE-conjugated 
CD90 (Thy1.2) MACS MicroBeads 
Dynabeads® mouse CD4 (L3T4) 
Dynabeads® mouse CD8 (Lyt-2) 
murine IFN-y ELISPOT Kit 
OptEIA™ mouse IFN-y Set 
OptEIA™ mouse IL-2 Set 
OptEIA™ mouse IL-4 Set 
OptEIA™ mouse IL-5 Set 
OptEIA™ mouse IL-S Set 
OptEIA™ mouse IL-10 Set 
FIB27 
RM2-S 
14S-2C11 
GK1.S 
53-S.7 
53-S.7 
Tib 213 
N418 
605 
RA3-6B2 
Mel-14 
16-10A1 
RMMP1 
53-2.1 
F4/80 
34-2-12 
19.191 
AMS-32.1 
YN.1/1.7 
2PH-1 
DX5 
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company or reference 
BO PharMingen, Hamburg (0) 
BD PharMingen, Hamburg (D) 
BD PharMingen, Hamburg (0) 
BD PharMingen, Hamburg (D) 
BO PharMingen, Hamburg (0) 
BD PharMingen, Hamburg (D) 
Prof. P. Altevogt, DKFZ, Heidelberg (D) 
BO PharMingen, Hamburg (0) 
Beckman Coulter, Krefeld (0) 
BO PharMingen, Hamburg (0) 
BD PharMingen, Hamburg (D) 
BD PharMingen, Hamburg (D) 
BD PharMingen, Hamburg (D) 
BO PharMingen, Hamburg (D) 
Serotec, Eching (0) 
BD PharMingen, Hamburg (0) 
Prof. G. Hammerling, DKFZ, 
Heidelberg (D) 
BD PharMingen, Hamburg (D) 
Prof. P. Altevogt, DKFZ, Heidelberg (D) 
Prof. P. Altevogt, OKFZ, Heidelberg (0) 
BO PharMingen, Hamburg (D) 
Dianova, Hamburg (D) 
Miltenyi Biotec, Bergisch Gladbach (D) 
Dynal, Hamburg (D) 
Dynal, Hamburg (D) 
Diaclone, Besanc;on Cedex (FR) 
BO PharMingen, Hamburg (0) 
BO PharMingen, Hamburg (0) 
BO PharMingen, Hamburg (0) 
BO PharMingen, Hamburg (0) 
BO PharMingen, Hamburg (0) 
BO PharMingen, Hamburg (D) 
Materials 
OptEIA™ mouse IL-12 (p70) Set 
OptEIA™ mouse TNF-a Set 
2.9 Proteins, peptides, and tetramers 
H-2L d _ TPHPARIGL tetramer, R-PE-conjugated 
ovalbumin, FITC-conjugated 
TPHPARIGL, ~-gal peptide 876-884 
YPHFMPTNL, MCMV pp89 peptide 168-176 
2.10 Enzymes, including kits for molecular biology 
Eco RV, 20,000 U/ml + NEBuffer 3 + BSA, 10 mg/ml 
Platinum Taq + 10x PCR buffer + 25 mM MgCI2 
proteinase K 
QIAquick Gel Extraction Kit 
REDTaqTM DNA Polymerase 
+ 10x REDTaq PCR buffer 
RNeasy Mini Kit 
SuperScript™ II RNase H- Reverse Transcriptase 
SuperScript™ Choice System for cDNA Synthesis 
T 4 polynucleotide kinase 
Xho I, 20,000 U/ml + NEBuffer 2 + BSA, 10 mg/ml 
company or reference 
BD PharMingen, Hamburg (0) 
BD PharMingen, Hamburg (0) 
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NIAID Tetramer Facility and NIH AIDS 
Research and Reference Reagent 
Program, Bethesda (USA) 
Molecular Probes, Leiden (NL) 
Gavin et al. 1993 
Reddehase et al. 1989 
New England Biolabs GmbH, 
SchwalbachlTaunus (0) 
Life Technologies, Karlsruhe (D) 
Roche Molecular Biochemicals, 
Mannheim (0) 
Qiagen GmBH, Hilden (0) 
Sigma, Oeisenhofen (O) 
Qiagen GmBH, Hilden (D) 
Life Technologies, Karlsruhe (0) 
Life Technologies, Karlsruhe (0) 
MBI Fermentas, St. Leon-Rot (D) 
New England Biolabs GmbH, 
SchwalbachlTaunus (0) 
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company or reference 
2.11 PeR-primers, nucleotides, oligonucleotides, and plasm ids 
[y-32p]_ATP 
100 bp DNA ladder 
dNTP,10 mM 
Oynabeads® Oligo (dThs 
A. DNA/Eco 911 (Bst Ell) Marker 
oligo (dT)18 and other oligonucleotides 
pCMVP 
PCR-primers 
riboATP 
2.12 Additional software 
Axiovision 3.0 
CELLQuest 
KS ELiSPOT 
Amersham Pharmacia Biotec, 
Freiburg (D) 
Life Technologies, Karlsruhe (D) 
Amersham Pharmacia Biotec, 
Freiburg (D) 
Oynal, Hamburg (D) 
MBI Fermentas, St. Leon-Rot (D) 
Life Technologies, Karlsruhe (D) 
Clontech, Heidelberg (D) 
Life Technologies, Karlsruhe (D) 
Roche Molecular Biochemicals, 
Mannheim (D) 
Carl Zeiss, Gottingen (D) 
BO Biosciences, Heidelberg (D) 
Carl Zeiss, Gottingen (D) 
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Methods 
3.1 Cell culture 
3.1.1 Cell culture conditions 
RPMI media 
coml2lete minimal nutrient 
RPMI1640 
FCS 5 % (v/v) + 
~-mercaptoethanol 0.05 mM + + 
L-Glutamine 2 mM + 
HEPES 10 mM + + 
penicillin 50 IU/ml + + 
streptomycin 50 Ilg/ml + + 
Passaging of cells occurs under sterile conditions in a laminar flow. All cell culture incubations are 
carried out at 3JOC, 5% CO2 and 96% humidity. Centrifugation steps during cell handling are for 5 
minutes at 250 x g unless indicated otherwise. 
Foetal calf serum (FCS) is heat-inactivated by a one-hour incubation at 56°C. 
Eb-derived cell lines, including the ESbL-Gal-variants, as well as P815, P815-Gal, and Ag8653 are 
incubated in complete RPMI with 3 passages per week. The adherent lines P815, P815-Gal, and 
Ag8653 are mechanically detached using a cell scraper. 
With the ~-galactosidase (~-gal) expressing cell lines ESbL-Gal, the variants thereof, and P815-Gal, 
G418 is applied at 500 Ilg/ml during the first passage. This selective agent is toxic to both 
prokaryotic and eukaryotic cells, unless they contain the neomycin resistance gene neo. In ESbL-
Gal and P815-Gal the neo gene was introduced together with the lacZ gene, which codes for ~-gal. 
3.1.2 Freezing and thawing of cells 
Ag8653 and primary dendritic cells (DCs, 3.1.9.2) are washed once and taken up in X-vivo 20 
medium, containing 10 % DMSO, while all other cells are taken up in RPMI with 40 % FCS and 
10 % DMSO. Cells are transferred to cryogenic vials in a total volume of 1 ml at a concentration of 
2 x 106 - 1 X 107 cells before freezing them at -70°C. 24 hours later, the vials are transferred to a 
liquid nitrogen tank. 
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Cells are thawed with pre-warmed medium, diluted 1 :20 and spun down by centrifugation. The 
pellet is taken up in fresh medium and given to a medium-sized tissue culture flask. 
3.1.3 Determination of viable cell numbers by trypan blue exclusion 
Twan blue staining solution 
ddH20 with 
trypan blue 
NaCI 
0.16 % (w/v) 
0.90 % (w/v) 
Trypan blue is used to differentiate viable from non-viable cells, due to its property to pass through 
holes which open up in the plasma membrane of dead cells, while remaining excluded from live 
cells. 
For cell counting, a cell sample is mixed with trypan blue staining solution at a desired dilution factor 
and allowed to fill a Neubauer chamber (haemacytometer) by capillary action. The unstained cells 
are counted in 4 large corner squares and the cellular concentration calculated using the following 
formula: 
cells I ml = average cell count per square x dilution factor x 104 
Overall cell viability of a cell sample is calculated as follows: 
% cells viability = total viable cells (unstained) + total cells (stained + unstained) x 100 
3.1.4 Preparation of cell Iysates 
1 x 106 ESbL-Gal/ml phosphate buffered saline (PBS) are lysed by repetitively freezing at ·198°C in 
liquid N2 and thawing at r/t. The sample is centrifuged for 10 minutes at 2000 x g and the soluble 
lysate obtained is stored at -20°C until use. 
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3.1.5 Isolation of cells from murine lymphoid organs 
For pathological analyses or isolation of cells or organs, experimental animals are killed with CO2, 
3.1.5.1 Preparing a single cell suspension from murine bone marrow 
Femurs and tibiae are removed from experimental mice and excess muscle tissue is removed 
mechanically with the help of paper towels. Both ends of the bones are cut off with a scalpel so that 
the bone marrow plugs can be flushed out with cold PBS, using a syringe with a 27 gauge needle. A 
single cell suspension is obtained by vigorous pipetting with a 1 ml Pasteur pipette. The resulting 
suspension is washed once with cold PBS before use. Where needed, lysis of erythrocytes is 
carried out (see 3.1.10). 
3.1.5.2 Preparing a single cell suspension from murine spleen 
All excess connective tissue is removed from isolated spleens with the help of forceps. The spleens 
are then placed into a folded 60 11m gauze inside a 60 mm Petri dish containing 3 ml PBS. A sterile 
plunger from a 2 ml syringe is used to crush the organ, thereby producing a single cell suspension. 
In order to extract a maximum number of splenocytes, the gauze is rinsed twice with fresh PBS. 
The cells are pelleted by centrifugation in a 15 ml centrifugal tube, the supernatant is discarded, and 
erythrocytes are lysed as described under 3.1.10. 
3.1.5.3 Preparing a single cell suspension from murine lymph nodes and thymus 
The preparation method is analogous to that described for spleens, except that erythrocyte lysis is 
not required. A single washing step is sufficient after dissociation of the organs. 
3.1.5.4 Isolation of peripheral blood leukocytes 
Heparin buffer 
PBS with 
heparin 
FCS 
sodium azide 
50.0 I.E.lml 
2.0 % (v/v) 
0.1 % (v/v) 
For the isolation of peripheral blood lymphocytes (PBL) from freshly killed animals, blood is isolated 
by puncturing the heart with a syringe and 27 gauge needle, while with live animals, blood is 
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obtained from the eye vein with the help of a glass capillary. In both cases, the blood is mixed well 
with 200 III of heparin buffer in a 1.5 ml Eppendorf tube, and then pipetted into a 10 x 50 mm glass 
tube containing 1 ml Ficoll. After a 20 minute centrifugation step at 900 x g without brake, the PBl-
containing interphase is pipetted off and washed once in PBS. 
3.1.5.5 Harvesting anti-ESbL-Gal immune peritoneal exudate cells (iPEC) 
For the production of anti-ESbl-Gal immune PEG, naNe DBN2 mice are primed with 5 x 104 ESbl-
Gal Le. (in the ear pinna) and restimulated on d7 with 1 x 107 100 Gy irradiated ESbl-Gal i.p. 
(intraperitoneally, see 3.2.2) (Schirrmacher et al. 1991). 3 days after the second tumour inoculation, 
the animals are killed and the fur removed from the abdomen. PEG are isolated by thoroughly 
flushing the peritoneal cavity with 10 ml ice-cold, sterile PBS using a 10 ml syringe and 20 gauge 
needle. The cells are washed once with sterile PBS and are ready for use. The cells obtained thus 
will be referred to as d3 iPEC. 
For the isolation of anti-ESbl-Gal specific memory cells from DBN2 or Balb/c nu/nu mice, the 
animals are restimulated with 1 x 107 100 Gy irradiated ESbl-Gal Lp. after a minimum of 30 days 
post primary tumour inoculation (and ADI, in the case of Balb/c nu/nu mice). Again, PEC are 
isolated 3 days later. The cells obtained in this way will be referred to as mPEC (memory PEG). 
3.1.6 Short-term cultures of immune cells for the production of culture supernatants 
PEC are isolated from ESbl-Gal-primed and Lp. restimulated DBN2 mice, washed twice in pre-
warmed complete RPMI and taken up in fresh medium at a concentration of 2 x 106 cells/ml. They 
are then plated out in a sterile, round-bottomed 96-well plate at 200 Ill/well and incubated under 
standard tissue culture conditions. After 24 hours, the plates are centrifuged for 3 minutes at 
160 x g, and the supernatants are transferred to 0.5 ml Eppendorf tubes. These are stored at -20°C 
until use. 
3.1.7 Isolation of dormant ESbL-Gal from the bone marrow 
6 weeks after priming DBN2 mice with 5 x 104 ESbl-Gal Le. a single cell suspension is prepared 
from the bone marrow as described under 3.1.5.1. The cells are washed twice in pre-warmed, pure 
RPMI 1640, taken up in 30 ml minimal nutrient medium supplemented with 10 Ilg/ml gentamycin, 
and given to a medium-sized tissue culture flask. This is placed in a 37°C incubator in an upright 
position in order to prevent the growth of adherent cells (e.g. macrophages). After 2 days of culture, 
500 Ilg/ml G418 are added to select for ~-gal expressing cells. Another 2 days later, the culture 
medium is changed to complete medium, and the cells are allowed to expand for 2-3 weeks 
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undisturbed. Cytospins are prepared as described under 3.6.1 for determination of ~-gal expression 
intensity by X-gal staining (see 3.6.2). 
3.1.8 Isolation of ESbL-Gal-variants from solid tumours 
Solid tumours are excised under sterile conditions, rinsed twice with sterile PBS and a -6 mm3 
fragment of each tumour is placed in a separate 20 x 150 mm Petri dish containing 20 ml minimal 
nutrient medium supplemented with 10 /lg/ml gentamycin. Using a sterile scalpel, the tumour 
fragment is chopped into small pieces in order to enable the release of tumour cells. into the 
medium. After two days of culture under standard cell culture conditions, the tumour fragments are 
removed and the cells washed once, taken up in 20 ml minimal nutrient medium containing 500 
/lg/ml G418, and transferred to a medium-sized tissue culture flask. Another 2 days later, the 
culture medium is changed to complete medium, and the cells are allowed to expand for 10 days 
undisturbed. Cytospins are prepared as described under 3.6.1 for determination of ~-gal expression 
intensity by X-gal staining (see 3.6.2). 
3.1.9 Preparing dendritic cells for antigen presenting functions 
3.1.9.1 Production of GM-CSF containing cell culture supernatant 
The GM-CSF producing cell line Ag8653 is cultured in X-vivo 20 medium. Twice a week, the culture 
supernatant is collected and cells are passaged. The GM-CSF containing supernatant is tested for 
effectiveness in stimulating outgrowth of DCs (see 3.1.9.2) from murine bone marrow against a 
supernatant of known effectiveness. 
3.1.9.2 Growth of dendritic cells from naIve bone marrow 
Myeloid-lineage Des are grown from the bone marrow of na"lve DBAl2 mice following a slightly 
altered version of the protocol proposed by Lutz et al. 1999. Briefly, bone marrow is isolated under 
sterile conditions as described in 3.1.5.1, and seeded at 2 x 106 cells/Petri dish (10 cm, 
bacteriological quality) in 10 ml X-vivo 20 medium containing 10 % GM-CSF supernatant (see 
3.1.9.1). After 3 days of culture under standard tissue culture conditions another 10 ml medium, 
10 % GM-CSF are added. At day 6 and day 8 of culture, 10 ml of the culture are collected in a 15 ml 
centrifugal tube. The cells are pelleted by centrifugation, the supernatant discarded, and the cells 
are re-suspended in 10 ml medium, 10 % GM-CSF (5 % GM-CSF on day 8 in order to prevent 
maturation of growing DCs) and transferred back to the culture dish. Immature DCs are harvested 
on day 10 - 11 of culture by aspiration of the non-adherent fraction and gently flushing the dish with 
fresh medium. Adherent cells remaining in the culture dish are mainly macrophages and fibroblasts. 
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Samples of the collected cells are tested by FACS analysis for their ability to macropinocytose 
antigen (a property of immature but not of mature DCs) (see 3.1.9.3), as well as for expression of 
CD11c and MHC class II (see 3.4.1.1). 
3.1.9.3 Loading dendritic cells with antigen 
In order to determine the maturation stage of DCs cultured under the above conditions (3.1.9.2), 
1 x 106 cells are incubated with 0.5 mg/ml FITC-conjugated ovalbumin (OVA-FITC) in FACS buffer 
(see 3.4.1.1) for 15 minutes at 37°C. A control sample is incubated at 4°C. Both are washed three 
times, and taken up in 100 III FACS buffer. The mean fluorescence intensity as determined by 
FACS analysis reflects uptake of the soluble OVA-FITC (Merkenschlager et al. 1999). 
For Ag-presentation purposes, DCs are seeded out in a 6-well plate at a concentration of 1 x 106 in 
X-vivo 20 medium and co-cultured o/n under cell culture conditions with 0.2 I1g peptide/ml. The cells 
are washed twice with fresh medium, and the Ag-pulsed DCs are ready for T-cell stimulation in an 
ELiSPOT assay (3.5.2). 
3.1.10 Red blood cell lysis 
Erythrocyte lysis buffer 
ddH20 with 
NH4CI 
KHC03 
Na2EDTA 
O.15M 
1.00M 
O.10mM 
pH 7.2-7.4; sterile filter; store at 4°C 
For the lysis of erythrocytes in ex vivo isolated single cell suspensions, pelletted cells are taken up 
in erythrocyte lysis buffer (-1 ml/108 cells, depending on the erythrocyte content in the sample). 
Atter a 1 minute incubation at r/t the cells are washed twice in medium or PBS. 
3.2 Animal experiments 
3.2.1 Holding conditions for experimental animals 
All animal experiments are carried out under controlled specific pathogen free (SPF) conditions. 
DBN2 and CD1 Swiss nu/nu mice are held in the central animal facilities of the DKFZ, 'barrier IV', 
while Balb/c nu/nu mice are housed in isolators. 
Methods 34 
3.2.2 Inoculations and anaesthesia 
Cells or DNA are taken up in sterile PBS and injected using a 1 ml syringe and a 27 gauge needle. 
The inoculation volume for injections in the ear pinna (Le.) and intradermally (Ld.) in the shaved 
flank is 50,.11. while for intravenous (Lv .• in the lateral tail vein) injections it is 100 ,.tI. Intraperitoneal 
(Lp.) tumour challenges are administered with a 10 ml syringe and 25 gauge needle in an 
inoculation volume of 1 ml. 
Anaesthetic (R/K) 
rompun (muscle relaxant) 
ketanest (general anaesthetic) 
PBS 
20 % (v/v) 
20 % (v/v) 
60 % (v/v) 
Animals are anaesthetised by injection of 100 JlI RlK i.p. 
3.2.3 Isolation of normal mouse serum 
For the isolation of normal mouse serum (NMS). na"ive DBAl2 mice are killed and their blood is 
isolated by puncturing the heart with a syringe and 27 gauge needle. The blood is transferred to 
1.5 ml Eppendorf tubes and incubated for 2 hours at room temperature before a 5 minute 
centrifugation at 2200 x g. The serum is removed. aliquoted. and frozen at -20°C until use. 
3.2.4 Whole-body irradiation 
Prior to tumour inoculation. Balb/c nu/nu mice receive sub-lethal whole-body irradiation at a dose of 
4.5 Gy from a C060 source. 
3.2.5 Therapy model 
Whole-body irradiated (d-1) Balb/c nu/nu mice are tumour-inoculated with 1 x 105 ESbL-Gal i.v. 
(dO). Adoptive immunotransfer (ADI) occurs on d1 by injection of 1 x 107 d3 iPEC (see 3.1.5.5) i.v .• 
while negative control animals remain without ADI treatment. 
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3.2.6 Delayed-type hypersensitivity (DTH) reaction 
Ear pinna immunised mice were challenged with 50 III ESbL-Gal lysate (3.1.4) in the contralateral 
ear pinna. and the DTH-reaction was evaluated 2 days later by classification of redness and 
swelling of the ear as previously described (Schirrmacher et al. 1994c). Table 3.1 summarises the 
grading system used for evaluation. 
grade 0 
grade 1 
grade 2 
grade 3 
erythema 
no 
yes 
yes 
yes 
swelling 
no 
no 
<0.5 mm 
>0.5 mm 
Table 3.1 Grading system for evaluation of DTH-reactions 
in the ear pinna. 
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3.3 Molecular biology 
3.3.1 Large-scale pCMV~ DNA preparation 
pCMV~ is a mammalian expression vector designed for high level expression of ~-gal in 
mammalian cells. Alongside the full-length Escherichia coli (E. coli) ~-galactosidase gene lacZ with 
eukaryotic translation initiation signals, the pCMV~ plasmid carries a polyadenylation signal from 
SV40 (Simian Virus 40) as well as the ampicillin resistance gene Amp'. 
Hind III 
(4531) 
Fig. 3.1 
Not I 
(4294) 
EcoRI 
(2) 
pCMV~ 
7.2 kb 
The pCMV~ plasmid. 
3.3.1.1 Expansion of bacterial cultures 
Luria-Bertani (LB) medium 
ddH20 with 
bacto-tryptone 
bacto-yeast extract 
NaCI 
1.0 % (w/v) 
0.5 % (w/v) 
1.0 % (w/v) 
Xho I (641) 
Not I (820) 
EcoRV 
(2070) 
The solutes are dissolved completely using a magnetic stirring apparatus before correcting the pH 
to 7.0 with 5N NaOH. The volume is adjusted to 1 litre with ddH20 , and the solution is sterilised by 
autoclaving for 20 minutes at 15 Ib/in2 on liquid cycle. LB-medium is stored at 4°C until use. 
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DH5a competent cells are an Escherichia coli (E. coli) line which can efficiently be transformed with 
large plasm ids. pCMV13-transformed DH5a cells were obtained from Dr. K. Chlichlia who had 
carried out the transformation according to the manufacturer's instructions. 
pCMV~-transformed DH5a cells are stored in LB medium, 15 % glycerol at -189°C. To recover 
bacteria for culture, the frozen surface of an aliquot is scraped with a sterile inoculation loop. The 
bacteria are inoculated into 250 ml LB medium containing 100 /-lg/ml ampicillin, and incubated oln at 
3rC under shaking at 250-300 rpm in a 500 ml Erlenmeyer flask covered with aluminium foil. 
3.3.1.2 DNA-isolation 
Qiagen Endofree Plasmid Maxi Kit 
Buffers: P1 - resuspension buffer 
P2 - lysis buffer 
P3 - neutralisation buffer 
ER - endotoxin removal buffer 
QBT - equilibration buffer 
OC - washing buffer 
ON - elution buffer 
TE - Tris-EDT A containing buffer 
The bacterial cultures are transferred to 500 ml centrifugal tubes and centrifuged for 10 minutes at 
6000 x g. The supernatant is discarded, while the pellet is resuspended in 10 ml ice-cold P1 buffer, 
containing RNase A, and transferred to a 50 ml centrifugal tube. The probe is removed from the ice 
before adding 10 ml P2 lysis buffer containing SDS and NaOH. The probe is mixed by repeatedly 
inverting the tube. After an incubation step of 5 minutes at rlt, 10 ml ice-cold P3 buffer is added. 
The sample is mixed immediately. The outlet nozzle of a QIAfilter column (contained in the kit) is 
blocked with a cap before giving the lysate onto the column. Following a 10 minute incubation at rlt, 
the cap is removed and the lysate it gently filtered into a 50 ml collection tube. 2.5 ml ER buffer is 
added to the flow-through. The sample is mixed by inverting, and incubated for 30 minutes on ice. 
A OIAGEN-tip 500 (supplied in the kit) is equilibrated by applying 10 ml OBT buffer and allowing the 
column to empty into a tub by gravity flow. The filtered lysate is given onto the OIAGEN-tip and 
allowed to enter the resin by gravity flow. The column is washed twice with 30 ml OC buffer before 
eluting the DNA into a 15 ml centrifugal tube with 15 ml ON buffer. The DNA is precipitated with 
10.5 ml isopropanol, and the sample is centrifuged for 30 minutes at 15.000 x g at 4°C. The 
supernatant is decanted and the DNA-pellet is washed with 5 ml endotoxin-free 70 % ethanol p.a .. 
The sample is centrifuged for another 10 minutes at 15.000 x g at 4°C, and the supernatant 
discarded. The pellet is air-dried for 5-10 minutes before redissolving the DNA in 350 /-ll endotoxin-
free TE buffer. 
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Optical density (00) of a diluted sample is measured at 260 nm using a spectrophotometer, and 
the DNA-content of the solution is calculated using the following formula : 
00260 nm X 0.05 x dilution factor = fl9/fll DNA 
3.3.2 pCMV~ digestion with Xho I and Eco RV 
The purified pCMV~ DNA is cleaved using specific restriction endonucleases in order to determine 
whether the plasmid is intact and has not lost the lacZ insert. Cleavage with Xho I should occur after 
base pair 641 , while Eco RV should cut after base pair 2070, yielding fragments of 1429 bp and 
5771 bp (see Fig . 3.1 pCMV~ plasmid) . 
10 units Xho I, 10 units Eco RV, 2 III 10x NEBuffer 2 as well as 0.2 Ilg BSA are added to 1.0 pg 
pCMV~ and the mixture is filled up to a total volume of 20 III with ddH20 . After incubating the 
sample for 1 hat 37DC, the restriction reaction is terminated by a 20 minute incubation step at 80DC. 
The result is analysed by gel electrophoresis as described under 3.3.7, using an 0.8 % agarose gel. 
A B 
5' ... ClTCGAG ... 3' 5' ... GATJATC .. . 3' 
3' .. . GAGCTJC .. . 5' 3' ... CTAJTAG ... 5' 
Fig. 3,2 Recognition sequences and cleavage sites (J) of the restriction 
endonucleases Xho I (A) and Eco RV (8). 
Methods 39 
3.3.3 RNA-isolation 
3.3.3.1 Isolation of total RNA from murine cells 
RNeasy Mini Kit 
Buffers: RL T - lysis buffer for tissues and cells 
RW1 - washing buffer 
RPE - ethanol containing buffer 
For isolation of total RNA from 5 x 106 to 1 x 107 suspension cells, the cells are pelleted by 
centrifugation, and resuspended in 600 ~I RL T lysis buffer containing 1 % ~-mercaptoethanol (v/v). 
The lysate is homogenised by applying it onto a QIAshredder column sitting in a 2.0 ml collection 
tube, and centrifuging it for 2 minutes at 15.000 x g. 600 ~I 70 % ethanol p.a. is added to the 
homogenised lysate, which is then applied to an RNeasy mini spin column sitting in a 2.0 ml 
collection tube. To bind the RNA in the filter, the probe is centrifuged for 15 seconds at 8.000 x g, 
and the flow-through is discarded. The filter column is washed, first with 700 ~I RW1 buffer, then 
with 500 ~I RPE buffer. For a final washing step. 500 ,.d RPE buffer are given onto the filter, and the 
column is centrifuged for 2 minutes at 15.000 x g. The column is placed in a fresh 1.5 ml collection 
tube, 30 ~I RNase-free H20 are given directly onto the filter membrane, and the sample is 
centrifuged for 1 minute at 8.000 x g. 
The flow-through contains the eluted RNA. Optical density (OD) of a diluted sample is measured at 
260 nm using a spectrophotometer, and the RNA-content of the solution is calculated using the 
following formula: 
OD260 nm X 0.04 x dilution factor = ~g/~I RNA 
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3.3.3.2 Isolation of mRNA from small cell numbers 
Oynabeads Oligo (dTh5 
Binding buffer 
ddH20 with 
Tris-HCI, pH 7.5 100 mM 
LiCI 500 mM 
EOTA, pH B.O 10 mM 
OTT 5 mM 
SDS 1 % (v/v) 
NP-40 I~sis buffer 
Tris-HCI, pH 7.5, with 
NP-40 1.0 % (v/v) 
NaCI 0.14 M 
KCI 5.0 mM 
Washing buffer 1 
ddH20 with 
Tris-HCI, pH 7.5 10 mM 
LiCI 150 mM 
EDTA 1 mM 
SDS 0.2 % (v/v) 
Washing buffer 2 
= washing buffer 1 without SDS 
For mRNA-isolation from small cell numbers (:s; 1.0 x 106 cells) the following protocol is applied: 
250 Ilg Oligo (dT)25 Dynabeads I 1 x 106 cells are transferred to a clean 1.5 ml Eppendorf tube, 
which is then placed in an MPC-E-1 magnet stand. When the solution is clear, the supernatant is 
removed, and the tube is removed from the magnet stand. The magnetic beads are then taken up 
in 200 III binding buffer. 
Cells are pelleted by centrifugation, resuspended in 100 III NP-40 lysis buffer, and placed on ice for 
1 minute. The sample is centrifuged for 30 seconds at 13,000 Xg. 
Pre-conditioned Oligo (dThs Dynabeads are placed on the magnet stand, the supernatant is 
removed, and beads are taken up in 100 III binding buffer after removing the tube from the magnet. 
The cell lysate is added and annealing is carried out under rotation for 5 minutes at room 
temperature. The sample is washed twice with 200 III washing buffer 1 and twice with 350 III 
washing buffer 2 before taking up the bead-coupled mRNA in 30 III H20-DEPC. 
The mRNA can directly be used for cDNA-synthesis in the solid phase, i.e. coupled to the beads. 
Methods 41 
3.3.4 RNA- and DNA-precipitation 
2 volumes ice-cold 100 % ethanol p.a., one tenth of a volume 3 M sodium acetate (pH 5.5), as well 
as 1 III glycogen are added to the RNA or DNA sample and incubated oln (minimum 1 hour) at 
_20DC. The mixture is centrifuged for 1 hour at 15,000 x g in a 4DC cold desk-top centrifuge, the 
liquid decanted and any remaining ethanol allowed to evaporate. The RNA or DNA is taken up in 
300 III ice-cold 70 % ethanol p.a. and pelleted by a 10 minute centrifugation step at 15,000 x g at 
4°e. The liquid is again decanted and remaining ethanol allowed to evaporate. The RNA or DNA is 
then taken up in a desired amount of H20-DEPe. 
3.3.5 cDNA-synthesis 
3.3.5.1 Synthesis of single-stranded cDNA (S5 eDNA) 
SuperScript II 
H20-DEPC 
ddH20 
DEPC 
1 I 
1 ml 
0.5 Ilg oligo (dT)12-18 is added to 1 Ilg RNA, which is adjusted to a total volume of 12 III with H20-
DEPC in an 0.5 ml Eppendorf tube. The mixture is heated for 10 minutes at 70DC, then quick-chilled 
on ice and briefly centrifuged. 4 III 5x First Strand Buffer, 2 III 0.1 OTT as well as 1 III 10 mM dNTP 
mix are added. After 2 minutes incubation at 42De, 1 III SuperScript II is given to the solution, and 
the incubation is continued for another 50 minutes. In order to inactivate the reverse transcriptase 
and thus terminate cDNA-synthesis, the temperature is raised to 70De for 10 minutes. 
The ss cDNA is ready for use in a polymerase chain reaction (PCR). 
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3.3.5.2 Preparation of circularised, double-stranded eDNA (ds eDNA) 
SuperScript™ Choice System for cDNA Synthesis 
The following mixture is incubated for 2 hours at 16°C: 
18 III first strand cDNA, -1 mg (synthesised as described under 3.3.5.1) 
93 III H20-DEPC 
30 III 5x Second Strand Buffer 
3 III 10 mM dNTP Mix 
1 III E. coli DNA ligase (10 units/ill) 
4111 E. coli DNA polymerase I (10 unitshd) 
1 III E. coli RNase H (2 units/ill) 
2 III T4 DNA polymerase (5 units/ill) is added to produce blunt ends, and the incubation is extended 
for another 5 minutes, before terminating the reaction by quick-chilling on ice. The DNA is purified 
by adding 10 1110.5 M EDTA, as well as 150 III phenol: chloroform: isoamyl alcohol (25:24:1). After 
a 5 minute centrifugation at 14,000 x g at r/t, 140 III of the upper, aqueous layer is transferred to a 
sterile 1.5 ml reaction tube. The DNA is precipitated as described in 3.3.4, and taken up in 40 ml 
H20-DEPC. 
For circularisation, the 40 III ds cDNA, 5 III 10x circularisation buffer, and 5 III T4 DNA ligase C3 
(1 U/IlI) are mixed and incubated oln at rlt. A 15 minute incubation at 68°C terminates the reaction. 
The ds cDNA is kept on ice until use in PCR. 
10x circularisation buffer 
ddH20 with 
Tris, pH 7.5 
MgCI2 
0.1 DTT 
riboATP 
500mM 
100 mM 
10mM 
5mM 
3.3.6 polymerase chain reaction (PCR) 
3.3.6.1 Conventional PCR 
1.0 Ilg ss cDNA is given to a mixture of 5 III 10x REDTaq PCR buffer, 200 11M dNTP, 250 pmol 
sense primer, and 250 pmol antisense primer. H20-DEPC is added to a total volume of 47.5 Ill. 
After a hot start of 5 minutes at 95°C, 2.5 III REDTaq DNA polymerase (= 2.5 units) are added per 
PCR probe. PCR amplification is carried out with 30 cycles of 95°C (30 seconds), varying annealing 
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temperatures as indicated in Table 3.2 (30 seconds), and 72°C (SO seconds). The PCR reaction is 
terminated by incubating the probes for 10 minutes at 72e C. 
annealing 
primer seguence S' ---+ 3' temperature reference 
V~1 CTG M T GCC CAG ACA GCT CCA AGC 5SoC Pannetier et al. 1993 
V~2 TCA CTG AT A CGG AGC TGA GGC SO°C Pannetier et al. 1993 
V~4 GCC TCA AGT CGC TTC CM CCT C SO°C Pannetier et al. 1993 
V~5.1 CAT TAT GAT AAA ATG GAG AGA GAT 55°C Pannetier et al. 1993 
V~5.2 MG GTG GAG AGA GAC AAA GGA TTC 55°C Pannetier et al. 1993 
V~8.1 CAT TAC TCA TAT GTC GCT GAC 5SoC Pannetier et al. 1993 
V~8.2 CAT TAT TCA TAT GT GCT GGC 55°C Pannetier et al. 1993 
V~8.3 TGC TGG CM CCT TCG M r AGG A SO°C Pannetier et al. 1993 
V~10 ATC MG TCT GTA GAG CCG GAG GA SO°C Pannetier et al. 1993 
V~13 AGG CCT AAA GGA ACT MC TCC CAC SO°C Pannetier et al. 1993 
V~14 ACG ACC M T TCA TCC T M GCA C 55°C Pannetier et al. 1993 
V~15 CCC ATC AGT CAT CCC MC TTA TCC 56°C Pannetier et al. 1993 
V~1S CAC TCT GM M T CCA ACC CAC 56°C Pannetier et al. 1993 
V~18 CAG CCG GCC AAA CCT MC ATT CTC 5Sec Pannetier et al. 1993 
V~20 TCT GCA GCC TGG GAA TCA GAA 5SoC Pannetier et al. 1993 
Cn CTT GGG TGG AGT CAC ATT TCT variable Abu-Hadid et al. 1996 
~-actin A T M MC GCA GCT CAG T M CAG TCC G 54-S1°C Klein et al. 1998 
~-actin S TGG M T CCT GTG GCA TCC ATG AAA C 54-S1°C Klein et al. 1998 
Table 3.2 PCR-primer sequences and their annealing temperatures. All V~-primers are 
sense primers used in conjunction with the antisense primer Cn which binds in the constant region 
gene of the TCR, TCR-C~. The size of the amplified TCR-V~ chain products is variable, depending 
on the TCR-D~ (diversity region) and TCR-J~ Uoining region) usage by individual TCRs, while the 
~-actin product is 349 bp. All primers where designed for the murine system. A: antisense; 
S: sense. 
3.3.6.2 Inverse PCR (iPCR) 
1.0 mg double-stranded circularised cDNA is mixed with 5 ml 10x PCR buffer II, 1.5 ml 25 mM 
MgCI2 solution, 400 IlM dNTP, 250 pmol Cn-primer, and 250 pmol BCS-primer. H20-DEPC is added 
to a total volume of 49.5 ml. After a hot start of 10 minutes at 95°C, 0.5 ml Platinum Taq DNA 
polymerase (= 2.5 units) are added, and the PCR reaction is carried out with 40 cycles of 95°C 
(30 seconds), 53°C (30 seconds) and 72°C (SO seconds). The reaction is terminated by incubating 
the probes for 10 minutes at 72°C. 
Methods 
vp op JP cp 
ds eDNA ~ blunl end liga,;on 
5' antisense primer ... 
! PCR-amplificaUon 
Fig. 3.3 Schematic representation of the iPCR method. RNA is used as a 
template to produce double-stranded (ds) cDNA. T4 DNA ligase then catalyses blunt 
end ligation. The resulting circular ds-cDNA is used as the substrate for PCR 
amplification . This method allows the amplification of unknown sequences, as primers 
lie in regions flanking the sequence(s) of interest, as well as the amplification of 
multiple sequences in a single PCR reaction . In this case, the primers were chosen to 
lie within the constant domain of the TCR-~ chain (TCR-C~) . 
Reaction products are separated on a 1 % agarose gel , southern blotted onto a nylon 
membrane and made visible by hybridisation with radioactively labelled TCR-V~ chain 
specific probes. 
Adapted from Weber-Arden et al. 1996. 
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The sense primer BCS (S'-TGG CCA GAG AGC TCA CCC-3') was chosen to lie towards the 3'-end 
of exon 1 of the TCR-C~ region . Its binding efficiency and optimal annealing temperature were 
tested in conventional PCR in conjunction with the antisense primer UTA (S'-CTA TGC GTG ACT 
AGT AGG-3'), the recognition sequence of which is located in the untranslated region . The 
antisense primer Cn (see Table 3.2) anneals towards the S'-end of the TCR-C~ region , and was 
tested against the TCR-V~8 sense primer BV8 (S'-TAC TGG TAT CGG CAG GAC-3') in 
conventional PCR. 
Methods 
3.3.7 Gel electrophoresis 
TAE-buffer 
ddH20 with 
Tris 
glacial acetic acid 
EDTA 
pH 7.5 - 8.0 
0.48 % (w/v) 
0.12 % (v/v) 
1 mM 
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TAE buffer containing 0.8 % agarose (w/v) for pCMV~ digests, 1 % agarose (w/v) for iPCR probes, 
or 2 % agarose (w/v) for conventional PCR probes is brought to the boil by heating it in a microwave 
until the agarose is completely dissolved. Before pouring the gel, 1 III ethidium bromide (10 mg/ml) 
per 30 ml agarose is added. The gel is left to polymerise. 
Results from enzyme restriction experiments, or RNA- and PCR-probes, as well as molecular 
weight markers are mixed with 6x loading buffer and loaded into the pockets. Where RedTaq DNA 
polymerase was used for PCR amplification reactions, addition of loading buffer is not required, as 
the DNA polymerase mix already contains a loading dye. 
Size fractionation is carried out at 100 V for 35' in an electrophoresis chamber, and results are 
documented by photography, using an ultraviolet (UV) lamp (254 nm) to visualise DNA-bound 
ethidium bromide. 
3.3.8 DNA-extraction from an agarose gel 
QIAquick Gel Extraction Kit 
Buffers: QG - removes residual agarose 
PE - ethanol containing buffer 
All centrifugation steps are carried out for 1 minute at 10,000 x g. 
The protocol proposed by the manufacturer is followed. Briefly, the DNA is visualised using a UV-
lamp (366 nm) and the DNA-fragment of interest (max. weight = 400 mg) is excised from the 
agarose gel by use of a scalpel. For 2 % agarose gels, 3 volumes of buffer QG are added to one 
volume of gel. During a 10 minute incubation period at 50°C the probes are vortexed every 2-3 
minutes. It is mandatory that the solution has changed colour to yellow (~pH 7.5) before adding one 
volume of isopropanol. If instead the solution is orange or violet, 10 III 3M sodium acetate (pH 5.0) 
are added before continuing with the protocol. After isopropanol has been added, the sample is 
applied to a QIAquick spin column placed in a 2.0 ml collection tube and centrifuged. The flow-
through is discarded and 500 III buffer QG are given onto the filter membrane of the spin column 
before centrifuging. The flow-through is again removed and 750 III PE buffer are given onto the filter 
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membrane. After soaking for S minutes, the sample is again centrifuged. The flow-through is 
discarded and the QIAquick spin column centrifuged anew before placing it into a clean 1.5 ml 
Eppendorf tube. For DNA elution, 30 III ddH20 are pi petted onto the membrane. After 1 minute, the 
sample is centrifuged and the column discarded. 
3.3.9 Southern blot and hybridisation 
3.3.9.1 Southern blot 
Denaturation buffer 
ddH20 with 
NaOH 
NaCI 
O.SM 
1.S M 
iPCR products are separated by gel electrophoresis as described in section 3.3.7. Under UV-light 
(366 nm), nicks are cut into the gel to indicate locations of DNA-size markers, before incubating the 
gel under gentle shaking for 45 minutes in denaturation buffer. Hybridisation transfer membrane as 
well as 3 sheets of gel-blotting paper (3 MM Whatman paper) are cut to an appropriate size and 
soaked in dH20 for at least S minutes. 2 extra sheets of gel blotting paper are left dry. 
The agarose gel is inverted and placed on a glass plate. The transfer membrane, the 3 soaked 
blotting papers, the 2 dry blotting papers, and a S cm stack of paper towels are subsequently 
layered onto the gel. The pile is wrapped air-tight with cling-film and weighed down with a weight 
placed onto another glass plate. 
DNA transfer from the gel to the membrane takes at least 1 hour. When the transfer is completed, 
markings are noted on the membrane before removing the gel. The DNA is then fixed to the 
membrane by UV-crosslinking using a Stratalinker. 
3.3.9.2 Radioactive 5'-end labelling of oligonucleotides 
10x reaction buffer 
ddH20 with 
Tris-HCI, pH 7.6 
MgCI2 
DTT 
spermidine 
EDTA 
SOOmM 
100 mM 
SOmM 
1 mM 
1 mM 
20 pmol oligonucleotides are admixed with 4 III 10x reaction buffer, 100 IlCi [y-32p]_ATP, and 10 U 
T 4 polynucleotide kinase. The mixture is filled up to a total volume of 40 III with H20-DEPC and 
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incubated at 3rC for 45 minutes. The reaction is terminated by incubating the sample for 
10 minutes at 70°C. 
STE buffer 
ddH20 with 
Tris-HCI (pH 7.5) 
NaCI 
EOTA 
20mM 
100mM 
10mM 
A NucTrap® probe purification column is prewet with 70 III STE buffer. 30 III 1 x STE are given to the 
radioactively labelled oligonucleotides before loading the sample onto the column. The probe is 
slowly forced through the column into a 1.5 ml collection tube using the plunger provided with the 
probe purification column. 70 III STE are loaded onto the column and flushed into the same 
collection tube. 
In order to test the success of [y-32p ]_ATP incorporation, 1 III of the probe is given onto a 1 cm2 
3 MM Whatman paper which is inserted into a pony vial. Radioactivity is determined by a Liquid 
Scintillation Analyser running a y_32p program. 
3.3.9.3 Hybridisation 
Church hybridisation buffer 
ddH20 with 
SOS 
BSA 
NaHP04 
EDTA 
Church washing buffer 
ddH20 with 
SDS 
NaHP04 
EDTA 
7 % (v/v) 
1 % (wlv) 
1 M 
1 mM 
1 % (v/v) 
40mM 
1 mM 
The Southern blot (3.3.9.1) is incubated in 15 ml Church hybridisation buffer for 15 minutes at 65°C. 
The buffer is discarded and replaced by 10 ml Church hybridisation buffer containing [y-32p]_ATP 
labelled oligonucleotides. After incubating the blot with the probe oln at 65°C under rotation, the 
membrane is washed 3x for 10 minutes in 100 ml pre-warmed (65°C) Church washing buffer. 
The membrane is briefly dried on the work bench before fastening it onto blotting paper with sticky 
tape, wrapping it in cling film, and exposing a BioMax MS-1 roentgen film at -70°C for varying time 
________ ~M~e~th=o~dS~____________________________________________________ 4X 
spans in a film exposure cassette containing a BioMax MS intensifying screen. The film is 
developed in a Cuvix 160 roentgen film developing machine. 
3.3.9.4 Stripping radioactive probes off southern blots 
Stripping buffer 
ddH20 with 
NaCI 
SDS 
1.5 M 
0.01 % (v/v) 
In order to remove DNA-bound [y-32p]_ATP labelled oligonucleotides from a southern blot, the 
membrane is incubated under rotation in 100 ml stripping buffer for 3 hours at 70°C. Subsequently, 
it is dried on blotting paper, and can be reused for another hybridisation experiment. 
3.4 Immunobiological methods 
3.4.1 Fluorescence-activated cell sorter (FACS) 
3.4.1.1 Staining of cell surface molecules with monoclonal antibodies 
FACS buffer 
PBS with 
FCS 
sodium azide 
1 % (vlv) 
0.01 % (v/v) 
Cells are added to FACS-tubes, and all incubation steps are carried out at a concentration of 
1 x 106 cells per 100 ,.tI. Cell surface Fc-R are blocked by incubating the cells for 15 minutes at 4°C 
with 1 % NMS (3.2.3). The cells are washed once with cold FACS buffer before incubating them for 
15 minutes at 4°C with fluorescently-conjugated antibodies (Abs). After washing the cells three 
times with 500 JlI cold FACS buffer, they are taken up in 200-400 III FACS buffer. Where 
unconjugated primary Abs are used, a second Ab-incubation step with a secondary fluorescently-
conjugated Ab is required. In the case of biotinylated primary Abs, fluorescently-conjugated 
streptavidin is used. 
10,000 - 100,000 events are counted on a FACScan flow cytometer and analysed using the 
CELLQuest Software. Unstained cells serve as autofluorescence controls. 
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3.4.1.2 Tetramer-staining 
For tetramer-staining, cells are given to a 1.5 ml Eppendorf tube. Before incubation with H-2Ld-
TPHPARIGL-PE tetramers for 1/2 hour at 37°C, cells are incubated with FITC-Iabelled anti-C08 
mAb (monoclonal Ab) following the protocol described in 3.4.1.1. This is necessary in order to 
prevent non-specific, C08-mediated binding of the tetra mer (communication of the NIAIO, 
Bethesda, USA) which would result in overestimation of H-2Ld-TPHPARIGL-reactive C08+ T-cells. 
After the tetramer-staining procedure, the cells are washed twice with fresh FACS buffer (3 .4.1.1). 
Shortly before FACScan analysis, propidium iodide (PI) is added to the probe in order to exclude 
dead cells from the evaluation of the results (see 3.4.1.4). 
3.4.1.3 Intracellular staining with FOG 
FOG-stock solution 
FOG 
OMSO 
ethanol p.a. 
ddH20 
20mM 
10 % (v/v) 
10 % (v/v) 
80 % (v/v) 
Fluorescein di-p-O-galactopyranoside (FOG) is used in order to detect p-gal expressing cells by 
FACS analysis . The non-fluorescent FOG is sequentially hydrolysed by p-gal , first to fluorescein 
monogalactoside (FMG), and then to the highly fluorescent fluorescein. 
OH ~OH _~_g_al_. OH ~gal a QH---. 
FOG FMG fluorescein 
Fig. 3.4 FOG hydrolysis by ~-galactosidase. A two-step hydrolysis of FOG by the 
bacterial p-galactosidase enzyme yields the green fluorescing protein fluorescein. 
In a 2 ml Eppendorf tube, 1 x 107 cells are taken up in 100 III FACS buffer (3.4.1 .1) and incubated 
in a waterbath at 37°C for 10 minutes. 100 III of a 2 11M FOG solution (diluted in ddH20) is also pre-
warmed to 37°C before adding it to the cells, and incubating the mixture for another minute at 37°C. 
FOG enters the cells during this incubation step by way of hypotonic shock. The tube is filled up with 
ice-cold FACS buffer and put on ice for 10 minutes before washing the cells twice with fresh FACS 
buffer. 
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3.4.1.4 Detection of dead cells according to propidium iodide uptake 
Propidium iodide (PI) staining allows the differentiation of dead from viable cells by FACS analysis, 
as dead cells exhibit holes in their membranes through which the PI can enter and bind to DNA. As 
a result, dead cells fluoresce intensely in the third channel (FI-3 = deep red) when analysed by flow 
cytometry. 
After staining the cells with f1uorescently labelled Abs as described in 3.4.1.1, PI is added to obtain 
a final concentration of 1 Ilg/ml, and the cells are allowed to incubate for one minute. The cells can 
then directly be analysed by FACS without having to wash off surplus PI. 
3.4.2 Isolating specific immune cell populations via cell surface markers 
3.4.2.1 Cell enrichment using Dynabeads 
An estimate is made of the number of target cells and a 7-fold number of Ab-coupled Dynabeads is 
transferred to a clean 1.5 ml test tube. The beads are washed by placing the tube in an MPC-E-1 
magnet stand for 2 minutes, pi petting off the fluid, and removing the tube from the magnet stand 
before resuspending the beads in 500 III FACS buffer (3.4.1.1). 
Cell surface Fc-R are blocked by incubating the cells for 15 minutes at 4°C with 1 % NMS (3.2.3). 
The cells are washed once with cold FACS buffer. The cell sample is then admixed with the beads 
in a 15 ml test tube and the mixture is diluted with FACS buffer to obtain a concentration of 1 x 107 
beads/ml. Incubation occurs on a rotation device for 20 minutes at 4°C. The tube is then placed on 
an MPC-L magnet stand. After 2 minutes, the unbound cells (negative fraction) are transferred to a 
fresh tube. while the magnetically labelled cells are washed twice with 10 ml FACS buffer before 
resuspending them in a desired volume. 
3.4.2.2 Cell enrichment using MACSbeads 
MACS buffer 
PBS with 
BSA 
EDTA 
pH 7.2 
0.5 % (w/v) 
2 mM 
Cell surface Fc-R are blocked by incubating the cells for 15 minutes at 4°C with 1 % NMS (3.2.3). 
The cells are washed once with cold FACS buffer (3.4.1.1). pelleted by centrifugation and taken up 
in 90 III FACS buffer per 1 x 107 cells. Ab-conjugated MACS MicroBeads are given to the cell 
suspension at a concentration of 10 III per 1 x 107 cells (= 10 beads/cell). The sample is mixed well 
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and incubated for 15 minutes at 4°C. 10 ml FAGS buffer are given onto the cell suspension, the 
cells are pelleted by centrifugation and resuspended in cold MAGS buffer at 50 III per 1 x 107 cells. 
An MS+ or LS+ column (see Table 3.3 below) is placed in the magnetic field of a MAGS separator 
and a 15 ml collection tube is placed underneath. The column is then pre-wet with an appropriate 
volume of MAGS buffer, and the cell suspension is applied. This is allowed to pass through 
completely before washing the column three times with MACS buffer. The column is then removed 
from the magnetic field and placed onto a clean collection tube. In order to retrieve the labelled cells 
from the column, an appropriate volume of MACS buffer is pipetted onto the column and flushed 
through using the plunger provided with the separation columns. 
All centrifugation steps are carried out for 5 minutes at 300 x g. 
max. no. of cells retained 
MACS Separator 
washing volume 
elution volume 
MS+ column 
1 x 107 labelled cells 
OctoMACS Separation Unit 
500 III 
1.0 ml 
LS+ column 
1 x 108 labelled cells 
Midi MACS Separation Unit 
3.0ml 
5.0ml 
Table 3.3 Technical data for MS+ and LS+ separation columns. 
3.4.2.3 Purification of cells using a FACSvantage 
Cells are stained with fluorescently labelled Abs as described in 3.4.1.1. Using a FACSvantage cell 
sorter, cell populations defined by the expression of several specific cell surface molecules are 
isolated and sorted into a clean collection tube. 
This method allows not the enrichment, but the purification even of rare cell types. 
Methods 
3.4.3 ELISA 
OptEIA Sets for various cytokines (see 2.8); TMB microwell peroxidase substrate system 
Coating Buffer 
ddH20 with 
sodium bicarbonate 
sodium carbonate 
pH 9.5 
Washing buffer 
PBS with 
Tween 20 
8.4 % (w/v) 
3.58 % (w/v) 
0.05 % 
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The manufacturer's protocols are followed for the detection of cytokines in the supernatants of short 
term cultures obtained as described in 3.1.6. Briefly, 96-well microtiter plates are coated o/n with in 
coating buffer diluted capture Ab at 4°C and washed three times. The plates are blocked with 100 ~I 
assay diluent per well. After an incubation of one hour at r/t the plates are washed again. Standards 
and samples are applied at 100 Ill/well and incubated for 2 hours at r/t. The plates are washed three 
times and incubated for one hour at r/t with 100 Ill/well detector solution containing both a 
biotinylated detection Ab and horseradish peroxidase (HRP)-conjugated avidin. All unbound working 
detector is thoroughly removed by washing 5 times. TMB substrate solution is applied at 100 ~I/well, 
and colour development allowed to take place in the dark. The colour reaction is terminated by 
adding 50 III 2 N H2S04 to each well and optical density is measured at 450 nm on an ELISA 
reader. 
A standard curve is prepared for each cytokine measurement. Linear regression of the standard 
curve allows the calculation of cytokine content in the culture supernatants using the GraphPad 
Prism software. 
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3.5 In vitro assays with live cells 
3.5.1 51Cr-release assay 
Effector cells 
d3 iPEC are produced as described in 3.1.5.5, washed twice in pre-warmed complete RPMI and 
diluted to a concentration of 2.5 x 106 viable effector cells, as determined by trypan blue exclusion 
(3.1.3). From this cell suspension, 200 III are plated out in a round-bottomed 96-well plate, and a 
1:2 serial dilution is carried out. With a constant target cell number (5 x 103• see below) this will give 
effector to target cell ratios (E:T ratios) of 50:1.25:1.12.5:1. and 6.25:1. All samples are produced 
in triplicates. 
Target cells 
Tumour cell lines should be in the exponential growth phase, i.e. at -5 x 105 cells/ml culture. 2 x 106 
target cells are pelleted in a 5.0 ml round-bottomed tube. taken up in 200 III pre-warmed complete 
RPMI. and incubated with 200 IlCi Na251Cr04 for 90 minutes at 37°C. In order to prevent 
sedimentation of the cells during this labelling step, which would result in unequal labelling and 
decreased viability, the samples are resuspended by shaking every 30 minutes. Labelled target 
cells are washed 3 times in pre-warmed complete RPMI and taken up in 1 ml medium. The 
samples are diluted to a concentration of 5 x 104 viable target cells per mi. as determined by trypan 
blue exclusion (3.1.3). 100 III of the cell suspensions are added to the effector cells. 
Co-culture of effector and target cells 
The plates are centrifuged for 3 minutes at 55 x g in order to provide optimal effector: target cell 
contact. The plates are wrapped in cling film to minimise loss of liquid due to evaporation, and 
incubated for 4 hours at 37°C. 
To ensure that all cell-associated Na251Cr04 is in the pellet. the plates are centrifuged for 5 minutes 
at 230 x g. 100 III of each supernatant are transferred to 6.5 x 38 mm polystyrene tubes. These are 
sealed with paraffin wax, and radioactivity of the probes is determined using an Automatic Gamma 
Counter. 
50 III of the target cell suspension is used as the maximum release control. while 100 III 
supernatant from target cells incubated without effector cells is taken as the minimum release. 
Specific lysis is determined by using the following formula: 
% specific release = 
experimental release - spontaneous release 
maximum release - spontaneous release x 100 
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3.5.2 Enzyme-linked immunospot assay (ELISPOT) 
Murine IFN-y ELiSPOT Kit; Alkaline Phosphatase Conjugate Substrate Kit 
The ELiSPOT assay is designed to enumerate cytokine producing cells in a single cell suspension. 
After cell stimulation, locally produced cytokines are captured by a specific mAb, and are then 
detected by a second, biotinylated Ab and a colour reaction. Coloured spots then indicate cytokine 
production by individual cells. 
Blocking buffer 
PBS with 
BSA 
Washing buffer 
PBS with 
Tween 20 
Detection Ab working solution 
PBS with 
detection Ab 
BSA 
Substrate solution 
ddH20 with 
AP colour development buffer 
AP colour reagent A 
AP colour reagent B 
5 % (w/v) 
0.1 % (v/v) 
550 Jll/mi 
1 % (w/v) 
4 % (v/v) 
1 % (v/v) 
1 % (v/v) 
contains nitroblue tetrazolium in aqueous 
dimethylformamide (DMF) and MgCI2 
contains 5-bromo-4-chloro-3-indolyl 
phosphate in DMF 
A 96-well plate bottomed with 0.45 Jlm cellulose ester membranes is incubated at r/t for 10 minutes 
with 100 JlI 70 % sterile ethanol per well. The plate is washed three times with 100 JlI PBS per well, 
before dispensing 100 JlI capture Ab (diluted 1: 1 00 in PBS) into each well and incubating the 
covered plate o/n at 4°C. 
After washing the plate as above, 100 III blocking buffer are given to each well, the plate is covered 
again and incubated for 2 hours at 37°C. Subsequently, the wells are emptied thoroughly but not 
washed. Ag-pulsed (see 3.1.9.3) or control DCs are co-incubated with T -cells enriched via one of 
the methods described in 3.4.2 at a ratio of T -cells : DCs = 5 : 1 in a volume of 200 JlI X-vivo 20 
medium per well. All samples are set up in triplicates, as well as with 3 cell dilutions. As a positive 
control, T-cells are incubated with PHA (5 Jlg/ml), while negative controls include T-cells alone and 
DCs alone, as well as co-incubations containing DCs pulsed with an irrelevant Ag. The cells are co-
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incubated for 24 hours at 37°C under standard tissue culture conditions (see 3.1.1). It is mandatory 
that the plate is not moved during this incubation step. 
The cells are discarded and wells are washed three times with 100 III washing buffer per well. 
During the last washing step, the washing buffer is left on the plate for 10 minutes before emptying 
the wells thoroughly. The plate is then incubated with 100 III detection Ab working solution per well 
for 1 % hours at 37°C and another 1 % hours at r/t. After washing three times with PBS, the plate is 
incubated for 45 minutes at 37°C with 100 III alkaline phosphatase (AP)-conjugated streptavidin per 
well. The plate is again washed three times with PBS and wells are thoroughly emptied before 
dispensing 100 III substrate solution to each well. The colour reaction is allowed to take place in the 
dark. In order to terminate the reaction, the wells are rinsed three times with ddH20. 
The protective plastic cover is removed from the cellulose-bottomed wells and the plate is dried 
while keeping it protected from direct light. The cellulose ester membranes are transferred onto 
adhesive plastic in order to evaluate the plate using an Axioplan 2 imaging microscope in 
combination with a 3 ceo video camera and the KS EllS POT Software. 
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3.6 Histological methods 
3.6.1 Preparation of cytospins 
1 x 105 to 5 x 106 cells are taken up in 200-500 IJ.I PBS and given into the funnel of a cytospin 
apparatus containing a filter mat and microscope slide. After a 5 minute centrifugation at 55 x g the 
microscope slide is removed from the cytospin apparatus and left to air-dry for 15 minutes before 
staining or freezing at -20°C for storage. 
3.6.2 Determination of lacZ expression by X-gal staining 
Fixing solution 
PBS with 
formaldehyde 
glutaraldehyde 
X-gal stock solution 
N,N-dimethylformamide with 
X-gal 
2.0 % (v/v) 
0.2 % (v/v) 
4.0 % (w/v) 
the solution is kept at -20°C, protected from light 
X-gal staining solution 
PBS with 
K3Fe(CN)6 5.0 mM 
~Fe(CN)6 x H2O 5.0 mM 
MgCI2 2.0 mM 
Na-deoxycholate 0.01 % (v/v) 
NP-40 0.02 % (v/v) 
X-gal stock solution 2.50 % (v/v) 
the solution is kept at 4°C, protected from light 
In order to evaluate p-gal expression in lacZ transduced cell lines or ex vivo isolated single cell 
suspensions, cytospins are prepared as described in 3.6.1 and fixed by incubating them for 
5 minutes under gentle shaking in fixing solution. After washing the slides for 10 minutes in PBS 
under gentle shaking, they are incubated o/n at 37°C in X-gal staining solution. The slides are 
washed thoroughly with PBS and the cytospins are covered with Kaiser's glycerol gelatine and a 
cover slip. 
upon hydrolysis by the p-gal enzyme, X-gal yields a localised, insoluble blue precipitate which can 
be detected by light microscopy. 
Methods 
CHHOH 
HOCO,p 
~ 
OH 
Cl 
Br 
Fig. 3.5 Molecular structure of X-gal. 
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For macroscopic determination of metastatic load in the liver and spleen of tumour-bearing animals 
the organs are thoroughly washed in cold PBS and fixed during a 2 hour incubation in fixing solution 
at 4°C. The organs are rinsed three times with cold PBS and incubated oln at 3rC in X-gal staining 
solution. After washing three times with PBS, the organs are stored at 4°C in fixing solution. 
3.7 Statistics 
Significance of differences between survival curves were compared using the Log-rank test. 
The Student's t-test was used to calculate whether the difference between two means was 
significant or not. 
Restricted Cubic Splines and the Wald Statistics were used for the primary kinetics of tetramer-
binding cells after ear pinna priming with ESbL-Gal tumour cells. These latter calculations were 
kindly carried out by Dr. A. Benner. 
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4.1 Characterisation of ESbL-Gal: a metastatic tumour line transfected with a foreign gene 
The tumour cell line used in this study, ESbL-Gal, is the bacterial ~-gal transduced variant of the 
DBAl2 mouse derived T-Iymphoma ESb 289. To test for the stability of ~-gal expression in vivo, 
tumour lines were established from ex vivo isolated tumour cells. Dormant tumour cells are known 
to persist for prolonged periods of time in syngeneic DBAl2 mice, mainly in the bone marrow and 
lymph nodes (MOiler et al. 1998). The ESbL-Gal-BM variant was isolated from such bone marrow 
residing dormant tumour cells by growth of bone marrow cells from ESbL-Gal-immunised mice in 
minimal nutrient medium. Occasionally, the persistence of dormant tumour cells has been 
observed to result in the outgrowth of tumour nodules following a tumour challenge (Schirrmacher, 
in press). This is probably due to a recruitment of tumour-reactive T-cells from the site of tumour 
dormancy to the site of tumour challenge. ESbL-Gal-ET (ear tumour), -ST (spleen tumour). And 
_ TT (throat tumour) are cell lines isolated from such solid tumour nodules. 
Analysis of ~-gal activity by X-gal and FOG staining revealed that ~-gal, although highly 
immunogenic, appears to be stably expressed in vivo, as all ESbL-Gal variants tested (ESbL-Gal-
ST and -TT not shown) had comparable ~-gal expression levels to the parental ESbL-Gal (Fig. 
4.1). Similar expression was also found in the unrelated DBAl2-derived mastocytoma P815-Gal, 
while the non-transfected ESbL cells served as a negative control. 
The ESbL-Gal tumour is thus a useful tool for the study of Ag-specific T-cell responses, as the 
main imunogenic Ag (~-gal) is not lost during in vivo malignant progression. 
Resul ts 
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Fig,4.1 ~-gal expression by ESbL-Gal, in vivo variants thereof, and P815-
Gal. Cultured tumour cel ls were tested for ~-gal expression by X-gal staining (blue 
precipitate). as well as by FOG-staining in combination with flow cytometry (insets) . 
Green histograms represent FOG-stained cells, red lines represent the 
autofluorescence. Parental ESb-L served as a negative control. 
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4.1.1 Cell surface expression of molecules on the parental ESbL·Gal tumour cell line and 
its bone marrow derived variant ESbL·Gal·BM 
To better characterise the tumour cell line used in the present study. ESbL-Gal as well as a bone 
marrow derived variant thereof. ESbL-Gal-BM. were analysed for the cell surface expression of 
leukocyte lineage markers and molecules involved in Ag-presentation and cell adhesion. 
4.1.1.1 Leukocyte lineage markers 
ESbL-Gal cells are of T-Iymphocyte origin (T-Iymphoma). It has been proposed that the parental 
ESb. which is a spontaneous in vivo variant of the methylcholanthrene induced Eb. arose through 
fusion of an Eb tumour cell with a host macrophage. ESbL-Gal cells have only very low expression 
of the T-cell marker CD3 (Fig. 4.2. mean fluorescence/peak channel: 93.35/7) and detectable 
surface expression of Thy1.2 only on a subset of cells (8.4 %). The B-cell markers CD19 (17.25/17) 
and B220 (182.90/117) were found to be expressed on ESbL-Gal. while the macrophage marker 
F4/80 could not be detected. 
Interestingly. the cell line established from dormant ESbL-Gal of the bone marrow. ESbL-Gal-BM. 
appear "naked" concerning cell surface expression of lymphocyte lineage markers. Whether this is 
due to in vivo selection of negative clones. a result of active down-regulation. or an altered 
phenotype due to further mutations is not known. 
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Fig. 4.2 Leukocyte lineage marker expression on ESbL-Gal and ESbL-Gal-
BM. Cells were taken from cultures during the exponential growth phase and 
incubated with FITC or R-PE conjugated mAb to the lineage markers C03 (clone 145-
2C11). Thy1 .2 (clone 53-2.1) , C019 (clone 605), 8220 (clone RA3-6B2), or F4/80 
(clone F4/80) . Stained ( ---) and unstained ( --- ) cells were analysed by flow cytometry. 
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4.1 .1 .2 Major histocompatib ility antigens 
ESb tumour cells have previously been shown to express the MHC class I molecules H_20d and 
H-2L d, as well as the class II molecu le I_Ad (Graf et al. 1985) . Consistent with these results, ESbL-
Gal expressed all three histocompatibili ty antigens although I_Ad expression was very low (Fig . 4.3, 
mean fl uorescence/peak channel : 138.68/34 for H-20 d, 76.02/58 for H-2Ld, 7.93/6 for I_Ad). ESbL-
Gal-BM, on the other hand , were found to be negative for I_Ad Surprisingly. this bone marrow-
derived variant expressed higher levels of the MHC class I molecule H-20 d (489 .24/453 ) than the 
parental ESbL-Gal. Whether this represents an up-regulation of class I expression or a selection of 
tumour cells with high expression levels is not clear. Unfortunately, no conclusive results were 
obtained for H-2Ld expression on ESbL-Gal-BM. 
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Fig. 4.3 Expression of major histocompatibili ty ant igens on ESbL-Gal and 
ESbL-Gal-BM T-Iymphoma cells. Cells were taken from cultures during the 
exponential growth phase and incubated with mAb to the major histocompatibility 
antigens H_20d (clone 34-2-12) , H-2Ld (clone 19.191), or I_Ad (clone AMS-32.1). 
Where unconjugated mAbs were used, binding was revealed by incubation with a 
secondary R-PE-Iabelled donkey anti-rat IgG Ab. Other mAbs were either labelled with 
R-PE. Stained ( ---) and unsta ined ( --- ) cells were analysed by flow cytometry. n.d .: 
not done . 
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4.1.1 .3 Adhesion molecules 
Adhesion molecules play an important role in the metastatic process as well as in the homing of 
disseminating tumour cells . Selected adhesion molecules were, therefore , analysed and found to be 
differentia lly expressed on the surface of the highly metastatic parental ESbL-Gal and its variant 
derived of bone marrow resident dormant tumour cells, ESbL-Gal-BM. 
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Fig. 4.4 Expression of selected adhesion molecules on ESbl-Gal and ESbl-
Gal-BM. (this and previous page) Cells were taken from cultures during the 
exponential growth phase and incubated with mAbs to the adhesion molecules LFA-1 
(clone Tib 213), LFA-2 (clone RM2-5), L-selectin (clone Mel-14), ICAM-1 (clone 
YN .1/1 .7), p7-integrin chain (clone FIB 27), or PSGL-1 (clone 2PH-1). Where 
unconjugated mAbs were used , binding was revealed by incubation with a secondary 
R-PE-Iabelled donkey anti-rat IgG Ab. Other mAbs were either directly labelled with 
FITC or R-PE. Stained ( ---) and unstained ( --- ) cells were analysed by flow 
cytometry. 
The leukocyte adhesion molecule LFA-1 (CD11a) preferentially interacts with ICAM-1, which is 
expressed on APCs and activated endothelium, mediating cell-cell and cell-matrix interactions . It 
was found to be expressed on ESbL-Gal tumour cells (Fig . 4.4 , mean fluorescence/peak channel : 
41 .56/32) , confirming previous reports (Rocha et al. 1996, Rocha et al. 1997), whereas no 
expression was detected on the bone marrow variant (6 .50/5) . 
LFA-2 (CD2) is an adhesion molecule present on a variety of haematopoietic cells, that binds to 
CD58, which is widely expressed on haematopoietic and non-haematopoietic cells. LFA-2 was 
found to be expressed on ESbL-Gal (41 .72/32) but not on ESbL-Gal-BM (2 .88/2) . Similarly, the 
leukocyte selectin , L-selectin (CD62L), was expressed on the parental ESbL-Gal (37.01/23) but not 
on the bone marrow derived ESbL-Gal-BM (5.77/5) . 
ICAM-1 , which is widely expressed on haematopoietic and non-haematopoietic cells, binds to 
LFA-1, and is important in mediating cell adhesion as well as enhancing Ag-specific T-cell 
activation. Increased levels of this adhesion molecule were detected on ESbL-Gal-BM (283.48/268) 
as compared to the parental ESbL-Gal (20.13/18). Expression levels of the Printegrin chain were 
also slightly more elevated on ESbL-Gal-BM (19.12/16) than on ESbL-Gal tumour cells (7 .93/5) . 
Likewise, the P-selectin glycoprotein ligand, PSGL-1 (CD162), was detected on ESbL-Gal cells 
(40.21/31) but not on ESbL-Gal-BM (6.21/5) . 
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4.1.2 In vivo dissemination 
The dissemination of ear pinna injected ESbL-Gal tumour cells was followed by FOG staining . To 
this end , bone marrow, spleen, and draining lymph node cells were loaded with FOG by osmotic 
shock and analysed by flow cytometry. ~-gal + tumour cells could be distinguished by the green 
fluorescence resulting from cleavage of the FOG substrate by the ~-ga l enzyme. The results are 
illustrated in Fig . 4.5. 
The frequency of tumour cel ls in the draining lymph node was below 0.2 % at all time points tested, 
although it is possible that a higher number would be present at earlier time points (within the first 
24 hours of priming) . Similar three-phasic kinetics were found in the bone marrow and spleen, with 
a first peak accumulation on day 5 post tumour injection (9 .9 % in the bone marrow, 5.9 % in th 
spleen) , a rapid decline thereafter to 0.5 % in the bone marrow and 1.8 % in the spleen on day 7, 
and a second increase in tumour cell numbers to 3.0 % in the bone marrow and 5.8 % in the spleen 
on day 14. Later time points were not analysed, but tumour cell levels are assumed to level off or 
possibly even decrease slightly, as ear pinna inoculated animals remain clinically healthy and the 
frequency of dormant tumour cells in the bone marrow is in the range of 10-100/106 total ce lls 
(MOiler et al. 1998). 
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Fig. 4.5 Tumour cell d issemination after ear pinna inoculation. 5 x 104 ESbL-
Gal cells were injected i.e. into the pinnae of both ears of syngeneic OSN2 mice. The 
migration kinetics of ESbL-Gal were followed in the bone marrow (SM , • ), spleen 
(SPL, A ), and draining lymph nodes (dLN , 'f ) by FOG staining . Each data point 
represents a measurement of pooled organs from 3 animals . 
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4.2 Primary ~-gal specific CDS+ T-cell response in vivo after i.e. priming of syngeneic 
DBAJ2 mice 
The primary CD8+ T-cell response to the immunodominant peptide of ~ -ga l a ctos idase (~_ga I876.88~ : 
TPHPARIGL) after ear pinna injection of ESbL-Gal was monitored in the bone marrow, spleen, and 
draining lymph nodes of the ear using peptide/MHC tetrameric complexes in combination with flow 
cytometry. The response was more pronounced in the bone marrow than in the draining lymph 
nodes of the ear (superfiscia cervicalis) or in the spleen (Fig . 4.6) . The frequency of tetra mer-
binding cells among live CD8+ T-cells in the bone marrow peaked on day 10 (5 .6 %, background : 
0.6 %), declining thereafter to 2.1 % by day 14. However, the decline was not down to zero , and 
memory T -cells were found to persist in the bone marrow for long periods of time (see 4.7.1) . 
Similar but less pronounced kinetics were found in the spleen , where the highest frequency of 
tetramer binding cells was also found on day 10 (1 .0 %, background : 0.3 %). This was significantly 
lower (p = 0.0087) than that detected in the bone marrow at the same time point. In the draining 
lymph nodes the highest frequency was measured 7 days after tumour inOCUlation (0 .8 %, 
background : 0.5 %), but, statistically, this was not significantly different from any of the other time 
points. Overall , the kinetics of ~_gaI876-884 specific CD8+ T-cells in the bone marrow differed 
significantly from those in both the spleen and draining lymph nodes (p = 0.0162). 
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Fig. 4.6 Primary T-cell response to a tumour cell-associated Ag in vivo. 
S x 104 ESbL-Gal were injected i.e. into both ears of syngeneic DBA/2 mice. The 
primary MHC class I (Ld) restricted CD8+ T-cell response to the immunodominant 
peptide of ~-gal was analysed by MHC/peptide tetramer staining. Shown are means 
and standard deviations of tetramer binding , live CD8+ T -cells from the bone marrow 
(BM , • ), spleen (SPL, A ), and draining lymph nodes (dLN , T ). The means are from 
3 independent experiments with 3 mice per time point and experiment. Bars indicate 
standard error mean (SEM) ; where no bars are shown , SEM was < 0.1 %. 
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It has previously been reported that the bone marrow can induce primary responses under 
conditions of disrupted lymphocyte traffic (Tripp et al. 1997). Here I demonstrate for the first time, 
that this also occurs under normal physiological conditions. 
4.3 Secondary anti-tumour T-cell response in the peritoneal cavity 
4.3.1 Immune cell populations present in d3 iPEC 
To determine the effect of intraperitoneal restimulation in ESbL-Gal-immune DBN2 mice on the 
relative proportions of the different immune cell populations, d3 iPEC and PEC from na'lve DBN2 
mice were incubated with cell type specific Abs and analysed by flow cytometry. 
Table 4.1 
na'lve PEC 
ESbL-Gal-immune d3 iPEC 
average yield I animal 
3.0 X 106 ± 0.5 x 106 
1.6 x 107 ± 0.8 x 107 
Average cell yield from the peritoneal cavity of nai've vs. ESbL-
Gal-primed DBAl2 mice after i.p. restimulation. DBN2 mice were inoculated with 
5 x 104 ESbL-Gal i.e. 7 days before restimulating intraperitoneally with 1 x 107 
irradiation-inactivated (100 Gy) ESbL-Gal. ESbL-Gal-immune d3 iPEC were isolated 3 
days later by peritoneal lavage. Na'lve PEC were obtained by injection of 1 ml cold PBS 
into the peritoneum of naIve DBN2, 1 day before isolation of the PEC. 
In d3 iPEC, total cell numbers were increased by a factor of 5.3 in relation to PEC from na'ive DBN2 
mice (Table 4.1). It is likely that this increase was not only due to proliferation of the cells already 
present within the peritoneum (see 4.3.3), but also due to an influx of primed T -cells and non-
specific inflammatory cells caused by a pro-inflammatory environment (see 4.3.3), which was 
provoked by the presence of irradiated tumour cells. 
In na'ive mice, the peritoneal cavity hosts mainly B-cells. Fig. 4.7 C shows the immune cell 
populations present within na'lve PEC (nPEC). 78.4 % of total nPEC were B-cells, while 9.8 % were 
macrophages, 5.7 % DCs and 4.9 % NK-cells. T-cells were represented by 5.8 % CD4+ and only 
0.5 % CD8+ cells (CD4+ : CD8+ T-cell ratio = 11.6: 1). 
In contrast, anti-ESbL-Gal d3 iPEC (Fig. 4.7 A) consisted of 18.6 % T-cells with a CD4+ : CD8+ 
T-cell ratio of 1 : 1.5. Professional Ag-presenting cells (APCs) were represented by 9.9 % DCs, 34.7 
% macrophages and 31.4 % B-cells. NK-cells constituted only a minor population of 2.6 %. Of the 
7.4 % CD8+ T-cells, 33.9 % bound to tetrameric complexes of the MHC class I molecule H2-Ld and 
the immunodominant ~-gal peptide TPHPARIGL (aa 876-884, Fig. 4.7 B, background: 0.7 % 
(Fig. 4.7 0)), making up 2.5 % of the total d3 iPEC. 
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The ESbL-Gal and ESb cell lines share a common , as yet un identified , H-2Kd (MHC class I) 
restricted TM wh ich is only weakly immunogenic in DBAJ2 mice (Bosslet et al. 1979). The 
immunogenicity of ESbL-Gal is markedly increased by expression of the bacterial facZ gene 
encod ing ~-gal (Kruger et al. 1994b). 
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Fig. 4.8 Ear pinna inoculation of ESbL-Gal in combination with i.p. 
restimu lation leads to a secondary /3-gal specific CTL-response in situ. Naive 
DBAJ2 mice were injected a sub-tumorigenic dose of 5 x 104 ESbL-Gal i.e. and 7 days 
later challenged with 1 x 107 irradiation-inactivated (100 Gy) ESbL-Gal i.p .. 3 days after 
the second tumour cell inoculation, d3 iPEC were harvested and tested for their anti-
ESbL-Gal cytotoxic activity ( • ) in a 4h 51 Cr-release assay. Specificity of the reaction 
was tested by including the following target ce ll lines: ESb 289, which expresses the 
same tumour Ag as ESbL-Gal , but is ~-ga l negative ( • ); P815-Gal , an ESbL-Gal-
unrelated , facT mastocytoma ( • ). 
All samples were measured in triplicates, and spontaneous release was always below 
15 %. Illustrated is one representative experiment of 8. 
The intraperitoneal secondary immune response after i.p. challenge of ESb-immunised mice with 
peak CTL-activity on day 3 has previously been establ ished (Schirrmacher et al. 1991). Here, the 
secondary CTL-response to ~-gal could be demonstrated for the fi rst time, and appears to be more 
dominant than the response to the ESb-derived T M . 
As shown in Fig. 4.8, CD8· T-cell mediated cytotoxicity of ESbL-Gal-stimulated d3 iPEC was mainly 
directed against the ~-gal protein, specific lysis being Significantly higher (p = 0.0011) against the 
facT ESbL-Gal (34.5 %) than against the facZ ESb (2.7 %) (values are given for E:T ratio = 50:1). 
The higher specific kill observed against P815-Gal (46.9 %) was not due to a more elevated ~-gal 
expression in these cells as compared to ESbL-Gal. In fact, as illustrated in Fig. 4.1, ~-gal 
expression is similar in both cell lines. The increased sensitivity of P815-Gal to d3 iPEC mediated 
cytotoxicity may be due to a higher sensitivity to CTL-Iysis and to some NK-mediated lysis, as P815-
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Gal are NK-sensitive (Donskov et al. 1996), while ESb, and by inference also ESbL-Gal are not 
(Schirrmacher 1981 ). Al though reproducible, the difference between the specific lysis of ESbL-Gal 
and P815-Gal was not sign ificant at any of the E:T ratios tested (p = 0.0605 at E:T = 50: 1). 
4.3.3 Recruitment of ~-gal specific COS+ T-cells to the peritoneal cavity 
As mentioned in 4.3.1, the peritoneal cavity of nafve DBN2 mice contains only few CD8+ T -cells 
(0 .5 %, see Fig . 4.7 A) . In the present experiment the origin of T-cells, in particular the ~ _ga I 676-664 
specific CD8+ T-cells , found with in d3 anti-ESbL-Gal iPEC was investigated. To this end, the 
frequenc ies of tetramer-binding cells within the CD8+ T-cell populations of spleen, bone marrow, 
regional lymph nodes of the ear, and of peripheral blood were measured . Organs from animals 
having received only the primary ear pinna inoculation (Fig . 4.9 gr. I) were compared with those 
from i.e. primed and i.p. re-stimulated animals (gr. II), as well as with those of nafve animals having 
received only the intraperitoneal challenge (gr. III) . 
II) 
Q) 
C.) 
~ 
+ co 
o 
u 
..-
o 
+ 
... 
Q) 
E 
co 
... 
... 
~ 
"<?-
spleen bone marrow 
:~ 
0 1 23456 7 8 0 1 23 4 56 7 8 
regional IN PBl 
14..-- ------, 
12 
0 1 2345678 0 1 23 4 56 7 8 
days post secondary challenge i.p. 
- gr. 1 
-'-gr.II 
- gr.II' 
.~ 
(] 
....J 
" a 
)( 
'" 
dO 
+ 
+ 
)( 
d7 
+ 
+ 
Fig. 4.9 Recruitment of Ag-specific T-cells after a secondary intraperitoneal 
challenge. DBN2 mice were primed with 5 x 104 ESbL-Gal i.e . and restimulated 7 
days later with 1 x 107 rad iation-inactivated (100 Gy) ESbL-Gal cells i.p. (gr. II , A. ) . 
Gr. I animals ( • ) were not restimulated , while gr. III mice ( T ) received only the 
intraperitoneal challenge. 3 mice per time point and group were sacrificed. Spleens, 
bone marrow, reg ional lymph nodes of the ear, and blood from each group were 
pooled and the percentage of tetramer-binding cells within the CD8+ T-cell 
compartment determined by FACS analysis. 
Shown are the results of a single experiment. 
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The results show that ~_gaI876-884 specific CD8+ T -cells of the regional lymph nodes were not 
affected by the Lp. challenge, the frequency of tetramer-binding cells decreasing to the same extent 
in non-re-stimulated (gr. I, 0.35 % on d3) as in restimulated primed mice (gr. II, 0.25 % on d3). 
Recruitment was most likely from the spleen and bone marrow, where lower percentages of 
tetramer-binding cells were measured after a secondary tumour challenge Lp., and probably 
occurred via the blood stream where increased frequencies were recorded after Lp. challenge of 
ESbL-Gal immune mice as compared to the frequencies in non-rechallenged animals. 
Intraperitoneal injection of 1 x 107 irradiated (100 Gy) ESbL-Gal cells yielded a measurable specific 
T-cell response in na"lve DBAl2 mice (gr. III), but later and at a lower level than in tumour primed 
mice (gr. I). 
4.3.4 Cytokine profile of iPEC and cytokine kinetics within the peritoneal cavity 
In order to further analyse the mechanisms involved in the secondary in situ anti-ESbL-Gal 
response, 24h culture supernatants of iPEC isolated 1-12 days post restimulation of ESbL-Gal-
immunised DBAl2 were tested for cytokine content. The results are shown in Fig. 4.10. 
Bioactive IL-12 (p70) is a heterodimer composed of two disulfide-linked subunits, p35 and p40, 
neither of which alone display any significant activity (Chizzonite et al. 1998). IL-12 is an early 
response Th1-promoting cytokine produced by B-cells, activated macrophages, and DCs (Zitvogel 
et al. 1995), which stimulates prOliferation, IFN-y production, and cytotoxicity of both activated 
T-cells and NK-cells (Trinchieri 1995). Consistently, IL-12 was produced only at early time points of 
the secondary immune response within the peritoneum, at levels of 118.4 pg/2 x 106 cells on d1 and 
decreasing to 8.4 pg/2 x 106 cells on d3. By d4 no IL-12 could be detected. 
Tumour necrosis factor-a (TNF-a) is produced by macrophages and T -cells, and activates the 
vascular endothelium, thus increasing vascular permeability. This leads to increased fluid drainage 
and cellular motility across the endothelium. Day 1 iPEC produced high levels of TNF-a (475.4 pg/2 
x 106 cells), thus allowing the influx of immune cells into the peritoneal cavity upon stimulation with 
irradiated tumour cells. Recruitment of immune cells to the site of tumour vaccination occurs in a 
short period of time (1-2 days), and TNF-a secretion levels decrease dramatically thereafter. The 
kinetics paralleled that of IL-12. 
Although DC, monocytes and macrophages can secrete some IFN-y, the main producers are 
inflammatory CD4+ T-cells, CD8+ T-cells and NK-cells. IFN-y primarily activates macrophages, but 
also affects T-cells by increasing the expression of MHC class I and class II molecules. Its capacity 
to stimulate the cytolytic activity of NK-cells has also been reported (de Maeyer et al. 1998). Thus, 
IFN-y is a cytokine that recruits macrophages to sites of infection or inflammation to act both as 
effector cells, through the production and secretion of reactive oxygen species, and APCs. Highest 
production of IFN-y by iPEC was found on d1 (5241.2 pg/2 x 106 cells), decreasing thereafter to 
137.7 pg/2 x 106 cells on d3 and 50.3 pg/2 x 106 cells on d6. There was still secretion of IFN-y on 
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d11 and d12, which might represent background levels produced constitutively by peritoneal 
macrophages, and thus indicate a return to cellular homeostasis. 
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Fig. 4.10 Cytokine production by iPEC. DBAl2 mice were primed with 5 x 104 
ESbL-Gal i.e. 7 days before restimulating with 1 x 107 radialion inactivated (100 Gy) 
ESbL-Gal i.p .. iPEC were isolated 1-12 days post restimulation and cultured for 24 
hours in a round-bottomed 96-well plate at 2.0 x 106 iPEC/ml. Supernatants were 
collected and cytokine content measured in duplicates by ELISA. Minimum detection 
limits were at 4 pg/ml for IL-2, IL-4, IL-5, IL-6, IL-10, and TNF-a, and at 15 pg/ml for 
IL-12 and IFN-y. 
Shown are the results from two independent experiments. 
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The type 2 cytokine IL-4 is produced by CD4+ T-helper cells, mast cells, eosinophils and basophils, 
and is involved in B-cell activation. Other effects of IL-4 include T-cell proliferation and survival, as 
well as inhibition of macrophage-activation. The effector phase of the immune response observed 
in the peritoneum of ESbL-Gal-primed DBAl2 after Lp. re-stimulation was found to be dominated by 
type 1 cytokines, such as IL-12 and IFN-y, and CDS+ CTL. IL-4 secretion was beginning on d5 and 
reaching a peak on d7 (16.7 pg/2 x 106 cells) before decreasing again. It is known that IL-4 inhibits 
Th1 type immune responses, and the late IL-4 production observed here is presumably involved in 
terminating the Th1 dominated effector phase. The 3.3 pg IL-4/2 x 106 cells measured on d1 might 
represent background levels present within the peritoneal cavity. 
Like IL-4 and TGF-~, IL-10 is an inhibitory cytokine, a potent suppressant of macrophage functions 
and inhibitor of Th1 responses. IL-10 decreases the T-cell stimulatory capacity of DCs as well as 
IL-12 production and can induce apoptosis of DCs (Cella et al. 1997). After intraperitoneal challenge 
of ESbL-Gal immune DBAl2 it was found to have similar expression kinetics as IL-4, with maximal 
secretion occurring on d7 (1444.2 pg/2 x 106 cells), except that its production started earlier (d3). 
Thus, it can be assumed that IL-10, in synergism with IL-4, acts to terminate the inflammatory 
response in the peritoneal cavity by turning off IL-12 induced IFN-y production by macrophages, and 
inhibiting the T-cell stimulatory action of DCs. 
IL-5 is a Th2-type cytokine produced by T-cells and mast cells, promoting eosinophil growth, 
differentiation, activation, and survival. It can also activate B-cells and induce IgA synthesis. It is a 
potent inducer of immunoglobulin (Ig) induced eosinophil degranulation (Sanderson et a\. 1998). 
The granules of eosinophils contain a crystalloid core of basic protein which, when released from 
the cell, causes damage to a number of pathogens, particularly to parasites. Of greater interest in 
the present situation are presumably the other granule components, namely histaminase and aryl 
sulphatase, which are involved in the down-regulation of inflammatory responses. IL-5 production 
exhibited similar kinetics as that of IL-4, with a peak production occurring 2 days later (d9 750.1 
pg/2 x 106 cells) than observed for IL-4 (d7). This supports a role for IL-5 in terminating the 
intraperitoneal inflammatory response elicited by Lp. challenge. 
IL-2 is a growth factor produced by activated CD4+ and CD8+ T-cells, which stimulates the 
proliferation of multiple immune cell types. In T-cells, it also enhances the differentiation, and 
cytotoxiC activity of CTL. It can also stimulate other IL-2 receptor positive cells, such as NK-cells. 
IL-2 is generally considered a T-cell differentiation factor, but which type of T-cells are activated by 
IL-2 seems to depend on other co-secreted cytokines (Thorpe 1996). IL-2 production by iPEC 
correlated more with Th2 than Th1 type cytokine expression, with secretion peaking on d9 (271.0 
pg/2 x 106 cells). It has been reported that activated T-cells show increased responses to IL-2 if IL-4 
is also present (Thorpe et a\. 1996). This indicates that in the present model system, IL-2 induces 
the expansion of Th2 type cells. 
IL-6 exhibits complex kinetics. It is produced by a wide range of cell types, including Th2 type 
T -cells, activated B-cells, mast cells, fibroblasts, and, most importantly, macrophages, one of its 
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effects being induction of B-cell growth and differentiation. Along with IL-1 and TNF-Cl it is referred 
to as an 'endogenous pyrogen' because it causes fever and is derived from endogenous sources. 
Elevated temperatures are beneficial to host defence, as they protect host cells from deleterious 
effects of TNF-Cl. Although IL-4 and IL-10 have been reported to inhibit IL-6 production by 
monocytes and macrophages (Richards 199B), the expression pattern of IL-6 on later time points 
after Lp. re-stimulation is similar to that of IL-4 and IL-10, except that the increase occurs later and 
is less dramatic. IL-6 plays a major part in the homeostatic response to inflammation by inducing 
the release of aU positive liver-derived acute-phase proteins (e.g. C-reactive protein, Cll-antitrypsin, 
Cll-antichymotrypsin), and inhibiting the release of negative acute-phase proteins by hepatocytes 
(e.g. albumin, transferrin). Many of the positive acute-phase proteins have anti-inflammatory 
properties, which could explain the relatively elevated IL-6 levels at later time pOints of the 
peritoneal immune response. 
4.3.5 TCR-VI3 repertoire analysis 
Prevalence of a limited set of TCR in an immune response might reflect selection of TCR binding a 
given peptide/MHC combination particularly well (Doffinger et al. 1997). In order to test whether 
T-cell clones expressing specific TCR-V~ chains are selected during immune responses to ESbL-
Gal, d3 iPEC were gained by the standard protocol (see 3.1.5.5) and compared with d3 iPEC from 
P815 (p-gal negative) immunised DBAl2 mice. CD4+ and CDB+ T-cells were purified by FACS 
sorting and analysed for expression of various Vp-chains by PCR. Total thymocytes served as 
positive controls. The analysis included three VI3-chains (VI35.1, V!35.2, Vp8.1), which have been 
reported to be clonally eliminated in DBAl2 mice due to the presence of endogenous proviruses. 
The results are illustrated in Fig. 4.11. 
All TCR-VP chains investigated, including those cion ally eliminated in peripheral T-cell populations, 
could be detected in thymus preparations, although for VP13, only an extremely faint band was 
visible after gel electrophoresis of the PCR-products. Polyclonal T-cell responses were found In 
both CD4+ and CD8+ T-cell compartments, after stimulation with ESbL-Gal or P815. Five of the Vp-
chains analysed, namely VP1, VpB.3, V1310, VP15, and VP20, were found to be represented In all 
T-cell populations investigated. The CD4+ T-cell fractions from animals immunised with ESbL-Gal 
or P815 tumour cells were very similar, and differed only in that VP4+ clones were well represented 
in the response to P815, but not in the ESbL-Gal induced response. The CD8+ T-cell fractions from 
the two animal groups were more dissimilar in their VI3-chain involvement, markedly in that VP4+ 
clones were more important in the ESbL-Gal reactive group, while the PB15 reactive cells generally 
involved a greater variety of V!3-chains with an important involvement of Vp8.2. 
It has previously been put forward that the Vl35-chains are expressed in DBAl2 mice (Schirrmacher 
et al. 1992), and indeed, some V!35.1 and V135.2 transcripts could be detected, albeit at very low 
levels. Whether these are also translated to form part of a functional TCR remains to be elucidated 
by another method, such as flow cytometry. The same applies to the Vp8.1 transcripts detected in 
T-cells from PB15 immunised DBAl2 mice. 
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Fig. 4.11 TCR-V~ repertoire of CDS+ vs. CD4+ T -cells in d3 iPEC. DBN2 were 
primed Le. and re-stimulated Lp. either with ESbL-Gal (left) or P815 (right) . CD8+ and 
CD4+ T-cells were purified from d3 iPEC by FACS sorting using a FACSvantage 
machine. TCR-VP chain expression was analysed by RT-PCR, using Cn (anneals in 
TCR-C region) as a counter-primer for Vp-specific primers. Thymocytes served as a 
positive control. The results obtained are summarised in the table. T8.Gal, T4.Gal: 
CD8+ and CD4+ T-cells, respectively, from ESbL-Gal immunised mice. T8.P815, T4. 
P815: CD8+ and CD4+ T-cells , respectively, from P815 immunised mice. -- , not 
detected; +1-, weakly expressed; +, involvement; , strong involvement. 
4.4 Therapeutic potential of secondary activated anti-~-gal effector cells 
I· 
An experimental system was needed to analyse the fate of memory T -cells in vivo. As described in 
the introduction (1 .3.2), a syngeneic ADI system had previously been established, where an 
immunotransfer of DBAl2-derived d3 iPEC to ESb tumour bearing DBAl2 mice resulted in long-term 
survival (Schirrmacher et al. 1994b, Schirrmacher 1995b). This protocol of graft versus leukaemia 
(GvL) ADI was altered to include T-cell deficient Balb/c nulnu mice as recipients of tumour and 
immune cells. 
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Fig. 4.12 ADI of pre-irradiated ESbL-Gal-bearing Balb/c nu/nu mice. One day 
before tumour inoculation with 1 x 105 ESbL-Gal i.v., Balb/c nu/nu mice received 
whole-body y-irradiation at a dose of 4.5 Gy. The control group (gr. II , • . n = 10) 
received no further treatment, while group I ( • , n = 30) received 1 x 107 d3 anti -
ESbL-Gal iPEC i.v . on d1 . Day 3 iPEC were produced as described in 3.1.5.5. 
p < 0.0001 . 
Illustrated is one representative experiment of 7. 
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Fig. 4.12 illustrates the survival of AD I-treated (gr. I) or -untreated (gr. II) Balb/c nu/nu mice after 
ESbL-Gal tumour injection i.v .. ESbL-Gal is a highly aggressive T-Iymphoma, which kill s its hosts 
within 8-10 days if it remains untreated . The DBAl2-derived anti-ESbL-Gal d3 iPEC, which could be 
shown to exert anti-p-gal specific killing activity in vitro (4.3.2) , proved to be highly effective also in 
vivo, prolonging survival of tumour-bearing Balb/c nu/nu mice. 
The altered AD I-protocol thus resulted in a very high therapeutic success , with ADI -treated animals 
surviving for over one year (see Fig . 4 .13 in section 4.4 .1). It, therefore, provides optimal conditions 
for the study of the protective effects and long-term fate of the tumour reactive T-cells . 
4.4.1 Pre-irradiation of therapy recipients improves survival 
The effects of sub-lethal y-irradiation (4 .5 Gy in mice) on the organism and the immune system are 
multiple (Schirrmacher et al. 1994a). Primary B- and T-Iymphocyte responses are suppressed, but 
the phagocytic activity of the reticuloendothelial system , including macrophages, is not affected. 
Secondary lymphoid tissues, such as the spleen and lymph nodes , are depleted of radio-sensitive 
leukocytes, providing additional space and improved take of transferred cells. Preceding a cellular 
transfer to immuno-competent animals , whole-body y- irradiation can eliminate the problem of host 
versus graft (HvG) reactions , in which mature host T -cells attack the grafted cells. 
Resul ts 
:> 
:> 
ro u <.9 
...J w 
.D a.. 
100 I ~ 
(f) M 
W "0 
>-
.,., 
'0 
c.9 0 
80 ...., - L() >< >< 
"<i 
n) 
> 60 .~ 
::J 
d -1 dO d1 
---I + + + 
'" ~0 40 -+- 11 + + 
-- III -- + + 
20 IV -- + 
o~~~~~~~~~ 
o 20 40 60 80 100 400 430 460 
days post tumour inoculation 
Fig. 4.13 Pre-irradiation of ADI recipients is necessary for achieving a 
complete therapeutic effect. 4.5 Gy y-irradiated (gr. I, • , n = 10) or non-irradiated 
(gr. III , • , n = 10) tumour bearing Balb/c nu/nu mice were treated with 1 x 107 d3 
iPEC. Negative controls were either whole-body y- irradiated (gr. II , • , n = 10) or not 
(gr. IV, • , n = 10) and received no AD!. 
Illustrated is a single experiment. 
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In the present system , which involves a cellular transfer to immunocompromised (athymic) mice, 
ADI was most effective in conjunction with whole-body irradiation of 4.5 Gy (Fig . 4.13 gr. I) . Such 
treatment resulted in long-term survival of ESbL-Gal tumour bearing Balb/c nu/nu mice, with most 
animals surviving for over 1 year. Although the immunotransfer alone resulted in a significant 
(p < 0.0001) increase in survival compared to control animals (gr. IV), non-irradiated AD I-recipients 
died within 1 month after tumour injection (gr. III) . The life expectancy of non-irradiated ADI-
recipients was significantly lower (p < 0.0001) than that of irradiated ADI-recipients (gr. I) . Control 
animals having received 1 x 105 ESbL-Gal Lv. but no ADI died within 8 days after tumour injection, 
no matter whether they received whole-body irradiation (gr. II) or not (gr. IV) . 
The AD I-model including whole-body y-irradiation and immunotransfer of 1 x 107 ESbL-Gal reactive 
d3 iPEC will hereafter be referred to as 'standard therapy'. The therapy scheme is illustrated in 
Fig. 4.14. 
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d-9 5x104 ESbL-Gal i.e. 
Donor: DBA/2 mouse 
adoptive transfer of iPEC 
Recipient: Balb/c nu/nu mouse 
d-1 4.5 Gy whole-body irradiation 
d-2 1 x1 07 irr. ESbL-Gal i.p. 
d1 iPEC-isolation 
dO 1x105 ESbL-Gal i. v. 
d1 1x107 iPEC i.v. 
Fig. 4.14 Schematic representation of the standard therapy protocol. Nafve 
DBAl2 mice were injected a sub-tumorigenic dose of 5 x 104 ESbL-Gal i. e. (day -9) 
and 7 days later challenged with 1 x 107 irradiation-inactivated (100 Gy) ESbL-Ga l i.p. 
(day -2) . 3 days after the second tumour cell inoculation (day 1), d3 iPEC were 
harvested and adoptively transferred to ESbL-Gal tumour-bearing Balb/c nu/nu mice 
by i.v. injection . These had been whole-body irradiated (day -1) one day before tumour 
inoculation with 1 x 105 ESbL-Gal i.v. (day 0) . 
7'1< 
In order to investigate the effect of this model of ADI in situ, the experiment described abov was 
repeated with all four groups. Livers and spleens (target organs of ESbL-Gal metastases) wer 
isolated at different time points after tumour injection and incubated with X-gal staining solution in 
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Fig. 4.15 B shows one gr. I and gr. III animal, respectively, 28 days after tumour inoculation. The 
non-irradiated gr. III animal exhibited multiple fast growing tumour nodules, presumably located in 
peripheral lymph nodes, while the pre-irradiated gr. I animal suffered no externally visible tumour 
growth and remained clinically healthy throughout the observation period (over one year). 
d3 iPEC transfer to ESbL-Gal-bearing Balb/c nu/nu thus appeared to be sufficient for eradicating 
liver and spleen metastases, as no micrometastases were evident macroscopically after X-gal 
staining even at late time points (d20). Although internal organs seemed to be free of tumour cells 
in both groups of AD I-treated animals, whole-body irradiation was necessary to prevent outgrowth 
of tumours in the periphery. 
4.4.2 MHC-compatible T-cell deficient recipients provide an optimal model system 
Two different strains of T-cell deficient nude mice were compared as d3 iPEC recipients, namely 
Balb/e nu/nu and CD1 Swiss nu/nu mice. Like the donor mice (DBN2), Balb/e nu/nu mice are back-
crossed and express the MHC class I allele H_2d, whereas CD1 Swiss nu/nu mice are outbred, 
exhibiting genetic variance at the MHC-Iocus. Thus, the former were used as MHC-identical and the 
latter as MHC-unidentical AD I-recipients. 
In both cases (Fig. 4.16 A), ADI without pre-irradiation of the therapy-recipients conferred 
significantly higher (p < 0.0001) survival times to ESbL-Gal-bearing mice than no treatment (gr. II). 
The overall therapy efficiency was significantly higher (p < 0.0001) in MHC-compatible Balb/c nu/nu 
miee than in MHC-unmatched CD1 Swiss nu/nu. While Balb/e nu/nu mice died between d18 to d33 
having a median survival of 29.5 days, CD1 Swiss nu/nu died already from d9 to d20 and had a 
median survival of 16 days. 
As the liver is a target of metastasis in the ESbL-Gal tumour model, a parallel ADI-experiment was 
set up in which 1-3 animals per group were killed at various time points in order to follow the 
metastatic load of the isolated livers by whole-organ X-gal staining. In Balb/c nu/nu mice, the livers 
remained clear of macroscopically visible metastases throughout the experiment (Fig. 4.16 B). 
There was, however, tumour growth at peripheral sites (see 4.4.1). In contrast, some CD1 Swiss 
nu/nu mice produced liver metastases as early as d8 post tumour inoculation, while on d12 
(= 11 days after immune cell transfer) no metastases were detectable by whole-organ X-gal 
staining. On d15, the livers stained blue all over, exhibiting a distinct mosaic-like pattern. The same 
pattern of metastasis has been found in immunocompetent DBAl2 mice 23 to 30 days after 
intradermal inoculation of ESbL-Gal (Kruger et al. 1994b). 
The results clearly show the superiority of H-2 matched Balb/c nu/nu (Le. MHC-compatible) as ADI-
recipients in the present therapy model. This also holds true for a protocol which does not include 
pre-irradiation of the treated animals. 
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4.4.3 Requirement of both CD4+ and CDS+ T-cells for a complete therapeutic effect 
T-Iymphocytes are the main mediators and effectors of anti-tumour immunity. CD4 ' T-cells play an 
important role during the initiation phase of an immune response, although they can also exert 
effects later on (Pardoll et al. 1998). CD8+ T-cells, on the other hand , are the main lymphocyte 
population exerting Ag-specific cytotoxicity and destroying tumour cells directly in situ. 
Surman and colleagues described the CD4 + T-cell mediated control of CD8+ T-cell reactivity to a 
model tumour Ag (Surman et al. 2000) . They used a Th1 -type CD4+ T-cell clone specific for ~-ga lto 
activate CTLs in situ in tumour bearing mice. It has previously been reported that the afferent phase 
of the anti-ESb tumour immune response is dependent on both CD4+ and CD8+ T-cells 
(Schirrmacher et al. 1994a), while the effector phase is mainly dependent on CD8+ T-cell mediated 
cytotoxicity (Schirrmacher et al. 1991, Schirrmacher et al. 1994a). In order to analyse to what extent 
these two T-cell populations are responsible for the therapeutic success of ADI treatment , ESbL-
Gal-bearing Balb/c nu/nu mice received a cellular transfer of CD4+ or CD8+ ce ll depleted ESbL-Gal-
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Fig. 4.17 Both CD4+ and COS+ T-cells are required for optimal anti-tumour 
protection. Balb/c nu/nu mice received whole-body y-irradiation at a dosis of 4 .5 Gy 
one day prior to tumour inoculation of 1 x 105 ESbL-Gal i.v .. On d1 , gr. I animals ( • , 
n = 12) received 6 x 106 CD4 + cell depleted d3 iPEC, while gr. II animals ( • , n = 12) 
received 6 x 106 CD8+ cell depleted d3 iPEC. Both treatments resulted in reduced 
survival of ESbL-Gal-bearing Balb/c nu/nu mice compared to animals having received 
the full dosis (1 x 107 cells) of total d3 iPEC (gr. III, & , n = 30) . Gr. IV (5 x 106 iPEC, • 
, n = 20) shows that this decreased survival is not solely due to the lower iPEC 
numbers applied. Negative control animals (gr. V, T , n = 3) received no ADI. 
Represented is one experiment of two. 
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CD4-depleted iPEC (Fig. 4.17, gr. 1,6 x 106 iPEC) conferred decreased survival in comparison to 
undepleted iPEC (gr. III and IV), though the difference to half-dose standard therapy (gr. IV, 5 x 106 
iPEC) was not significant (p = 0.0918). ADI with CD8-depleted iPEC resulted in an even lower 
survival rate, which proved significantly different than that of animals having received half-dose 
standard therapy (p = 0.0058). The median survival time of animals having received CD8-depleted 
iPEC (gr. II) was 29 days, while that of CD4-depleted iPEC recipients (gr. I) was 51.5 days. In spite 
of this, the two groups were not significantly different (p = 0.2131). The fact that gr. IV animals 
having received 5 x 106 total iPEC had a better median survival (69 days) demonstrates that the 
decreased survival of gr. I and gr. II animals in comparison with those having received the full 
therapy (gr. III: 1 x 107 total iPEC) was not only due to the lower cell numbers applied (6 x 106). 
The results clearly support previous data, demonstrating that the induction of optimal systemic anti-
tumour immunity involves both CD4+ and CD8+ T-cells specific for tumour-associated Ag 
(Schirrmacher et al. 1992; Hung et al. 1998). 
4.5 Long-term immunological memory 
One of the most important features of adaptive immune response is its ability to provide protective 
immunity, for instance against re-infection with the same pathogen, or, in the case of cancer, 
against outgrowth of dormant tumour cells or minimal residual disease. 
4.5.1 Anti-ESbL-Gal long-term protection 
To determine whether the present anti-ESbL-Gal therapy model results in long-lasting immune 
protection, i.e. whether or not it yields anti-ESbL-Gal specific immunological T-cell memory, 
successfully treated Balb/c nu/nu mice received an intravenous tumour challenge of live ESbL-Gal 
more than 2 months after their first exposure to ESbL-Gal. 
Tumour doses as high as 5 x 107 cells were successfully rejected (Fig. 4.18 gr. I) and 66 % of the 
animals survived for over 8 months. Although untreated memory animals (gr. II) had a better 
survival than tumour-challenged mice, this difference was not significant (p = 0.0999). 
The cells involved in long-term immune protection are memory cells by definition, as tumour 
challenge was done over 2 months after the initial effector phase had subsided. This experiment 
illustrates that the therapy model used produces long-lived memory T -cells which can rapidly be 
activated to expand and eliminate high doses of ESbL-Gal tumour cells. It was, therefore, 
concluded that this model provides a suitable system for studying features of T-cell memory. 
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Fig. 4.18 Anti-ESbL-Gallong-term protection. Balb/c nu/nu mice having survived 
anti-ESbL-Gal ADI for over 2 months received a tumour challenge of 5 x 107 ESbL-Gal 
i.v. (gr. I, • , n = 6) . Animals from the same ADI experiment obtaining no second 
tumour injection served as positive controls (gr. II, 'f , n = 27), while na"i"ve Balb/c 
nu/nu mice receiving 1 x 105 ESbL-Gal i.v. served as negative controls (gr. III , • , 
n = 10). 
The graph shows one of two experiments. 
4.5.2 Radiation-resistance of memory T-cells 
Biologic functions of na"i"ve T-cells requiring proliferation and differentiation are adversely affected by 
y-irradiation, while effector functions of T-cells activated before administration of irradiation are not 
suppressed (Igietseme et al. 1995). It has previously been reported that immunological memory, 
similar to an immunological effector phase, is resistant to 5 Gy y-irradiation (Muller et al. 1998). If 
memory T-cells were as radiation-sensitive as naive T-cells , whole-body irradiation of memory 
animals should result in the destruction of memory cells via radiation induced apoptosis. Thus, 
administration of irradiation prior to a secondary tumour challenge would as a consequence prevent 
the tumour cells from being attacked by T-cells (destroyed T-cell memory) and WOUld , therefore, 
markedly reduce survival. 
The results of the experiment shown in Fig. 4.19 support previous reports that memory T-cells are 
radio-resistant. The survival of memory animals, which were irradiated (gr. II) was not significantly 
different (p = 0.3408) from that of non-irradiated (gr. I) memory animals after high dose tumour 
challenge (5 x 107 ESbL-Gal i.v.). The reduction seen was , nevertheless, reproducible . 
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Fig. 4.19 Anti-ESbL-Gal specific memory T -cells are long-lived and radio-
resistant. 2 months post ADI , Balb/c nu/nu mice received a tumour challenge of 
5 x 107 ESbL-Gal i.v. , either without (gr. I, • , n = 6) or with prior whole-body 
y-irradiation of 4.5 Gy (gr. II , • , n = 6) . Positive control animals remained without 
tumour challenge (gr. III , A , n = 10), while nafve Balb/c nu/nu inoculated with 1 x 1Or. 
ESbL-Gal i.v. served as negative controls (gr. IV, • , n = 5). 
Shown is one representative experiment of two. 
4.6 Longevity and therapeutic potential of memory T-cells after multiple transfers 
X5 
In order to determine whether donor T-cells retain their tumour-reactivity in vivo, Balb/c nu/nu mice 
having received standard therapy (4.4.1) were restimulated intraperitoneally one month after ADI 
transfer. mPEC (memory PEC) were isolated 3 days after i.p. challenge and transferred to 
secondary ESbL-Gal tumour-bearing Balb/c nu/nu (Fig . 4.20, gr. I) . 
The presence of ESbL-Gal tumour reactive memory immune cells was demonstrated in ADI-trea ted 
Balblc nulnu mice. These cells could be attracted to the peritoneum by i.p. stimulation with 1 x 107 
irradiated (100 Gy) ESbL-Gal for transfer into a secondary tumour-bearing Balb/c nu/nu host (gr. I) . 
66 % of the secondary hosts survived for 5 months. Negative control animals received whole-body 
y-irradiation and tumour cells but no immune cell transfer (gr. II) . Their survival was significantly 
lower than that of animals having received mPEC (p < 0.0001) . Balb/c nu/nu mice trea ted by 
standard therapy were used as positive controls (gr. III) . The difference in survival between gr. I and 
gr. III animals was found to be statistically significant (p = 0.0343) . 
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Fig. 4.20 ADI by transfer of memory cells to tumour bearing Balb/c nu/nu 
mice. Tumour bearing Balb/c nu/nu mice received 1 x 107 mPEC isolated from AD I· 
treated memory Balb/c nu/nu mice (3.7 months post ADI) (gr. I, • , n = 11). Negative 
control animals received no treatment (gr. II , • , n = 10), while positive controls 
received 1 x 107 d3 iPEC isolated from DBAl2 mice (gr. III , • , n = 3) . All animals were 
whole-body irrad iated with a dosis of 4.5 Gy 1 day prior to receiving a tumour 
inoculation of 1 x 105 ESbL-Gal i.v . . 
Illustrated is one of two experiments. 
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Memory cells can thus be attracted to the peritoneal cavity by antigenic stimulation from where 
they can be recovered for further in vivo and in vitro experiments. 
One way of monitoring the division rate of cells is by telomere analysis, as the length of telomere 
restriction fragments (TRF) is reduced at every cell division. Telomeres are the term inal repeat 
sequences (5'-TTAGGG-3') of chromosomes which are necessary for correct replica tion during 
cell division , as well as for prevention of chromosome loss (Harley et al. 1995, Artandi et al. 2000) . 
However, telomere analysis is not very practicable in the murine system (Lansdorp 1995) . 
To determine how often ESbL-Gal-stimulated immune cells can be expanded in vivo before 
exhaustion and loss of function, the standard AD I-protocol was extended to include multiple 
transfers of immune cells from one host to another. 
As illustrated in Table 4.2, Ag-specific memory T-cells retained their reactivity and protective 
capacities for a long period of time (test duration: 8 months) , even when repeatedly stimulated to 
proliferate and expand. Gr. III and IV animals reveal a marked increase in survival (compared to 
untreated controls) with half the dose of PEC (5 x 106) than that which is normally administered for 
ADI , and nevertheless, protective immunity was transferred . 
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ADI nu/nu duration of deaths: untreated control: 
performed with host PEC within day and death day and 
host frequencyl) frequencyl) 
1 x 107 DBAl2 iPEC 1° 33 days 0/21 d9 5/5 
1 x 107 gr. I mPEC 2° 43 days 0/19 d8 2/2 
5 x 106 gr. II mPEC 3° 41 days d40 1/10 d9 2/2 
5 x 106 gr. III mPEC 4° 145 days d39 1/3 d10 2/2 
d78 1/3 
d145 1/3 
Table 4.2 Multiple transfer of memory cells. All animals received 4.5 Gy whole-
body irradiation before being inoculated with 1 x 105 ESbL-Gal i.v . . Gr. I animals were 
treated with 1 x 107 d3 iPEC obtained from ESbL-Gal-immunised DBAl2 mice . mPEC 
were isolated from AD I-treated Balb/c nulnu mice by injecting 1 x 107 irradiated (100 
Gy) ESbL-Gal i.p., 3 days before mPEC-isolation. These were used to cure ESbL-Gal-
bearing Balb/c nu/nu mice (gr. II) following the standard ADI protocol. This procedure 
was repeated 3 times, leaving the immune cells within one host for a minimum of one 
month (see time spans indicated) before re-isolation and transfer to the next host. 
Total duration of the experiment: 8 months. 
Shown are the results from a single experiment. 1) frequency indica tes the number of 
dead animals from the total number of animals per group. 
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Fig. 4.21 mPEC from Balb/c nu/nu are as potent as iPEC isolated from DBAl2 
mice in a GvL ADI transfer. Whole-body irradiated (4 .5 Gy) ESbL-Gal tumour bearing 
Balb/c nu/nu received 5 x 106 iPEC from DBAl2 (gr. I, • , n = 20) , 5 X 106 mPEC from 
the quaternary host (see Table 4.2) (gr. II , & , n = 3), or no treatment (gr. III , • , n = 2). 
Shown is a single experiment. 
Results 
To test whether mPEC were equally potent as DBN2-derived iPEC, the survival of quaternary 
host animals (table 4.2 gr. IV = Fig. 4.21 gr. II) was compared to that of tumour-bearing Balb/c 
nu/nu mice having received half-dose standard therapy (Fig. 4.21 gr. I). Both groups were treated 
with 5 x 10s ESbL-Gal reactive PEC. In both cases, the low dose of 5 x 10s PEC was insufficient 
for providing long-term survival of ESbL-Gal-bearing Balb/c nu/nu mice. Survival curves for the 
two groups are virtually identical, and the differences not statistically significant (p = 0.6464). 
4.7 Persistence of Ag in the long-term maintenance of tumour specific memory T -cells 
4.7.1 Distribution of memory T-cells throughout the body as visualised by tetramer 
staining 
The efforts in T-cell memory research are mainly focused on elaborating their requirements for 
long-term survival and maintenance of Ag-reactivity. Whether compartments exist in vivo where 
memory T-cells preferentially localise has hardly been investigated. 
In order to address this question. single cell suspensions were prepared from spleen. bone marrow, 
peripheral lymph nodes. and peripheral blood from Balb/c nu/nu mice having received ESbL-Gal 
tumour cells as well as ADI 6.4 months before. The frequency of l3_gaI87s.884/MHC tetra mer binding 
cells within the CDa+ compartment was determined by flow cytometry, and the results are illustrated 
in Fig. 4.22. The highest frequency of tetra mer binding cells among coa+ cells was detected in the 
bone marrow (26.3 %). while the spleen hosted only 3.4 % and peripheral lymph nodes only 0.7 % 
tetramer binding cells. Of the blood circulating coa+ cells. 4.2 % bound the tetrameric complexes. 
Organs from naIve aged Balb/c nu/nu mice served as negative controls, where the frequency of 
tetramer binding cells ranged from 0 % in the bone marrow to 0.5 % in peripheral lymph nodes. 
Memory T-cells thus appear to accumulate in the bone marrow, indicating that this 
microenvironment might be of major importance in the maintenance of such long-term surviving 
cells. 
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expression and tetramer-binding. The frequency of tetramer binding cells within the live CD8+ 
population was extremely low (~ 0.5 %, Fig. 4.23), and tetramer binding was mainly unspecific (no 
tight tetramer+ populations, compare with Fig. 4.22). Organs from naIve aged Balb/c nu/nu mice 
served as negative controls, where the frequency of tetra mer binding cells was in the same range 
(0.0 - 0.5 %) as in the organs from animals in the parking experiment (0.1 - 0.5 %). 
It is, therefore, concluded that in the present model Ag-persistence is necessary for the 
maintenance of Ag-specific memory T-cell numbers. 
4.8 Anti-~-gal DNA-vaccination 
In the ADI experiments described so far, d3 iPEC were generated in DBAl2 mice by anti-tumour 
immunisation in the ear pinna, followed by i.p. restimulation with irradiated ESbL-Gal tumour cells. 
In this situation, the CTL present within the d3 iPEC will be reactive against a panel of tumour Ags, 
including the endogenous ESb TAA and the bacterial ~-gal expressed by this T-Iymphoma cell line. 
DNA-vaccination allows to restrict the immunisation against a single protein Ag, such as ~-gal, or 
even against single peptide epitopes. This would facilitate the ex vivo analysis of memory T -cells, 
especially for elaboration of their functional properties. 
The following experiments using DNA-vaccination were designed to determine whether iPEC 
reactivity against the ~-gal protein is sufficient to prevent rapid death due to liver metastasis in 
tumour-inoculated Balb/c nu/nu mice after ADI, and whether DNA-vaccination results in the 
development of long-term T-cell memory. 
4.8.1 Induction of delayed type hypersensitivity (DTH)-reactivity following DNA or cellular 
vaccination 
Delayed type hypersensitivity (DTH) reactions can be induced by a large variety of Ags and appear 
to depend upon a special subset of CD4+ T-Iymphocytes which secrete inflammatory cytokines. The 
inflammatory reaction following an Ag-specific challenge of immunised individuals can typically be 
observed to start 6 - 12 hours after Ag-administration, peaking between 24 - 72 hours, and 
decreasing again thereafter. The stronger the DTH response, as determined by the degree of 
redness and swelling at the site of Ag-challenge, the stronger the T-cell response (de Weck 1998). 
Here, a DTH test was used to analyse T-cell activation following either DNA or cellular ear pinna 
vaccination. To this end, DBAl2 mice received either one or two ear pinna injections (with a 2 week 
interval) of either pCMV~ DNA (coding for ~-gal) or ESbL-Gal tumour cells. 5 days after 
immunisation, the animals were challenged with ESbL-Gal lysate in the contralateral ear pinna, and 
the DTH reaction was evaluated two days later as previously described (Schirrmacher et al. 1994c). 
The results are illustrated in Fig. 4.24. 
Results 
c:::J grade 0 
c:::J grade 1 
c:::J grade 2 
grade 3 
d-19 left ear DNA cells 
d-5 left ear DNA DNA cells cells 
dO right ear lysate lysate lysate lysate 
Fig. 4.24 DTH-reaction following DNA or cellular vaccination in the ear pinna. 
DBAJ2 mice were primed in the left ear pinna as indicated and challenged 5 days after 
the last stimulus in the contralateral ear pinna with 50 III ESbL-Gal lysate (from a cell 
suspension of 2 x 106 cells/ml) . 48 hours after the lysate injection, DTH reaction was 
evaluated using an established grading system. grade 0: no erythema and no swelling 
( 0 ); grade 1: erythema without swelling ( ); grade 2: erythema with swelling of 
<0.5 mm ( • ); grade 3: erythema with swelling of >0.5 mm ( • ). %: percentage 
animals per group with the indicated DTH-grade; DNA: 50 119 pCMV~ plasmid DNA; 
cells: 5 x 104 ESbL-Gal. 
Shown are the results of a single experiment with 4 animals per group. 
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After two DNA-injections administered with an interval of 2 weeks, the reaction was stronger in 
responding animals (grade 2-3) than after a single injection (grade 1), though in both cases half the 
animals still had no measurable DTH-reaction (grade 0) following ear pinna challenge with ESbL-
Gal lysate. After a single cellular vaccination , the DTH-response ranged from grade 1-3, while in 
ESbL-Gal double immunised animals, the intensity of swelling ranged from 0.5 to 2.5 mm (grade 3) . 
In all groups, erythema and swelling declined after 72 hours. 
The results indicate that, under the present conditions , cellular priming results in a stronger T-cell 
response than does DNA-vaccination, though with both types of stimuli, two injections were more 
efficient than one in the induction of Ag-reactive CD4+ T -cells. In the case of the tumour primed 
animals, the priming and DTH stimuli contained more than one common Ag (the Esb-derived T AA 
and ~-gal) , while in DNA-primed animals there was only one common Ag (~-gal) . This might, at 
least partially, explain the more elevated responses observed in ESbL-Gal primed mice. 
The experiment will have to be repeated with more animals per group to determine the significance 
of the present preliminary data. Additionally, the DTH-stimulus should be chosen to have only one 
common Ag with both pCMV~ and ESbL-Gal, in order to provide more comparable conditions for 
the cellular and DNA-vaccination . 
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4.8.2 DNA-vaccination is less efficient than cellular vaccination in the induction of CTls 
It is known that bacterial DNA can circumvent the need for CD4+ T-cells in the activation of Ag-
specific CTls, as the recognition of unmethylated CpG motifs present in bacterial DNA by TlR9 on 
DCs can directly condition the DCs to provide the signals necessary for CTl-activation (Cho et al. 
2000, Akira et al. 2001). As the results presented in the previous section (4 .8.1) indicated a lower 
efficiency of a DNA-vaccine, as compared to a cellular stimulus, in the induction of Ag-specific 
CD4+ T-cell responses, the efficiency of CD8+ T-cell induction was now investigated. 
To this end, animals received either a single ear pinna injection of 5 x 104 ESbL-Gal , or four pCMV~ 
injections administered in intervals of 1 week. Ag-reactive immune cells were recru ited to the 
peritoneal cavity by intraperitoneal injection of radiation-inactivated ESbl-Gal and analysed for 
T -cell content by flow cytometry. 
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Fig. 4.25 T-cell and B-cell content in iPEC from DNA-vaccinated or ESbl-Gal 
immunised DBAl2 mice. DBN2 mice were primed with either 5 x 104 ESbL-Gal (gr. I, 
) or 50 ~g pCMV~ i.e. (4x in weekly intervals, gr. II, • ) and restimulated with 1 x 
107 irradiation-inactivated ESbL-Gal i.p . . iPEC were isolated 3 days later and analysed 
by 2-colour flow cytometry for the presence of CD4+ and CD8+ T -cells, and B-cells. 
Shown is one of two experiments. 
While iPEC from ESbL-Gal immunised DBN2 mice contained 9.1 % CD4+ and 18.9 % CD8+ T-cells 
(Fig. 4.25, gr. I), iPEC from DNA-vaccinated animals contained only 5.2 % CD4+ and 4.4 % CD8+ 
T-cells (gr. II) . The ratio of CD4+ to CD8+ T-cells was also different in gr. II iPEC (1 .2 : 1) and gr. I 
iPEC (1 : 2.1) . In contrast to the low frequency of T-cells in DNA-vaccinated animals, the frequency 
of B-cells was higher in iPEC from these mice (36.5 %) than in iPEC from ESbL-Gal immunised 
mice (24.1 %) . This might indicate a more important involvement of Ab-mediated immune 
responses following DNA-vaccination than following a cellular stimulus. 
Taken together these data indicate that, under the present experimental conditions, vaccination with 
DNA coding for a protein Ag might not be sufficient to induce strong secondary CTl responses. 
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4.8.3 Generation of cytotoxic killer cells after DNA-vaccination 
In order to test whether iPEC from DNA-primed DBAl2 mice , albeit their low CD8+ T-cell content, 
are able to exert Ag-specific cytotoxicity, it was evaluated which vaccination regimen would be most 
suitable for the production of peritoneal CTL. To this end, DBAl2 mice were vaccinated with pCMV~ 
plasmid DNA in the ear pinna 1 week (Fig. 4 .26 gr. III), 2 weeks (gr. II) , or 3 weeks (gr. I) before i.p . 
re-stimulation with irrad iation-inactivated P815-Gal. iPEC were isolated 3 days later and tested for in 
vitro cytotoxic activity against ESbL-Gal in a 51 Cr-release assay. 
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Fig. 4.26 In vitro cytotoxicity of d3 iPEC from DNA-vaccinated animals. NaIve 
DBAl2 mice were primed with 50 I1g pCMV~ Le. and restimulated with 1 x 107 
irradiation-inactivated P815-Gal i.p . . gr. I ( • ) received the second injection 3 weeks, 
gr. II ( ~ ) two weeks and gr. III ( • ) one week after priming. iPEC were isolated 3 
days after restimulation and tested for cytotoxic activity against ESbL-Gal (A) , ESbL 
(B) , or P815-Gal (C) in a 4h 51Cr-release assay. 
Highest specific lysis was achieved when DNA-vaccination occurred 2 weeks before Lp. 
restimulation (Fig. 4.26 A gr. II , 13.7 %). A time lapse of 3 weeks between the priming and 
restimulating inoculum yielded a lower reactivity against ~-gal (Fig . 4 .26 A gr. I, 8.5 %), whereas a 
time span of one week between the two inoculations was not sufficient to raise specific lysis levels 
above the unspecific 51 Cr-release from ~-gar target cells (Fig . 4.26 B, <5 %) (values are given for 
E:T = 50:1). These conclus ions were also supported by the results obtained with the more sensitive 
target cell line P815-Gal. W ith ESbL-Gal as target cells the difference in specific kill between 
groups I and II was not significant (p = 0.0584) , but the greater cytotoxic activity of gr. II iPEC was 
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statistically significant when using P815-Gal as targets (p = 0.0343) Only iPEC from gr. III animals 
(1 week between primary and secondary challenge) caused no release of 51Cr from P815-Gal target 
cells upon co-culture. 
Overall the resu lts demonstrate that ~-gal reactive iPEC can be obtained from DNA-primed 
animals . The time span between priming i.e. and re-stimulation i.p. needs to be longer (2 weeks) 
than in ESbL-Gal primed animals (1 week, Fig. 4 .7, 4.3 .2) . 
4.8.4 Anti-ESbL-Gal ADI with iPEC from DNA-vaccinated DBAJ2 mice 
The question arose whether anti-~-gal reactive iPEC from DNA-vaccinated were potent enough to 
yield long-term survival of LCI-bearing Balb/c nu/nu mice after adoptive transfer. To this end , DBAl2 
mice were primed with ~-ga l coding pCMV~ plasmid DNA 2 weeks prior to receiving an 
intraperitoneal challenge with irradiation-inactivated P815-Gal tumour cells . iPEC were isolated 3 
days later and transferred to ESbL-Gal tumour bearing Balb/c nu/nu mice. 
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Fig. 4.27 Therapy of ESbL-Gal-bearing mice by ADI of anti-~-gal d3 iPEC. One 
day before tumour inoculation with 1 x 105 ESbL-Gal i.v., Balb/c nu/nu mice received 
whole-body y-irradiation at a doses of 4 .5 Gy. The control group (gr. II , • , n = 5) 
received no further treatment, while the experimental group (gr. I, • , n = 17) received 
1 x 107 d3 anti-~-gal iPEC i.v. on d1. d3 iPEC were isolated from DBAl2 primed with 50 
f,lg pCMV~ two weeks before i.p. restimulation with 1 x 107 irradiation-inactivated P815-
Gal. 
Represented are the results of a single experiment. 
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In combination with whole-body irradiation, ADI of d3 iPEC from pCMV~ primed and P815-Gal 
restimulated DBAJ2 mice (Fig. 4.27 gr. I) was significantly less efficient (p < 0.0001) than treatment 
with ESbL-Gal-primed and restimulated d3 iPEC (Fig . 4.12 in 4.4) . Nevertheless, survival was 
significantly better (p < 0.0001) than in untreated controls (Fig . 4.27 gr. II) , with treated animals 
having a median survival of 36 days, while untreated animals died on days 10-11 post tumour 
inoculation. 
4.8.5 Long-term T-cell memory after DNA or cellular vaccination 
Immunisation with naked DNA provides an enormous potential for developing new vaccines, but, as 
tumour vaccines are not only aimed at inducing protective anti-tumour immunity but also at 
producing long-term T-cell memory, vaccination protocols need to be designed that provide such 
long-lasting T-cell memory. 
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Fig . 4.28 Long-term CTL memory after DNA- VS. cellular vaccination. DBAJ2 
mice were primed as indicated and challenged i.p . with 1 x 107 irradiation-inactivated 
(100 Gy) ESbL-Gal. iPEC were isolated 3 days later and Ag-specific killing activity 
tested in a 4h 5t Cr-release assay. Standard ESbL-Gal-specific d3 iPEC were used as a 
positive control, while PEC from DBAJ2 having received only the secondary i.p. 
challenge served as a negative control. i.e. priming/ injection: either 50 I1g pCMV~ 
plasmid DNA (DNA) or 5 x 104 ESbL-Gal i,e (cells) . The values given are for E:T ratio 
of 50:1. 
The results are from a single experiment. 
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Vaccination with the pCMV~-plasmid can induce immunological memory directed against ~-gal. 
DBAl2 mice which received a s.c. challenge with ~-gal expressing tumour cells 3 weeks after DNA-
vaccination Le. rejected the tumour to variable degrees, depending on the aggressiveness of the 
tumour line used (Schirrmacher et al. 2000). Experiments using the T-Iymphoma line ESb 289 
demonstrated that a single Le. injection is not sufficient to initiate long-lasting CTL memory, while 
Le. immunisation followed by an intra-peritoneal challenge 9 days later resulted in the maintenance 
of tumour specific CTL over a period of at least two months (Schirrmacher 1999). 
The preliminary data shown in Fig. 4.27 indicate that DNA-vaccination did not result in long-term 
surviving Ag-specific memory T-cells. Anti-P815-Gal cytotoxic activity of PEC from DNA-primed 
animals was below the negative control (10.2 %, Lp. challenge only). PEC from DBAl2 mice having 
received two ear pinna injections of ESbL-Gal exerted ~-gal specific cytotoxic activity (18.7 %) 
which was significantly higher than that from negative control animals (p = 0.0327). The difference 
in kill by PEC from negative controls and mice having received a single injection of ESbL-Gal (13.2 
%) was not significant (p = 0.1428). After a priming regimen with two cellular stimuli, Ag-specific 
memory T-cells survived over a long period of time (6 months) and retained their capability of 
exerting Ag-specific effector functions. In contrast, a single cellular injection or DNA-vaccination did 
not result in the maintenance of ~-gal specific memory T -cells. 
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Discussion 
5.1 Cell surface expression of molecules on the parental ESbL-Gal tumour cell line ad its 
bone marrow derived variant ESbL-Bal-BM 
ESbL-Gal are a lacZ-transfected variant of the murine T -lymphoma ESb, expressing the bacterial 
enzyme ~-galactosidase as an additional, highly immunogenic TAA. As the ESb-derived TAA could 
not be identified so far, 13-gal provides an ideal model Ag for the analysis of primary and secondary 
tumour-specific immune responses, as well as the effect of Ag-removal on the memory T-cell pool. 
To this end, it was a prerequisite that 13-gal expression is not lost during tumourigenic progression in 
vivo. Analysis of ex vivo isolated ESbL-Gal from bone marrow derived dormant tumour cells, ESbL-
Gal-8M, and the immune escape variants ESbL-Gal-ET, -ST, and -TT obtained from solid tumour 
nodules revealed that 13-gal is stably expressed in vivo (Fig. 4.1). Furthermore, many other tumour 
nodules were isolated, all of which consisted of /3-gal+ cells, as determined by whole-organ X-gal 
staining. The ESbL-Gal tumour thus represents a relevant model for the study of Ag-specific 
immune responses to cell-bound Ag. 
As mentioned, ESbL-Gal is a variant of the ESb 289 T-Iymphoma. The ESb tumour arose 
spontaneously in vivo, and, in contrast to the parental Eb-line, is highly metastatic. Early studies 
indicated that ESb might have evolved by fusion of an Eb tumour cell with a host macrophage, as 
experimental hybridomas of ESb cells with bone marrow-derived macrophage cultures resembled 
ESb and not Eb in respect to TAA expression, metastatic behaviour, and aggressiveness (Larizza 
et al. 1984). Intriguingly, the macrophage marker F4/80 could not be detected on ESbL-Gal, 
whereas these cells were found to express the 8-cell specific markers CD19 and 8220 (Fig. 4.2), 
suggesting that the in vivo fusion partner of Eb cells might also have been a 8-cell. Furthermore, 
the macrophage cultures used for the fusion experiments were not purified, so that the presence of 
8-cells could not be excluded. In order to clarify the etiology of ESb cells, it would be instructive to 
repeat such fusion experiments using purified macrophages or B-cells. 
Nevertheless, the expression of B-cell markers does not necessarily point toward a B-cell origin, as 
tumour cells can lose Ags specific for their tissue of origin while acquiring others during malignant 
progression. Additionally, the macrophage markers MOMA and Sn have been found to be 
expressed by ESbL-Gal tumour cells in vitro, albeit at a low level, suggesting a possible 
macrophage origin (Rocha et al. 1997). 
Many tumours have been shown to have defective MHC biosynthesis pathways as a strategy of 
immune escape (Alimonti et al. 2000, Seliger et al. 2000). The dormant tumour cell derived ESbL-
Gal-8M where found to be negative for MHC class II, whereas a low level expression was detected 
on the parental ESbL-Gal T-Iymphoma cell line. 80th ESbL-Gal and ESbL-Gal-BM expressed MHC 
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class I molecules on their surface, with expression levels being more elevated in the latter cell line 
(Fig. 4.3), indicating that they can present endogenously derived peptides, including those of the 
model tumour Ag ~-gal. Thus, they could potentially stimulate tumour-reactive CTL directly. To what 
extent the high surface expression of MHC class I plays a role in the sensitivity of tumour cells to 
the host's immune system is unclear. 
How dormant tumour cells protect themselves against elimination by the immune system remains to 
be determined. It has been shown that dormant tumour cells are prevented from expansion on a 
population level by CD8+ T-cells, depletion of which results in the rapid outgrowth of tumour cells 
and death of the animals (MOiler et al. 1998). The dormant tumour cells are thus under tight control 
of the host's immune system, without being completely eliminated. 
Bosslet and colleagues have demonstrated a high frequency development of ESb tumour variants 
in vivo. Such variants had altered T AA expressions as compared to ESb, and this altered 
phenotype proved to be genetically transmitted and stable both in vitro and in vivo (Bosslet et al. 
1982). ESbL-Gal-BM can thus be assumed to closely represent the phenotype of ESbL-Gal-derived 
dormant tumour cells, providing an optimal tool for the analysis of factors that could influence the 
persistence of tumour dormancy in immunocompetent hosts. 
The highly metastatic ESbL-Gal expressed a variety of adhesion molecules, including LFA-1, LFA-
2, L-selectin, ICAM-1, and PSGL-1, and minimally also the ~rintegrin chain (Fig. 4.4), which might 
be necessary for its metastatic phenotype. Injection of ESbL-Gal tumour bearing mice with mAbs to 
LFA-1 and ICAM-1 has been shown to prolong their survival, thus demonstrating an involvement of 
these two molecules in tumour progreSSion (Rocha et al. 1996). 
Bone marrow metastases of cancer patients could be shown, without exception, to express ICAM-1 
(Putz et al. 1999), which could point towards an involvement of this molecule for homing and 
survival in the bone marrow. Consistently, ICAM-1 expression was found to be increased on ESbL-
Gal-BM. In combination with the high expression of MHC class I on the dormant tumour cells, high 
expression levels of ICAM-1 could also indicate that these cells are able to activate tumour-specific 
CTL activity in situ, without the need for APC, thus being directly involved in the control and 
maintenance of a steady population size of dormant tumour cells within the bone marrow 
microenvironment. 
L-selectin mediates the initial adhesion of lymphocytes to high endothelial venules of peripheral 
lymph nodes, an interaction required for the entry of blood circulating na"ive T -cells into the lymph 
nodes. L-selectin expression on ESbL-Gal has previously been published (Rocha et al. 1997). 
Rapid loss of L-selectin expression following T-cell activation may be required for the detachment of 
leukocytes from the endothelium to allow their migration into tissues. Likewise, the fact that ESbL-
Gal-BM proved to be negative for this adhesion molecule might be involved in the seeding of this 
tumour variant to the bone marrow. 
~7-chain integrins as well as PSGL-1 are involved in the migration and homing of leukocytes. The 
~7-integrin chain forms a functional adhesion molecule in combination with either the <X.t- or the <Xe-
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integrin chain, and expression of the latter appears to be restricted to intra-epithelial lymphocytes 
(Lefranyois et al. 1999). «4lh functions as a mucosal homing receptor and its ligands include the 
vascular cell adhesion molecule-1 (VCAM-1), fibronectin, and the mucosal addressin cell adhesion 
molecule-1 (MadCAM-1). <X.!~7 expression on LB lymphoma cells could be shown to strongly 
suppress metastasis formation at a stage subsequent to infiltration of the target organs spleen, 
lymph nodes, liver, lung, and kidney. Only expansion in the bone marrow was not affected by <X.!P7 
integrin expression (Gosslar et al. 1996). A weak expression of the ~7-integrin chain was detected 
on ESbL-Gal tumour cells, which correlates with their ability to form metastases in the liver and 
spleen. Studies on human multiple myeloma peripheral blood B-cells implicated «4P7 in the tumour 
cell adhesion to bone marrow fibroblasts (Masellis-Smith et al. 1997). Likewise, the slightly 
increased ~7-integrin expression on ESbL-Gal-BM might be involved in the retention of dormant 
tumour cells within the bone marrow. 
PSGL-1 has been shown to mediate specific rolling of haematopoietic stem and progenitor cells 
(HSPC) on constitutively expressed P-selectin (platelet selectin) of bone marrow microvenules and 
sinusoids, and has, therefore, been proposed to be involved in the specific homing and 
extravasation to the bone marrow of HSPC following bone marrow transplantation (Greenberg et al. 
2000). PSGL-1 could thus be involved in the homing of some ESbL-Gal cells to the bone marrow. In 
contrast to the parental line, ESbL-Gal-BM were found to be negative for this adhesion molecule. As 
adhesion via PSGL-1 has been shown to suppress the proliferation of HSPC (Levesque et al. 
1999), down-regulation of PSGL-1 on ESbL-Gal-BM might be a strategy to allow their proliferation 
within the bone marrow microenvironment. Again, whether this involves an actual down-regulation 
of PSGL-1 expression or a selection of PSGL-1 negative tumour cells is not clear. 
ESbL-Gal-BM are more sensitive to CTL-mediated cytotoxicity in vitro than the parental ESbL-Gal 
(data not shown) but, nevertheless, persist for prolonged periods of time in the presence of tumour-
reactive memory CTL (MOiler et al. 1998). One explanation for these findings could be that 
adhesion molecules are more important for CTL-tumour cell interactions in vivo than in vitro. The 
expression of only few adhesion molecules on tumour cells could complicate CTL-tumour cell 
interactions in situ, thus allowing for the co-existence of CTL-sensitive tumour cells and tumour 
reactive killers in the bone marrow microenvironment, whereas the close cell-cell contact during 
cytotoxicity assays owing to the experimental conditions could circumvent the need for interaction 
via specific adhesion molecules. 
In contrast to the parental ESbL-Gal, the bone marrow derived variant, ESbL-Gal-BM, appears to 
have a rather naked cell surface concerning not only adhesion molecules but also leukocyte 
markers. As an exception to this, MHC class I and ICAM-1 were highly expressed on these cells, 
both with elevated levels as compared to the parental ESbL-Gal. A general down-regulation of 
adhesion molecules required for rolling interactions with the vascular endothelium during migration 
and dissemination could indicate that dormant tumour cells are a non-migratory population. 
Selective up-regulation of ICAM-1 and «4P7, might then be important for the retainment of these 
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cells within the bone marrow. Down-regulation of PSGL-1 might be involved in allowing bone 
marrow resident tumour cells to proliferate, as it has been shown that adhesion via PSGL-1 
suppresses the proliferation of HSPC of the bone marrow (Levesque et al. 1999). 
5.2 In vivo dissemination of ESbL-Gal following ear pinna inoculation 
ESbL-Gal have been shown to rapidly disseminate to the draining lymph node after ear pinna 
injection, and tumour cells were detected in the subcapsular space of the spleen as early as 15 
minutes after inoculation (Schirrmacher et al. 1997). The tumour cells thus drained quickly from the 
injection site, via lymphatic fluid, into the lymph node where they could induce a primary anti-tumour 
T-cell response. Dissemination to the spleen, on the other hand, occurred via the blood circulation. 
Similar to the spleen, bone marrow is vascularised by blood vessels (Osmond 1994), suggesting 
that tumour cell dissemination to this microenvironment could be equally fast. Unfortunately, no 
data were obtained for early time points (less than 4 days) to test this hypothesis. Nevertheless, 
tumour cells could be detected in the bone marrow with a peak accumulation on day 5 after ear 
pinna injection (Fig. 4.5). Similar kinetics of tumour cell numbers where found in the spleen and 
bone marrow. As the bone marrow stroma contains macrophages that are specialised in 
phagocytosing incorrectly developed blood elements (Krstic 1994) as well as foreign material 
invading the bone marrow microenvironment, it is highly likely that these macrophages, similar to 
those in the spleen, are capable of internalising disseminated tumour cells or products thereof, 
providing the possibility of initiating a tumour-specific T-cell response directly in situ. 
5.3 Bone marrow functions as a secondary lymphoid organ 
The rapid dissemination of tumour cells after ear pinna inoculation not only to the draining lymph 
node but also to other lymphoid organs, such as the spleen and bone marrow, suggests that anti-
tumour reactive T-cells might also be primed in these compartments. 
The spleen is a secondary lymphoid organ where immune responses can be initiated. Consistently, 
phagocytic cells of the spleen have been shown to internalise ESbL-Gal cells already 3 hours after 
tumour injection. Tumour Ag can thus be processed and presented to CD4+ T-cells via MHC class II 
and to CDS+ T-cells via MHC class I, providing one of the necessary conditions for T-cell priming in 
the spleen (Schirrmacher et al. 1997). 
The bone marrow, on the other hand, is classically known as a primary lymphoid organ where 
haematopoiesis and lymphopoiesis take place. To date, its potential role in secondary immune 
functions has been ignored. 
Findings from our group demonstrate that bone marrow APC can take up soluble blood-borne Ag 
for presentation to T-cells both in vitro and in situ (Feuerer et aI., submitted), thus indicating that the 
bone marrow is able to behave like a secondary lymphoid organ where primary T-cell responses 
can take place. Staining with peptide/MHC class I tetrameric complexes has now allowed the 
monitoring of Ag-specific T-cell kinetics directly ex vivo following priming, and revealed that the 
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highest frequency of tetra mer binding cells within the CD8+ population are present in the bone 
marrow, peaking 10 days after tumour inoculation (Fig. 4.6). It is unlikely that this is solely due to an 
influx of primed cells into the bone marrow from the spleen or lymph nodes, and indicates that 
T-cell responses to cellular antigenic material can be initiated in the bone marrow 
microenvironment, although, as also found in the spleen, with slower kinetics than in lymph nodes. 
These findings parallel previously published data demonstrating that the bone marrow supports the 
majority of all Ig-secreting cells which exhibit slower induction of Ig-production, but an overall longer 
lasting response than that observed in other lymphoid compartments (Benner et al. 1981). 
Taken together, the data demonstrate the ability of bone marrow to function as a secondary 
lymphoid organ, and, together with its body distribution and size, suggests that the bone marrow 
can be considered of central importance also for the establishment of immune responses and 
systemic immune control. 
5.4 Secondary anti-tumour T-cell response in the peritoneal cavity 
Intraperitoneal challenge of tumour-primed DBAJ2 mice with radiation-inactivated ESbL-Gal resulted 
in a S.3-fold increase of immune cell numbers within the peritoneal cavity (Table 4.1). While the 
immune population of the naIve peritoneum mainly consisted of B-cells (78.4 %) and contained only 
low numbers of T-cells (S.8 % CD4+ and O.S % CD8+ T-cells), T-cell numbers increased 
dramatically after a secondary challenge at this site (Fig. 4.7). Most markedly, CD8+ T-cell numbers 
exploded to 11.2 % on day 3 post challenge, with 33.9 % of these binding ~_gaI876-884 peptide/MHC 
class I tetrameric complexes. Consistently, iPEC tested at this time point for ex vivo Ag-specific 
CD8+ T-cell mediated killing activity exhibited a high ~-gal specific lysis of target cells (34.S % 
specific lysis of ESbL-Gal at an E:T ratio of SO:1, Fig. 4.8). Tumour-specific CD8+ T-cells were most 
likely recruited from the spleen and bone marrow as exemplified by tetra mer staining of ~_gaI876-884 
reactive cells (Fig. 4.9). Three days after the secondary stimulus, their frequency was demonstrated 
to be lower in these organs as compared to organs from animals having received only the primary 
ear pinna tumour inoculation. 
Influx of immune cells into the peritoneal cavity was enabled by the production of high amounts of 
TNF-a early after tumour challenge, which is known to increase vascular permeability by activating 
the vascular endothelium. Overall, the early phase (days 1 to 3) of the secondary immune response 
within the peritoneum was dominated by type 1 cytokines, namely TNF-a, IL-12, and IFN-y (Fig. 
4.10). These pro-inflammatory molecules were involved in inducing the activation and maturation of 
tumour-reactive CTL.ln contrast, during the late phase (days 4 to 12) of the immune response, type 
2 as well as inhibitory cytokines were dominating, as illustrated for IL-4, IL-S, and IL-10, with IL-2 
acting as a growth factor for Th2 type cells. 
The secretion kinetics for IL-4 and IFN-y correlated well, considering that these cytokines 
reciprocally inhibit each other's production, as well as the activation of the respective secreting cell 
populations. At time points when one was highly expressed the other was suppressed and vice 
versa. 
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Polyclonal T-cell responses were found in both CD4+ and CDS+ T-cell compartments, although the 
CDS+ T-cell pool appeared to use a more restricted number of V13-chains (Fig. 4.11). Overall, the 
TCR-V13 chain repertoire appeared rather similar to that of iPEC from animals challenged with an 
ESbL-Gal unrelated, 13-gal negative tumour (P815). Whether specific V13-chains are better suited to 
recognise the immunodominant peptide of 13-gal (aa S76-SS4, TPHPARIGL) than others and 
whether such T-cells preferentially accumulate during the memory phase remains to be elucidated. 
5.5 ADI model in syngeneic nude mice 
Athymic nude mice were chosen as recipients for the adoptive transfer of Ag-specific cells 
(Fig. 4.12) in order to be able to monitor the fate of tumour-reactive T-cells in an otherwise T-cell 
deficient environment. In this context it was of importance to use ADI recipients (Balb/c nu/nu mice: 
H-2d) that were MHC compatible to the immune cell donors (DBAl2 mice: H_2d) in order to obtain an 
optimal therapy outcome and long-term survivors in which long-term T-cell memory could be 
studied. Use of unmatched recipients (CD1 Swiss nu/nu: outbred) resulted in outgrowth of hepatic 
metastases and premature death of the animals (Fig. 4.16). 
However, a characteristic mosaic-like pattern of metastases was observed in the livers of CD1 
Swiss nu/nu mice 14 days post immune cell transfer (= 15 days after tumour inoculation). In the 
DBAl2 model, this mosaic-like pattern was exclusively detected at very late stages of the disease, 
with tumour cells preferentially localising to periportal regions of liver lobuli. Perivenous areas 
hosted only a low metastatic load (Kruger et al. 1994b). ESbL-Gal were demonstrated to have a 
3-phasic growth characterised by an initial growth phase (dO to d9), a plateau phase (d9 to d20), 
and a secondary expansion phase (d20 to d30) as determined by measurement of the tumour 
diameter after Ld. inoculation into DBAl2 mice (KrOger et al. 1994b). This might explain the present 
results of liver metastases (Fig. 4.16 B), where d12 (no visible metastatic expansion) would lie 
within the plateau phase of tumour growth. In the present model where tumour cells are applied 
intravenously, allowing for a rapid systemic spread, the secondary expansion phase appears to 
commence earlier than in the DBAl2 system, with the mosaic-like pattern of metastases appearing 
already on d15. 
As an effect of HvG should be negligible in nude host mice, it is possible that GvH reactions are at 
least partially responsible for the diminished therapeutic efficiency (Fig. 4.16 B) and premature 
death (Fig. 4.16 A) of tumour-bearing ADI-recipients obtained when using CD1 Swiss nu/nu mice. 
Another reason could be that host APC are required for an optimal therapeutic outcome as 
demonstrated in an allogeneiC immunotransfer system, where Sn+ liver macrophages were shown 
to form tight clusters with donor CD4+ and CDS+ T-cells. Kupffer cell depletion by chlodronate-
treatment resulted in loss of the therapeutic effect (Muerkoster et al. 1999). Such interactions of 
host APC with donor T-cells requires donors and recipients to express identical MHC molecules. 
Best therapeutic effect of ESbL-Gal tumour-bearing Balb/c nu/nu mice was achieved when adoptive 
transfer of ESbL-Gal reactive d3 iPEC was combined with a whole-body irradiation regimen 
Discussion I 04 --------~~~~-----------------------------------------------
administered one day before tumour-inoculation and two days before ADI (Fig. 4.13). Although 
cellular treatment alone was sufficient to prevent macroscopically visible metastases in internal 
organs (liver and spleen, Fig. 4.15 A) as visualised by X-gal staining, tumour nodules were able to 
grow at peripheral sites (Fig. 4.15 B). In contrast, ADI in combination with pre-irradiation of the 
animals prevented tumour outgrowth at both internal and peripheral locations. 
Here, the most important effect of pre-irradiating the AD I-recipients was probably the damage to 
vascular endothelial cells, as this improves the extravasation of immune cells, thus enabling their 
rapid migration and distribution throughout the body. Feurgard and colleagues (1999) found that 
ionising radiation alters the hepatic cholesterol metabolism and plasma lipoproteins. They 
suggested that lipoprotein modifications could result from an induced inflammatory state and may 
further contribute to vascular damage. 
CD4+ T-cells act as mediators of anti-tumour immunity, producing cytokines that induce the 
accumulation and activation of accessory cells such as tumoricidal macrophages, as well as the 
differentiation of NK-cells into Iymphokine activated killer cells (LAK-cells) (Cohen et al. 2000). They 
can also activate DCs, enhancing their ability to stimulate naYve CD8+ cytotoxic T-cells (Ridge et al. 
1998). This explains why CD4+ cell depletion of d3 iPEC prior to ADI reduced survival but did not 
have as severe effects as CD8+ cell depletion, CD4+ T-cells being mainly required during the 
initiation phase of both the primary (Schild et al. 1987) and secondary (Schirrmacher et al. 1994c) 
immune responses, in this case after ear pinna priming, as well as after restimulation of DBN2 
mice in the peritoneum (Fig. 4.17). CD8+ T-cells, on the other hand, function during the effector 
phase after transfer to the ESbL-Gal-bearing Balb/c nu/nu. In the CD8 negative ADI group, the 
prolonged survival, as compared to untreated controls, was presumably due to eosinophils and the 
production of oxygen radicals, namely nitric oxide and superoxide, by tumoricidal macrophages, 
activated by CD4+ T-cell secreted IFN-y (Toes et al. 1999). 
5.6 Characteristics of memory T-cells 
The ADI model presented in this thesis is highly efficient in providing long-term survival of tumour-
bearing nude mice (over 1 year), thus representing optimal conditions for the study of long-term 
memory T-cells in vivo and ex vivo. 
High dose tumour challenge (by Lv. injection of 5 x 107 live tumour cells) of such long-term 
survivors (2 months) resulted in 33 % decreased survival over a time period of 5.3 months 
compared to untreated control mice from the same ADI experiment (Fig. 4.18), and in 66 % 
mortality if the challenge was preceded by whole-body irradiation (Fig. 4.19). Although the 
difference in survival rates did not prove statistically significant, it was reproducible. This could pOint 
towards the increasingly accepted view that there exist two distinct subsets of memory T -cells with 
different homing potentials and effector functions (Bell et al. 1998, Mackay 1999, Sallusto et al. 
1999), one subset resembling activated effector cells ("memory primed") while the other being more 
similar to naYve T -cells ("memory revertant"), with the exception of an elevated precursor frequency 
(see Table 1.2 of the introduction). If this is so, it is conceivable that the effector-like memory T-cells 
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are radio-resistant, while the naIve-like memory T-cells, similar to naIve cells, are radio-sensitive, as 
it is known that naIve T-cells are radio-sensitive while activated T-cells are not (Schirrmacher et al. 
1994a, Igietseme et al. 1995). I am not aware of any publications on the radio-sensitivity of the 
different memory T-cell pools. 
In the case of whole-body irradiation prior to tumour challenge (Fig. 4.19 gr. II) the memory T-cell 
pool would then be depleted of the naIve-like memory cells, thus accounting for the slightly reduced 
survival as compared to the non-irradiated group (Fig. 4.19 gr. I). 
Overall, immunological memory against ESbL-Gal proved to be long-lived and the immune cells 
could be demonstrated to retain their tumour reactivity, as ESbL-Gal inoculated Balb/c nu/nu mice 
having received standard therapy could reject a high dose tumour challenge of 5 x 107 cells with 
66 % efficiency (over a time course of 5.3 months). 
5.7 Recruitment of memory T-cells for multiple ADI transfers 
ESbL-Gal specific memory T-cells retained their tumour reactivity for long periods of time, as mPEC 
isolated from tumour bearing Balb/c nu/nu mice having been treated according to the standard ADI 
protocol 3.7 months earlier could transfer tumour protection to secondary tumour-bearing Balb/c 
nu/nu hosts (Fig. 4.20). As the naIve peritoneal cavity contains only few CDS+ T-cells (0.5 %. see 
4.3.1), most T -cells obtained by the present method of peritoneal antigenic challenge of tumour 
immune animals will be primed with the Ag of choice, although some irrelevant T-cells will also be 
attracted due to bystander effects. Thus, when using Balb/c nu/nu mice as hosts for the monitoring 
of memory T-cells, the majority of T-cells present in the hosts should be Ag-primed, originating from 
anti-ESbL-Gal immunised DBN2 mice. Nevertheless, in sites like the bone marrow, memory T-cells 
will represent only a very small percentage of total cells (of total bone marrow cells only -2 % are 
T-cells), which means that laborious procedures would have to be applied in order to harvest even a 
few memory T -cells. The present protocol of T-cell reactivation in the peritoneal cavity allows for the 
enrichment of Ag-reactive T -cells as well as their recruitment to a site from where isolation is 
uncomplicated. The recent stimulation will result in the activation and expansion of Ag-specific cells, 
thus increasing their numbers. This activation also means, though, that this method is inappropriate 
for the isolation of cells in the memory state. If interested in analysing features of ex vivo memory 
T-cells, one would have to segregate these from the large number of irrelevant cells, e.g. from the 
bone marrow. 
Advantage 
recruitment and enrichment 
of memory cells 
Disadvantage 
memory cells are activated, 
i.e. isolated in an effector phase 
Table 5.1 Advantage and disadvantage of isolating memory cells by 
antigenic stimulation in the peritoneal cavity. 
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It is known that normal somatic cells are unable to divide indefinitely and will die after a certain 
number of divisions. Telomeres are required for complete replication. They prevent chromosome 
loss during cell division. Nevertheless, telomere length decreases with every cell division. This 
eventually leads to truncated chromosome ends, to chromosome ends binding to each other, and 
to chromosome loss (Harley et al. 1995, Artandi et al. 2000). 
Telomere length analysis thus allows the estimation of the number of cell divisions a cell has 
experienced. This tool could be exploited to monitor cell division rates of memory cells over a given 
time course. Unfortunately, detection of changes in telomere length is rather difficult in inbred 
mouse strains, as they have extremely long TRF (Prowse et al. 1995). Mus musculus species have 
unusually long telomeres among mice (>30 kb; wild-derived species Mus spretus: <25 kb (Prowse 
et al. 1995); humans: 5-15 kb (Rhyu et al. 1995)), and TRF length in a given murine tissue can 
differ between individuals of the same age (Kipling 1990, Prowse et al. 1995). Furthermore, inbred 
mice were shown to have sequences with homology to tel om eric repeats at intra-chromosomal 
sites, making telomere analysis of murine tissues extremely problematic (Lansdorp 1995). 
For this reason, longevity of memory T-cells had to be evaluated by an alternative approach. To this 
end, the tumour specific T -cells were recruited to the peritoneum as described and tested indirectly 
for their capacity to expand before exhaustion and loss of function in a multiple transfer experiment. 
The cells were transferred from one group of ESbL-Gal tumour bearing nude mice to the next, 
leaving them to "rest" for at least one month in every host. At every transfer, the cells could prevent 
premature death of the host animals and mPEC isolated from the tertiary host were shown to be as 
efficient as iPEC from DBN2 mice in prolonging the survival of ESbL-Gal inoculated Balb/c nu/nu 
mice (Fig. 4.21). 
Nevertheless, the number of tumour reactive cells appeared to decrease with every transfer. While 
the donor: recipient ratio from the 1 ° to 2° host was 1.1 : 1, for the 2° to 3° host transfer it was 
3.8 : 1 (half the number of cells were transferred to half the number of mice), and for the 3° to 4° 
host transfer it was 3:1 (Table 4.2). This is probably a result of elimination of a memory T-cell 
fraction following over-stimulation, which results in prolonged proliferation and terminal 
differentiation of Ag-specific T-cells, and ultimately in their apoptosis (Sprent et al. 2001). 
The memory T-cells produced in DBN2 mice by ear pinna immunisation and intraperitoneal 
challenge with ESbL-Gal tumour cells were thus long-lived and retained their reactivity over a long 
period of time (8 months, including four T-cell expansion phases following i.p. challenge of the 
respective hosts). Repeated antigenic stimulation probably resulted in a reduction of the memory T-
cell pool. This is consistent with data from other groups indicating that persistent antigenic 
stimulation results in terminal differentiation and exhaustion of the reactive T-cell population 
(Moskophidis et al. 1993). 
5.8 Bone marrow is a central compartment for memory T -cells 
It has previously been found that the frequency of CD4+ T-cells with an activated or memory 
phenotype is four- to fivefold higher in the bone marrow as compared to the peripheral lymphatics 
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This is not only true for immunised mice, but also for untreated, conventionally housed animals, that 
are in contact with environmental Ags (Price et al. 1999), which gives one more reason to work with 
an immunotransfer system to T-cell deficient nude mice for the phenotypical analysis of memory 
T -cells. Like this, all T -cells present in the host with a memory phenotype will have developed in 
response to the Ag of choice and not due to unrelated, environmental stimuli. 
So far, it could not be demonstrated in which organ(s) CD8+ memory T-cells survive until 
reactivation, although it has been published that they occur at higher frequencies in the bone 
marrow as compared to peripheral blood, and that the bone marrow resident Ag-specific T-cells 
were superior to their blood circulating counterparts in Ag-specific cytotoxicity, cytokine production, 
and in vivo therapeutic potential (Feuerer et al. 2001). In the case of the present ADI model system, 
memory T-cells were known to be present in the bm, but it was not clear whether this is the only 
"memory compartment". 
Using peptide/MHC class I tetrameric complexes it could now be demonstrated that the bone 
marrow is not the only, but by far the major, compartment for CD8+ memory T -cells. The frequency 
of ~_gaI876-884 specific cells within the CD8+ T-cell pool in this organ was 7.7 x higher than in the 
spleen and 37.6 x higher than in the lymph nodes. A fraction of tetramer-binding cells were also 
detected in the blood, "patrolling" the circulation for ~-gal+ cells. 
It is not known what makes the bone marrow microenvironment so attractive for memory CTls, but 
the unique structural organisation could play a part. A fine network of arterioles and sinuses 
provides an optimal blood supply. The bone marrow stroma also produces vital growth factors, and 
stromal cell derived type I IFNs have been implicated in the long-term maintenance of memory T-
cells (Akbar et al. 2000). 
It would now be instructive to try in situ tetra mer stainings of bone marrow plugs in order to 
determine which cells tetramer-binding cells interact with and whether they preferentially locate to 
defined sites within this organ. This would give further insights into the mechanisms and factors 
involved in the preferential localisation of memory T-cells to this anatomical site. An in situ tetramer 
(1ST) staining technique has recently been set up, using spleens from TCR-transgenic mice. TCR-
transgenic T -cells could also be detected in spleen sections after adoptive transfer to non-
transgenic animals, and sensitivity of 1ST proved to be comparable to flow cytometry (Skinner et al. 
2000). 
5.9 The role of Ag-persistence in the maintenance of long-term memory T-cells 
It has previously been found that CD4+ and CD8+ T-cell memory can perSist in the absence of Ag, 
as well as in the absence of MHC (Goldrath et al. 1999), but most of the work has been done in 
viral systems where low level Ag may persist in specialised depots, as for example in follicular 
dendritic cells. In the present tumour model, the presence or absence of Ag does make a difference 
for long-term survival of CD8+ memory T-cells. In a "parking experiment", tetramer-staining 
revealed the disappearance of ~_gaI876-884 specific CD8+ T -cells in bone marrow, spleen, lymph 
nodes and blood in the absence of Ag. 
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Many memory CD8+ T -cells specific to one pathogen may disappear after infection with subsequent 
pathogens (Varga et al. 2001). One explanation for this phenomenon might be the fact that CD8+ 
T-cells proliferate vigorously upon Ag-stimulation. This poses a high selective pressure on them 
once the infection has been cleared, as there will be a competition for space in the respective 
memory T-cell compartment which is controlled by homeostatic mechanisms. Recently activated 
memory cells may displace older ones from their protective niches. Even those memory T-cells that 
may have been rescued from apoptosis by stromal cell derived type I IFNs will slowly be replaced, 
or at least decimated, owing to competition with other, more recently activated, T-cells for survival 
factors (Akbar et al. 2000). 
Homeostatic regulation limits the expansion of the T-cell pools as well as the size of lymphoid 
organs. Therefore, the memory T-cell pool increases only moderately in size with age. As a 
consequence, the CD8+ T-cell memory pool would quickly fill to capacity if CTL memory for each 
pathogen that a host experiences were preserved at a similar frequency. 
Antigenic stimulation of the memory T-cell pool will induce proliferation of specific T -cells, boosting 
the Ag-specific memory T-cell pool at the cost of other memory T -cells. It could be possible that low 
level Ag-persistence may ensure survival of respective memory cells, even if the dose were not 
sufficient for triggering proliferation and/or differentiation to effector cells. This might explain the 
great difference in the frequency of ~_gaI876-884 specific CD8+ memory T -cells in the presence 
(26.3 % in the 8M) or absence of Ag (0.4 % in the 8M). As mentioned in 4.3.2, the ESb derived 
tumour Ags expressed by ESbL-Gal are only weakly immunogenic. In contrast, the introduced ~-gal 
is highly immunogenic, with TPHPARIGL (aa 876-884) being its immunodominant peptide. This 
might confer clonal dominance to ~_gaI876-884 specific CD8+ memory T -cells through Ag-driven 
selection. It is then conceivable, that such clonal dominance is lost following Ag-removal. 
Although it has been published that memory T-cell survival is independent of TCR-signals and that 
these cells can persist over extended periods of time in the absence of Ag, it could be 
demonstrated that, following Ag-removal, the memory T-cell pool decreases in size, often falling 
below detection levels for tetramer staining. Nevertheless, Ag-specific T-cell numbers were found to 
increase again rapidly after rechallenge with Ag (Faint et al. 2001). 
Whether in the present "parking experiment" the absence of Ag also resulted in the loss of Ag-
reactivity or only in a drastic reduction in Ag-specific cells remains to be tested. 
5.10 DNA-vaccination 
Under the conditions used in the present study, a systemic ~-gal specific T-cell response could be 
measured following dual ear pinna injection of pCMV~ DNA. Injection of a cell lysate from the ~-gal 
positive ESbL-Gal tumour line into the contralateral ear pinna resulted in the induction of a weak 
DTH-response (Fig. 4.23). Stronger DTH-responses were obtained in animals having received 
cellular vaccination, which might indicate that the immune response induced by DNA-vaccination 
either develops more slowly or occurs at a more local level than immune responses following 
tumour cell inoculation. It is known that tumour cells disseminate rapidly to lymph nodes, spleen. 
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and possibly also to other organs after i.e. injection (Schirrmacher et al. 1997), which could allow for 
a systemic activation of tumour reactive immune cells (see also 4.2). Stimulation with pCMV~, on 
the other hand, results in the uptake and expression of ~-gal at the site of injection (Forg et al. 
1998), thus generating a more local immune response, which could playa role in the development 
of weaker DTH-responses after Ag-stimulation at a location distant from the priming site. 
The more elevated DTH-responses observed in ESbl-Gal primed mice as compared to DNA-
vaccinated animals could also be due to the fact that in the former case, the priming and DTH 
stimuli contained more than one Ag in common, namely the Esb-derived TM and ~-gal, while in the 
latter situation there was only one Ag in common (~-gal). 
Forg and colleagues were able to produce ~-gal specific CTl by pCMV~ inoculation i.e. followed by 
a 5 day co-culture of splenocytes, isolated 9 days post DNA-vaccination, together with the H2-l d 
restricted ~-gal peptide TPHPARIGl (Forg et al. 1998). pCMV~ vaccination also resulted in the 
induction of a protective anti-tumour immunity, causing rejection of subsequently s.c. injected lacZ+ 
tumours (Schirrmacher et al. 2000). 
Here, ~-gal reactive iPEC could be produced following ear pinna DNA-vaccination with pCMV~ by 
an intraperitoneal challenge with P815-Gal tumour cells. Such iPEC specifically lysed the ~-gal 
positive tumour cell lines ESbl-Gal and P815-Gal (Fig. 4.25). iPEC isolated from pCMV~ primed 
and ESbl-Gal restimulated DBN2 mice contained only few CD8+ T-cells (Fig. 4.24, 4.4 %) 
compared to iPEC from ESbl-Gal primed and restimulated animals (18.9 %), which might account 
for the comparably lower cytotoxic activity of iPEC for DNA-vaccinated mice. 
Nevertheless, such iPEC were able to significantly prolong the survival of ESbl-Gal inoculated 
Balb/c nu/nu after adoptive transfer (Fig. 4.26). Preliminary results indicated that DNA-vaccination 
(no Ag-persistence) is not sufficient for the maintenance of long-term surviving (6 months) memory 
CTl as determined by cytotoxicity of iPEC isolated after Ag-specific challenge (Fig. 4.27). This 
could indicate either that, at least in this system, maintenance of memory T-cells does require the 
persistence of Ag, or that the ~-gal specific memory T-cells were displaced by other, more recently 
activated (by environmental stimuli), memory T -cells. Although studies have been published on the 
generation of B-cell memory (He et al. 2001), I am not aware of any publications on the induction of 
long-term T-cell memory following DNA-vaccination. 
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Conclusion 
In this thesis, a novel model system for the study of anti-tumour T-cell memory was introduced, 
comprising an adoptive transfer of tumour reactive immune cells, including effector cells and APCs, 
to pre-irradiated, tumour-bearing, T-cell deficient hosts. The immune cell mixture used for the 
adoptive transfer was produced by injection of a subtumorigenic dose of the highly aggressive, 
~-gal transduced T-Iymphoma ESbL-Gal into the ear pinna of syngeneic immunocompetent DBN2 
mice, followed by an intraperitoneal challenge with irradiation-inactivated tumour cells. This resulted 
in the recruitment of Ag-specific CDS+ T -cells into the peritoneal cavity, most probably from the 
spleen and bone marrow, as revealed by peptide/MHC class I tetramer staining. The Lp. challenge 
caused a pro-inflammatory environment in the peritoneum which, during the early phases, was 
dominated by the type I cytokines TNF-a., IL-12, and IFN-y. Production of the T-cell growth factor 
IL-2 occurred at later time points and appeared to be involved in the expansion of Th2 type cells 
which secreted the type 2 and inhibitory cytokines IL-4, IL-5, and IL-10. These seemed to played a 
role in the general down-regulation of the intraperitoneal immune response. 
Three days after the challenge with ESbL-Gal, the number of immune cells in the peritoneal cavity 
had multiplied 5.3-fold, and contained increased numbers of T-cells. Most markedly, CDS+ T-cells 
now represented 11.2 % of total iPEC (na'ive PEC: 0.5 %), 33.9 % of which specifically recognised 
the immunodominant peptide of ~-gal, as demonstrated by peptide/MHC tetra mer staining. 
Consistently, CDS+ CTL mediated cytotoxicity was directed against ~-gal, and no specific lysis was 
detected against the ESb derived TM. The TCR-V~ repertoire of both CD4+ and CDS+ iPEC T-cells 
was polyclonal, although it appeared more restricted than that of iPEC generated against the 
unrelated DBN2 derived mastocytoma PS15. Whether this indicates that some TCR-V~ chains are 
better suited for the recognition of ~-gal derived peptides, and that, because of the high frequency 
of CDS+ T -cells reactive to a Single ~-gal derived peptide, are thus enriched, remains to be 
investigated. 
The immunisation protocol used could thus be shown to yield tumour-reactive CDS+ CTL exerting a 
highly specific ~-gal directed cytotoxicity. It would now be interesting to investigate which factors 
(chemokines) are involved in the recruitment of such Ag-specific CTL to the peritoneal cavity in 
response to the secondary Lp. stimulus. 
Upon transfer to pre-irradiated, tumour-bearing, MHC-compatible Balb/c nu/nu mice, ESbL-Gal 
reactive iPEC conferred tumour protection and long-term survival. Pre-irradiation of the reCipients 
proved to be a prerequisite for the prevention of metastases formation both in internal organs and at 
peripheral sites. A critical involvement of both CD4+ and CDS+ T-cells for optimal therapeutic 
success could be demonstrated. 
Conclusion III --------~~~-----------------------------------------------
Even after successful therapy, dormant tumour cells persist for extended periods of time in the host. 
Analyses of reisolated tumour cells both from solid tumour nodules and from bone marrow resident 
dormant tumour cells demonstrated that ~-gal expression by ESbl-Gal was stable in vivo. 
Comparison of the parental ESbl-Gal with the bone marrow derived ESbl-Gal-BM variant revealed 
that, in contrast to its parental cell line, the latter possesses a rather naked cell surface concerning 
the expression of leukocyte lineage markers and adhesion molecules. Interestingly, H-2Dd (MHC 
class I), ICAM-1 and the ~rintegrin chain where found to be upregulated, with high expression 
levels of the former two molecules. This might explain the apparent contradiction between high 
sensitivity to iPEC mediated cytotoxicity in vitro and in situ co-existence with tumour-reactive 
memory CTls in the bone marrow microenvironment. The adhesion molecule ICAM-1 and the ~r 
integrin chain might also be involved in the retention of dormant tumour cells at this unique 
anatomical site. It would be interesting to further exploit this model system in order to elucidate the 
factors involved in tumour dormancy. 
Following ADI, anti-tumour immunological memory proved to be long-lived and, at least partially, 
radiation-resistant. Memory T-cells could be demonstrated to retain their Ag-reactivity as well as 
their potential of exerting tumour protection in a multiple transfer study. The bone marrow could be 
identified as the major compartment for the long-term survival of Ag-specific memory T -cells, the 
frequency of tetra mer-binding cells within the CDS+ pool being much more elevated at this 
anatomical site as compared to the spleen and lymph nodes. However, a 'parking experiment' 
revealed that Ag-persistence in the form of dormant tumour cells appeared to be required for the 
maintenance of Ag-specific memory T-cell numbers. These data were supported by preliminary 
findings that DNA-vaccination (no Ag-persistence) does not result in the long-term persistence of 
CTl memory. 
Analysis of bone marrow plugs from long-term survivors using the noveliST staining technique 
(Skinner et al. 2000) would be very instructive, as this promises to give inSights into the cell-cell 
interactions and precise localisation of memory T -cells within the bone marrow microenvironment. 
Moreover, investigation of chemokine receptor expression on memory T-cells could further indicate 
why these cells appear to be predominantly attracted to this anatomical site. 
Recently, type IIFNs have been proposed to be of central importance in the long-term maintenance 
of memory T -cells, as they could be demonstrated to prevent apoptosis of activated T -cells without 
simultaneously inducing their proliferation (Akbar et al. 2000). In collaboration with Dr. R. Zawatzky, 
type I IFN-receptor knockout mice are currently being backcrossed onto the DBN2 background. 
This will provide a valuable research tool for determining the involvement of type I IFNs in T-celJ 
memory directly in vivo. The use of ESbL-Gal reactive iPEC generated in such mice for the ADI 
transfer system presented in this thesis should reveal to what extent type I IFNs are responsible for 
the long-term survival of Ag-specific CTL and whether alternative mechanisms can also provide the 
necessary survival signals. 
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Appendix 
8.1 Abbreviations 
aa aminoacids 
Ab, Abs 
ADI 
Ag. Ags 
AICD 
AlP 
AP 
APC 
ATP 
bp 
CCR7 
CD .. 
CD62L 
CD95L 
cDNA 
CTL 
DCs 
ddH20 
DE PC 
dH20 
DNA 
dscDNA 
DTH 
E. coli 
Eb288 
ECM 
ELISA 
ELiSPOT 
ER 
ESb 289 
ESb-L 
ESbL-Gal 
ESbL-Gal-BM 
ESbL-Gal-ET 
antibody. antibodies 
adoptive immunotransfer 
antigen, antigens 
activation-induced cell death 
apoptosis-inhibitory proteins 
alkaline phosphatase 
Ag presenting cell(s) 
adenosine triphosphate 
base pairs 
chemokine receptor-7 
cluster of differentiation 
L-selectin; leukocyte selectin 
CD95 ligand, Fas ligand 
complementary DNA; single-stranded 
cytotoxic T -lymphocytes 
dendritic cells 
double-distilled water 
diethyl pyrocarbonate 
single-distilled water 
deoxyribonucleic acid 
double-stranded cDNA 
delayed-type hypersensitivity 
Escherichia coli 
methyl-cholanthrene induced T-Iymphoma of the DBAl2 mouse; L5178Y/E 
extracellular matrix 
enzyme-linked immunosorbent assay 
enzyme-linked immunospot assay 
endoplasmatic reticulum 
spontaneous, highly metastatic variant of Eb 288 
more aggressive form of ESb 289, isolated from a liver metastasis 
bacterial/acZ gene transduced Esb-L subline (clone L-CJ.5s) 
ESbL-Gal variant isolated from bone marrow resident dormant tumour cells 
ESbL-Gal variant isolated from an ear tumour 
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ESbL-Gal-ST 
ESbL-Gal-TT 
FACS 
FasL 
FCM 
Fc-R 
FDC 
FDG 
Fig. 
FITC 
g 
GvH 
GvHD 
GvL 
Gy 
HLA-... 
HSPC 
HvG 
ICAM-1 
ICOS 
ICs 
i.d. 
i.e. 
IFN-.. 
IL-.. 
IL-2R 
i.p. 
iPCR 
iPEC 
ISS 
1ST 
i.v. 
kb 
LAK 
LFA-1 
LN 
L-selectin 
mAb 
MACS 
MadCAM-1 
MCMV 
ESbL-Gal variant isolated from a spleen tumour 
ESbL-Gal variant isolated from a throat tumour 
fluorescence-activated cell sorter 
Fas ligand 
fibroblast conditioned medium 
Fc-receptor, binding Abs via their Fc-region 
follicular dendritic cells 
f1uorescein-di-~-D-galactopyranoside 
figure 
f1uoroisothiocyanate 
gravitational force; 9.8066 m/s2 
graft versus host reaction 
GvH disease 
graft versus leukaemia reaction 
Gray; unit of radioactive dosis; 1 Gy = 100 rad 
human leukocyte Ags 
haematopoietic stem and progenitor cells 
host versus graft reaction 
intracellular adhesion molecule-1 
inducible co-stimulatory molecule 
Ag : Ab immune complexes 
intra-dermal injection 
intra-ear pinna injection 
interferon 
interleukin 
IL-2 receptor 
intra-peritoneal injection 
inverse PCR 
immune PEC 
immunostimulatory DNA sequences 
in situ tetra mer staining 
intra-venous injection 
kilobases 
Iymphokine-activated killer cells 
lymphocyte function-associated Ag-1 
lymph nodes 
leukocyte selectin; CD62L 
monoclonal antibody/antibodies 
magnet-activated cell sorting 
mucosal addressin cell adhesion molecule-1 
murine cytomegalovirus 
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!lCi 
MHC 
MIiCs 
MMTV 
mPEC 
mRNA 
N 
NK-cells 
nm 
NMS 
nPEC 
oln 
OVA-FITC 
P815 
P815-Gal 
p.a. 
PBl 
PBS 
pCMV~ 
PCR 
PE 
PEe 
PHA 
PI 
PKC-o 
P-selectin 
PSGL-1 
rLN 
RNA 
RNase A 
R-PE 
rpm 
r/t 
RT-PCR 
s.c. 
SEM 
Sn 
SPF 
SV40 
micro-Curie 
major histocompatibility complex 
MHC class II compartments 
mouse mammary tumour virus 
memory PEC 
messenger RNA 
normality, a measure for the concentration of solutions 
natural killer cells 
nanometer 
normal mouse serum 
naive PEC 
overnight 
FITC-conjugated ovalbumin 
methyl-cholanthrene induced mastocytoma of the DBAl2 mouse 
bacterial/acZ gene transduced subline of P815; commonly known as P13.1 
pro analysis 
peripheral blood lymphocytes 
phosphate buffered saline 
plasmid carrying the gene coding for l3-galactosidase under the human 
cytomegalovirus (CMV) immediate early gene promoter 
polymerase chain reaction 
see R-PE 
peritoneal exudate cells 
phytohemagglutinin 
propidium iodide 
protein kinase C-O 
platelet selectin; CD62P 
P-selectin glycoprotein Iigand-1 
regional lymph nodes 
ribonucleic acid 
ribonuclease A 
R-phycoerythrin 
rounds per minute 
room temperature 
reverse transcriptase PCR; analysis of RNA expression by PCR after 
transcription to cDNA 
sub-cutaneous injection 
standard error mean 
sialoadhesin 
specific pathogen free conditions for experimental animals 
Simian Virus 40 
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TM tumour-associated Ag(s) 
TCR T-cell antigen receptor 
TCR-C~ constant region of the TCR j3-chain 
TCR-D~ diversity region of the TCR ~-chain 
TCR-J~ joining region of the TCR ~-chain 
TCR-V~ variable region of the TCR ~-chain 
TGF-~ tumour growth factor-~ 
TLRs Toll-like receptors 
TMB tetramethylbenzidine 
TNF-a tumour necrosis factor-a 
TRF telomere restriction fragment(s) 
U units 
VCAM-1 vascular cell adhesion molecule-1 
v/v volume per volume 
w/v weight per volume 
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8.2 Testing of reagents of own production 
8.2 .1 pCMV~ digest 
To test whether the pCMV~ plasmid isolated was intact, the DNA was digested using specific 
restriction endonucleases. The results are depicted in Fig. 8.1. 
6369 bp 8453 bE-
'-
4822 bp 5687 bJY-
3675 bp-
1371 bp 
-1264 bp-
2 3 4 5 
...... 
. ........ 
........ . . 
.... 
··· 1··. 
. .. ~-. 
= 
2072 bp 
1500 bp 
- 600 bp 
Fig. 8.1 pCMV~ digest with Xho I and Eco RV. pCMV~ plasmid DNA was left 
uncut (lane 2), linearised by Xho I digest (lane 3) or fragmented by an Xho IIEeo RV 
double-digest (lane 4). Lane 1 contains the A DNNEeo 91 1 (Bst Ell ) marker and lane 5 
contains a 100 bp DNA ladder. 
Supercoiled DNA runs faster through an agarose gel than does linearised DNA of the same size. 
This explains why the uncut pCMV~ plasmid (lane 2) had an apparent size of -5 kb, while the 
linearised plasmid (lane 3) ran at the expected 7.2 kb. A double-digest with the restriction 
endonucleases Xho I and Eco RV yielded one fragment of 5.8 kb and one of 1.4 kb, indica ting that 
the isolated plasmid DNA had not lost the lacZ insert and could therefore be used for experimental 
purposes. 
8.2.2 Phenotype of and Ag-uptake by in vitro grown DCs 
Myeloid DCs are specialised for the activation of naNe T-cells . Immature DCs are characterised by 
a high capabil ity for Ag-capture and processing, but low T-cell stimulatory activity. As DCs mature, 
they express increasing numbers of MHC class II molecules on their surface, owing to reduced 
internalisation and increased biosynthesis (Cella et al. 1997). Such increased expression allows the 
loading of many antigenic peptides shortly after an inflammatory stimulus and can be visualised by 
a higher fluorescence intensity when staining with class II specific mAb. With maturation they also 
lose their capacity to internalise exogenous Ag , and become increasingly specialised in Ag-
processing and -presentation (Lutz et al. 1999). 
Lutz and colleagues expanded bone marrow derived DCs in medium supplemented with 10 % FCS. 
FCS is recognised as a non-self Ag by murine DCs, and is consequently internalised, processed 
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and presented in conjunction with MHC molecules on the cell surface of DCs. As this could affect 
the results of Ag-presentation assays, in vitro culture of DCs was carried out in the serum-free 
medium X-vivo 20. Fig 8.2 A demonstrates that this altered culture regimen yielded functional DCs 
which expressed the DC-marker CD11 c, as well as intermediate levels of MHC class I and 1\, and 
the co-stimulatory molecules CD80 and CD86. The cultured DCs were able to phagocytose FITC-
conjugated ovalbumin (OVA-FITC) at 3r c (Fig . 8.2 8) . Incubation of DCs with OVA-FITC on ice 
also resulted in fluorescently labelled DCs, but in this situation the OVA adhered to the surface of 
DCs and was not taken up. 
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Fig. 8.2 Phenotype of and Ag-uptake by immature DCs. DCs cultured from 
murine bone marrow were analysed by FACS analysis on d1 0 of culture. Expression of 
cell surface MHC class I (H-2Dd) and class \I (I_Ad) and of the co-stimulatory molecules 
CD80 and CD86 was measured and plotted against CD11 c expression (A) . Ag-uptake 
capacity was tested by incubating the DC with OVA-FITC either at 37°C or on ice (8) . 
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CD11 c· cells remain ing in the cultures are most probably granulocytes, which also expand in GM-
CSF containing cultures Lutz et al. 1999). 
Expression levels of MHC class II (I-A\ class I (H-2Dd), CDSO and CDS6 molecules is increased 
on the ce ll surface of ~-gal peptide-pulsed DCs as illustrated in Fig. S.3, with a marked increase in 
MHC class II expression . Murine cytomegalovirus (MCMV) peptide-pulsed DCs exhibited a similar 
cell surface phenotype (data not shown) . The Ag-pulsed DCs had matured , expressing elevated 
levels of co-stimulatory molecules, and therefore appropriate for use in Ag-specific T-cell 
responses. Maturation of DCs is normally induced by GM-CSF or inflammatory cytokines, such as 
TNF-a (Cella et al. 1997). Under the present conditions , mere pipetting as well as transfer to fresh 
culture plates could induce the maturation process, as previously described (Lutz et al. 1999). 
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Phenotype of Ag-pulsed Des. Immature d11 DCs were pulsed oln with 
~_gaI876-884 peptide. Expression levels of cell surface MHC class I (H-2Dd) and class II 
(I_Ad) and of the co-stimulatory molecules CDSO and CD86 was compared on 
immature d10 DCs (left) and mature Ag-pulsed d12 DCs (right) . The red line ( --- ) 
depicts the autofluorescence of unstained DCs. Mean fluorescences and peak 
channels are indicated in the top right corner of every histogram (mean I peak 
channel). 
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8.3 Preliminary data 
8.3.1 iPCR for TCR-V~ chains 
An inverse PCR (iPCR) for the TCR-VP chains would have the advantage of allowing to amplify the 
transcripts of all Vp-chains in one reaction and under the same conditions . Quantitative expression 
analysis could then be carried out using Southern Blot hybridisation with Vp-chain specific probes 
as a read-out system. 
A 1 2 3 4 567 
2.3 kb __ 
1.9 kb--
__ 600 bp 
-- 400 bp 
B 2 3 4 5 6 
800 bp --
450 bp --
280 bp --
pnmers 
C 2 3 4 5 6 
450 bp --
280 bp --
pnmers 
Fig. 8.4 The combination of Cn and BCS primers is unsuitable for iPCR 
under the present conditions. cDNA from the following probes was amplified in an 
inverse PCR reaction using the BCS and Cn primers: thymocytes (lane 2) , d3 iPEC 
from ESbL-Gal-immunised DBAl2 (lane 3) , CD4+ and CDS+ d3 iPEC (lane 4) , naYve 
PEC (lane 5) , and CD4+ and CDS+ immune BM from ESbL-Gal-immunised DBAl2 
(lane 6) . Lane 1 (A. DNAlEco 911) and 7 (100 bp DNA-ladder) contain DNA size 
markers. Shown are an ethidium bromide stained agarose gel (A) , a Southern Blot 
hybridised with a [y-32p]_ATP labelled BCS-probe (B), and one hybridised with a [y_32p]_ 
ATP labelled Cn-probe. The BCS but not the Cn primer binds to the amplified DNA-
fragments, indicating an iPCR reaction double-primed by the BCS-primer. 
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In order to develop such a TCR-V~ iPCR, the both primers were chosen to anneal in the constant 
region (see 8.4.1.2). Unfortunately, iPCR was unsuccessful under the present conditions (see Fig. 
8.4), with the amplification reaction being double-primed by the BCS-primer (no annealing of the Cn-
probe was detectable in the Southern Blot). This could indicate that the binding-conditions for en are 
much more stringent than those for BCS, with non-specifically primed sequences competing for 
amplification during iPCR, suppressing the amplification of specific sequences. 
Another indication that the bands visualised by BCS-priming are the result of false priming is the 
size of the fragments. In an iPCR correctly amplifying the TCR-V~ sequences one would expect 
fragment sizes of over 800 nucleotides. Here, the two major bands are at 450 and 280 bp, 
respectively, with minor bands of higher molecular size up to 1 kb. 
One would now have to design new primers, at least one replacing the BCS-primer, and start again 
from the beginning, testing the primers separately in conventional PCRs before applying them in 
another iPCR. 
Once set up, iPCR is a good method for the simultaneous amplification of several gene sequences 
as e.g. the TCR-V~ genes, but developing the ideal conditions is difficult. One can try changing 
primer sequences, primer concentrations as well as the annealing temperature, but there is no way 
of knowing whether circularisation of the ds cDNA was successful. 
It would be relevant to try and develop a reliably working iPCR for the TCR-V~ genes, but as my 
project was mainly concerned with the development of a suitable system for the analysis of tumour 
specific T -cell memory, there was not sufficient time to do so. Therefore, I decided to analyse the 
TCR-V~ repertOire by conventional PCR, using gene-specific primers in combination with Cn (4.3.4). 
8.3.2 IFN-y production of memory T -cells after in vitro restimulation 
An ELiSPOT assay was used to enumerate the ex vivo isolated memory T-cells producing IFN-y in 
an Ag-specific manner. For this purpose, d3 mPEC (memory PEC) were isolated from ESbl-Gal 
tumour bearing Balb/c nulnu mice having received standard therapy 1.5 months prior to 
intraperitoneal re-stimulation. Memory T-cells were purified from the d3 mPEC using Thy1.2 
MACSbeads and co-cultured for 24 hours with Ag-pulsed DCs. 
Although the cells had been restimulated in vivo 3 days before isolation, this was not expected to 
cause a high background spot formation as the cytokine-production kinetics of ex vivo isolated PEC 
between d1 and d12 after Lp. restimulation (see Fig. 4.9) indicated a low production of IFN-yfor this 
time point. Indeed, background levels proved to be very low, with an average of one IFN-y 
producing cell per 3401 cells (Fig. 8.5, T-ce"s without DCs or Ag). In contrast, co-culture with ~­
gaI876-884 peptide-pulsed DCs resulted in a 26.6-fold increase in the number of IFN-y producing T-
cells, giving a frequency of ~_gaI876-884 specific T-cells within mPEC of 1 : 128. The difference in the 
frequency of IFN-y producing cells after a specific stimulus (~_gaI876-884 peptide) and a non-specific 
stimulus (MCMV pp89 peptide 168-176, ld-restricted) was highly significant (p = 0.0004). 
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Unfortunately, the positive control for T-cell responsiveness , phytohemagglutinin (PHA) , failed . 
Subsequent analysis in the laboratory revealed that the PHA batches used were inactive or only 
weakly immunogenic, with responses being measurable only at late time points. 
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Fig. 8.5 Ag-specific IFN-"( production after in vitro restimulation of PEC-
derived memory T-cells. S DBN2 mice were primed with S x 104 ESbL-Gal i.e. 7 days 
before obtaining a secondary challenge with 1 x 107 irradiation inactivated ESbL-Gal 
i.p .. After 1.S months the animals received another intraperitoneal challenge. mPEC 
were isolated 3 days later, and T -cells were isolated from the pooled cells using Thy1 .2 
MACSbeads. The T-cells were then co-cultured with Ag-pulsed DC for 24 hours and 
IFN-y producing cells were measured in an ELiSPOT assay. (A) number of IFN-y 
producing cells per well (S x 104 T-cells). b-gal : ~-gal peptide 876-884; MCMV: MCMV 
pp89 peptide 168-176. (8) representative wells showing spot formation after co-culture 
of T -cel ls with ~-gal pulsed DCs, and background IFN-y production in the presence of 
non-Ag-pulsed DCs. 
All samples were measured in triplicates . ** : significantly higher (p < O.OOS) than the 
control groups. 
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8.4 mRNA sequences of genes analysed by PCR 
All sequences are given in a 5' -? 3' direction. 
8.4.1 Murine TCR mRNA sequences 
8.4.1.1 TCR-V~ segments 
TCR-V~ primers used for PCR amplifica tion in combination with the Cn-prlm r for th TC -C r I n 
(see 8.4 .1.2) are highlighted in blue. 
(Barth et al. 1985, EMBL accession no.: X02778) 
1 AACACTAAAA TTACTCAGTC ACCAAGATAT 
51 TAAGTCTTTG GAATGTGAGC AACATCT G 
1 01 ATAAACAGAG CGCTGAGAAG 
151 AAACAGTTGA TTCGAAATGA 
2 01 CCCAGACAGC TCCAAGCTAC TTTTACATAT 
25 1 ACTCAGCTGT CTATTTTTGT GCCAGCAG 
(Barth et al. 1985, EMBL accession no.: X02780) 
1 GTGACTTTGC TGGAGCAAAA CCCAAGGTG 
51 AGCTGTGAAC CTACGCTGCA TCTTGAAGAA 
1 51 GCTGGTATCA GCAGGATCTC CAAAAGCAA 
2 01 CGGAGTCCTG GGGACAAAGA GGTCAAATCT 
25 1 GGCCACACGG GTCACTGATA CGGAGCTGAG 
3 01 GCCAGGGCAG AACCTTGTAC TGCACCTG A T 
(Barth et al. 1985, EMBL accession no.: X02781) 
1 GACCCGAAAA TTATCCAGAA ACCAAAATAT 
51 CGAAAAAATC CTGATATGCG AACAGTATCT 
1 01 GGTATAGACA AAGTGCTAAG AAGCCT TA 
151 TATCAAAAAC TTATGGACAA TCAGACTGC 
2 01 AAGTTCAAAG AAAAACCATT TAGAC A 
251 ATGACTCGGC CACATACTTC A 
V~5.1 (Barth et al. 1985, EMBL accession no.: X02782) 
1 AATTCTGGGG TTGTCCAGTC TCCAAGATA 
51 AAGGTCCATT CTAAAATGTA CTCCCAT T 
101 GGTATCAACA GACTCAGGGG CAGGAA TAA 
151 GATAAAATGG AGAGAGATAA AGGAAA 
2 01 ACAGTTTGAT GACTATCACT CTGA AT 
251 AGGACTCTGC CGTGTACTTC TGTG 
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(Iwamoto et al. 1987, EMBL accession no.: X05737) 
1 GATTCTGGGG TTGTCCAGTC TCCAAGACAC ATAATCAAAG AAAAGGGAGG 
51 AAGGTCCGTT CTGACGTGTA TTCCCATCTC TGGACATAGC AATGTGGTCT 
101 GGTACCAGCA GACTCTGGGG AAGGAATTAA AGTTCCTTAT TCAGCATTAT 
151 GAAAAGGTGG AGAGAGACAA AGGATTCCTA CCCAGCAGAT TCTCAGTCCA 
201 ACAGTTTGAT GACTATCACT CTGAAATGAA CATGAGTGCC TTGGAACTGG 
251 AGGACTCTGC TATGTACTTC TGTGCCAGCT CTCTCG 
(Barth et al. 1985, EMBL accession no.: X02783) 
1 GAGGCTGCAG TCACCCAAAG TCCAAGAAGC AAGGTGGCAG TAACAGGAGG 
51 AAAGGTGACA TTGAGCTGTC ACCAGACTAA TAACCATGAC TATATGTACT 
101 -(": '"1'-""'" ... .-. • ~ -uu ............ '>...vu'-.. :-. GG.;:'.CACGGGG CATGGGCTGA GGCTGATCCA TTACTCATAT 
151 GTCGCTGACA GCACGGAGAA AGGAGATATC CCTGATGGGT ACAAGGCCTC 
201 CAGACCAAGC CAAGAGAATT TCTCTCTCAT TCTGGAGTTG GCTTCCCTTT 
251 CTCAGACAGC TGTATATTTC TGTGCCAGCA GT 
The sequence highlighted in green is the primer BV8 used for testing the Cn-primer prior to 
application in iPCR. 
(Barth et al. 1985, EMBL accession no.: X02784) 
1 GAGGCTGCAG TCACCCAAAG CCCAAGAAAC AAGGTGGCAG TAACAGGAGG 
51 AAAGGTGACA TTGAGCTGTA ATCAGACTAA TAACCACAAC AACATGTACT 
101 GG7 ;".'7 Guc.; GG.;;CACGGGG CATGGGCTGA GGCTGATCCA TTATTCATAT 
151 GGTGCTGGCA GCACTGAGAA AGGAGATATC CCTGATGGAT ACAAGGCCTC 
201 CAGACCAAGC CAAGAGAACT TCTCCCTCAT TCTGGAGTTG GCTACCCCCT 
251 CTCAGACATC AGTGTACTTC TGTGCCAGC 
The sequence highlighted in green is the primer BV8 used for testing the Cn-primer prior to 
application in iPCR. 
(Chou et al. 1987) 
1 AGGCTGCAGT CACCCAAAGC CCTAGAAACA AGGTGACAGT AACAGGAGGA 
51 AACGTGACAT TGAGCTGTCG CCAGACTAAT AGCCACAACT ACATGTACTG 
101 GT.;; TCGGC;'.G GACACTGGGC ATGGGCTGAG GCTGATCCAT TACTCATATG 
151 GTGCTGGCAA CCTTCGAATA GGAGATGTCC CTGATGGGTA CAAGGCCACC 
201 AGAACAACGC AAGAAGACTT CTTCCTCCTG CTGGAATTGG CTTCTCCCTC 
251 TCAGACATCT TTGTACTTCT GTGCCAGCAG TGATG 
The sequence highlighted in green is the primer BV8 used for testing the Cn-primer prior to 
appl ication in iPCR. 
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VB10 (Behlke et al. 1985) 
1 TCCTATTGGT ACAAGCAAGA CTCTAAGAAA TTGCTGAAGA TTATGTTTAG 
51 CTACAATAAT AAGCAACYCA TTGTAAACGA AACAGTTCCA AGGCGCTTCT 
101 CACCTCAGTC TTCAGATAAA GCTCATTTGA ATCTTCGAAT CAAGTCTGTA 
151 GAGCCGGAGG ACTCTGCTGT GTATCTCTGT GCCAGCAGCG CCC 
VB13 (Morahan et al. 1989. EMBL accession no.: M25913) 
1 GTACTGTCTG AAGCTGGAGT CACCCAGTCT CCCAGATATG CAGTCCTACA 
51 GGAAGGGCAA GCTGTTTCCT TTTGGTGTGA CCCTATTTCT GGACATGATA 
101 CCCTTTACTG GTATCAGCAG CCCAGAGACC AGGGGCCCCA GCTTCTAGTT 
151 TACTTTCGGG ATGAGGCTGT TATAGATAAT TCACAGTTGC CCTCGGATCG 
201 ATTTTCTGCT GTGAGGCCTA AAGGAACTAA CTCCACTCTC AAGATCCAGT 
251 CTGCAAAGCA GGGCGACACA GCCACCTATC TCTGTGCCAG 
VB14 (Behlke et al. 1986. EMBL accession no.: M11858) 
1 GCTCAGACTA TCCATCAATG GCCAGTTGCC GAGATCAAGG CTGTGGGCAG 
51 CCCACTGTCT CTGGGGTGTA CCATAAAGGG GAAATCAAGC CCTAACCTCT 
101 ACTGGTACTG GCAGGCCACA GGAGGCACCC TCCAGCAACT CTTCTACTCT 
151 ATTACTGTTG GCCAGGTAGA GTCGGTGGTG CAACTGAACC TCTCAGCTTC 
201 CAGGCCGAAG GACGACCAAT TCATCCTAAG CACGGAGAAG CTGCTTCTCA 
251 GCCACTCTGG CTTCTACCTC TGTGCCTGGG 
VB15 (Behlke et al. 1986. EMBL accession no.: M11859) 
1 GGAGCACTCG TCTATCAATA TCCCAGAAGA ACCATCTGTA AGAGTGGAAC 
51 TTCCATGAGG ATGGAGTGTC AAGCTGTGGG TTTTCAGGCA ACTTCCGTAG 
101 CTTGGTATCG TCAATCGCCT CAAAAGGCAT TTGAACTGAT AGCACTTTCT 
151 ACTGTGAACT CAGCAATCAA ATATGAACAA AATTTTACCC AGGAAAAATT 
201 TCCCATCAGT CATCCCAACT TATCCTTTTC ATCTATGACA GTTTTAAATG 
251 CATATCTTGA AGACAGAGGC TTATATCTCT GTGGTGCGG 
V~16 (Behlke et al. 1986. EMBL accession no.: M11860) 
1 GGACCCAAAG TCTTACAGAT CCCAAGTCAT CAAATAATAG ATATGGGGCA 
51 GATGGTGACC CTCAATTGTG ACCCAGTTTC TAATCACCTA TATTTTTATT 
101 GGTATAAACA GATTTTAGGA CAGCAGATGG AGTTTCTGGT TAATTTCTAC 
151 AATGGTAAAG TCATGGAGAA GTCTAAACTG TTTAAGGATC AGTTTTCAGT 
201 TGAAAGACCA GATGGTTCAT ATTTCACTCT GAAAATCCAA CCCACAGCAC 
251 TGGAGGACTC AGCTGTGTAC TTCTGTGCCA GCAGCTTAC 
VB18 (Singer et al. 1986. EMBL accession no.: M14294) 
1 TCTTTGGAGC CAAGTTCCAG GAACAGAGCT TGATGCTCAT GGCAACTGCA 
51 AATGAAGGCT CTGAAGCCAC ATACGAGAGT GGATTCACCA AGGACAAGTT 
101 TCCAATCAGC CGGCCAAACC TAACATTCTC AACGTTGACA GTGAACAATG 
151 CAAGGCCTGG AGACAGCAGT ATCTATTTCT GTAGTTCTC 
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VB20 (Six et al. 1991) 
1 GGCTCTTTTG ATGCTGCAGT TACACAGAAG CCAAGATATT TGATCAAAAT 
51 GAAAGGCCAG GAAGCAGAGA TGAAATGTAT CCCTGAAAAG GGGCACACTG 
101 CTGTTTTCTG GTATCAACAA AAGCAGAGCA AAGAATTAAA GTTCCTGATT 
151 TACTTTCAGA ATCAACAGCC TCTTGATCAA ATAGACATGG TCAAGGAGAG 
201 ATTCTCAGCT GTGTGCCCCT CCAGCTCACT CTGCAGCCTG GGAATCAGAA 
251 CGTGCGAAGC AGAAGACTCA GCACTGTACT TGTGCTCCAG CAGT 
8.4.1.2 The TCR-Cb segment 
(Gascoigne et al. 1984) 
Cn-primer (antisense) 
1 GAGGATCTGA GAAATGTGAC TCCACCCAAG GTCTCCTTGT TTGAGCCATC 
(1) 
51 AAAAGCAGAG ATTGCAAACA AACAAAAGGC TACCCTCGTG TGCTTGGCCA 
101 GGGGCTTCTT CCCTGACCAC GTGGAGCTGA GCTGGTGGGT GAATGGCAAG 
151 GAGGTCCACA GTGGGGTCAG CACGGACCCT CAGGCCTACA AGGAGAGCAA 
20 1 TTATAGCTAC TGCCTGAGCA GCCGCCTGAG GGTCTCTGCT ACCTTCTGGC 
251 ACAATCCTCG CAACCACTTC CGCTGCCAAG TGCAGTTCCA TGGGCTTTCA 
BCS-primer (sense) 
301 GAGGAGGACA AGTGGCCAGA GGGCTCACCC AAACCTGTCA CACAGAACAT 
35 1 CAGTGCAGAG GCCTGGGGCC GAGCAGACTG TGGGATTACC TCAGCATCCT 
(2) (3) 
401 ATCAACAAGG GGTCTTGTCT GCCACCATCC TCTATGAGAT CCTGCTAGGG 
4 51 AAAGCCACCC TGTATGCTGT GCTTGTCAGT ACACTGGTGG TGATGGCTAT 
5 01 GGTCAAAAGA AAGAATTCAT GAAGTCAGAT GTGAAGATGA ATACAAGAGC 
(4) (5) 
551 TGACAACACA TTGTGTTAAT ACAGATTTTC TTCTCCCAGA ACTTCTGAA 
UT A-primer (antisense) 
60 1 GAGCTATTCT CATTTGTCTG TGCATCCCAA ATTCTGCCTA CTAGTCACGC 
651 ATAGGTGCAT TTGTATGTCT GAAATTCTTG TGACCTAGAA AATGCCTACA 
70 1 CTTACAATCA AACCAATAAA CATGTTCTAG GACGGCCTG - poly (A) 
Underlined bases mark the first codon of the respective exon , with exon 1 (1) being the external 
part of the TCR-CP, exon 2 (2) the hinge-like region, exon 3 (3) the transmembrane domain and 
exon 4 (4) the cytoplasmic tail. The next underlined codon (5) indicates the beginn ing of the 3' 
untranslated region , which contains the poly (A) addition signal , highlighted in green. 
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8.4.2 The murine cytoskeletal ~-actin mRNA sequence 
(Tokunaga et al. 1986, EMBL accession no.: X03672) 
1 CCGGTCGAGT CGCGTCCACC CGCGAGCACA GCTTCTTTGC AGCTCCTTCG 
51 TTGCCGGTCC ACACCCGCCA CCAGTTCGCC ATGGATGACG ATATCGCTGC 
101 GCTGGTCGTC GACAACGGCT CCGGCATGTG CAAAGCCGGC TTCGCGGGCG 
151 ACGATGCTCC CCGGGCTGTA TTCCCCTCCA TCGTGGGCCG CCCTAGGCAC 
201 CAGGGTGTGA TGGTGGGAAT GGGTCAGAAG GACTCCTATG TGGGTGACGA 
251 GGCCCAGAGC AAGAGAGGTA TCCTGACCCT GAAGTACCCC ATTGAACATG 
301 GCATTGTTAC CAACTGGGAC GACATGGAGA AGATCTGGCA CCACACCTTC 
351 TACAATGAGC TGCGTGTGGC CCCTGAGGAG CACCCTGTGC TGCTCACCGA 
401 GGCCCCCCTG AACCCTAAGG CCAACCGTGA AAAGATGACC CAGATCATGT 
451 TTGAGACCTT CAACACCCCA GCCATGTACG TAGCCATCCA GGCTGTGCTG 
501 TCCCTGTATG CCTCTGGTCG TACCACAGGC ATTGTGATGG ACTCCGGAGA 
551 CGGGGTCACC CACACTGTGC CCATCTACGA GGGCTATGCT CTCCCTCACG 
601 CCATCCTGCG TCTGGACCTG GCTGGCCGGG ACCTGACAGA CTACCTCATG 
651 AAGATCCTGA CCGAGCGTGG CTACAGCTTC ACCACCACAG CTGAGAGGGA 
701 AATCGTGCGT GACATCAAAG AGAAGCTGTG CTATGTTGCT CTAGACTTCG 
851 AGCAGGAGAT GGCCACTGCC GCATCCTCTT CCTCCCTGGA GAAGAGCTAT 
801 GAGCTGCCTG ACGGCCAGGT CATCACTATT GGCAACGAGC GGTTCCGATG 
851 CCCTGAGGCT CTTTTCCAGC CTTCCTTCTT GGGTATGGAA TCCTGTGGCA 
901 TCCATGAAAC TACATTCAAT TCCATCATGA AGTGTGACGT TGACATCCGT 
951 AAAGACCTCT ATGCCAACAC AGTGCTGTCT GGTGGTACCA CCATGTACCC 
1001 AGGCATTGCT GACAGGATGC AGAAGGAGAT TACTGCTCTG GCTCCTAGCA 
1051 CCATGAAGAT CAAGATCATT GCTCCTCCTG AGCGCAAGTA CTCTGTGTGG 
1101 ATCGGTGGCT CCATCCTGGC CTCACTGTCC ACCTTCCAGC AGATGTGGAT 
1151 CAGCAAGCAG GAGTACGATG AGTCCGGCCC CTCCATCGTG CACCGCAAGT 
1201 GCTTCTAGGC GGACTGTTAC TGAGCTGCGT TTTACACCCT TTCTTTGACA 
1251 AAACCTAACT TGCGCAGAAA AAAAAAAAAT AAGAGACAAC ATTGGCATGG 
1301 CTTTGTTTTT TTAAATTTTT TTTAAAGTTT TTTTTTTTTT TTTTTTTTTT 
1351 TTTTTTTTAA GTTTTTTTGT TTTGTTTTGG CGCTTTTGAC TCAGGATTTA 
1401 AAAACTGGAA CGGTGAAGGC GACAGCAGTT GGTTGGAGCA AACATCCCCC 
1451 AAAGTTCTAC AAATGTGGCT GAGGACTTTG TACATTGTTT TGTTTTTTTT 
1501 TTTTTTTGGT TTTGTCTTTT TTTAATAGTC ATTCCAAGTA TCCATGAAAT 
1551 AAGTGGTTAC AGGAAGTCCC TCACCCTCCC AAAAGCCACC CCCACTCCTA 
1601 AGAGGAGGAT GGTCGCGTCC ATGCCCTGAG TCCACCCCGG GGAAGGTGAC 
1651 AGCATTGCTT CTGTGTAAAT TATGTACTGC AAAAATTTTT TTAAATCTTC 
1701 CGCCTTAATA CTTCATTTTT GTTTTTAATT TCTGAATGGC CCAGGTCTGA 
1751 GGCCTCCCTT TTTTTTGTCC CCCCAACTTG ATGTATGAAG GCTTTGGTCT 
1801 CCCTGGGAGG GGGTTGAGGT GTTGAGGCAG CCAGGGCTGG CCTGTACACT 
1851 GACTTGAGAC CAATAAAAGT GCACACCTTA CCTTACACAA AC 
Indicated in blue are the docking sites of the primers used (Klein et al. 1998), which yield a 
fragment of 349 bp. 
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8.4.3 The genetic code 
1st position 2nd position 3rd position 
(5'-end) (3'-end) 
U C A G 
Phe Ser Tyr Cys U 
U Phe Ser Tyr Cys C 
Leu Ser STOP STOP A 
Leu Ser STOP Trp G 
Leu Pro His Arg U 
C Leu Pro His Arg C 
Leu Pro Gin Arg A 
Leu Pro Gin Arg G 
lie Thr Asn Ser U 
A lie Thr Asn Ser C 
lie Thr Lys Arg A 
Met Thr Lys Arg G 
Val Ala Asp Gly U 
G Val Ala Asp Gly C 
Val Ala Glu Gly A 
Val Ala Glu Gly G 
U = uracil; C = cytosine; A = adenine; G = guanine 
In DNA molecular complexes, the complementary nucleotide for adenine (A) is not uracil (U) as in 
RNA, but thymine (T). 
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8.4.4 The amino acids 
3-letter single-
amino acid code letter code 
alanine Ala A 
cysteine Cys C 
aspartic acid Asp 0 
glutamic acid Glu E 
phenylalanine Phe F 
glycine Gly G 
histidine His H 
isoleucine lie I 
lysine Lys K 
leucine Leu L 
methionine Met M 
asparagine Asn N 
proline Pro P 
glutamine Gin Q 
arginine Arg R 
serine Ser S 
threonine Thr T 
valine Val V 
tryptophane Trp W 
tyrosine Tyr Y 
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